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ABSTRACT 
Ribosomes are vital molecular machines involved in catalysing mRNA translation 
into proteins. Understandably, when ribosome production is disrupted, there are 
mechanisms available to prevent further cell growth. The main complex involved in this 
process is the 5S RNP, a ribosome assembly intermediate consisting of the ribosomal 
proteins RPL5 and RPL11, and the 5S rRNA. The 5S RNP induces the tumour suppressor 
p53 by interacting with, and inhibiting, MDM2 an ubiquitin ligase responsible for 
maintaining low levels of p53 in the cell. The 5S RNP-p53 pathway has been implicated in 
diseases known as ribosomopathies, however the regulation of these pathways have not 
been fully characterised and there is still much that is unknown. The aim of this project 
was to identify the components involved in regulating 5S RNP integration into the 
ribosome and to determine what further components may be required for 5S RNP-
mediated p53 activation.  
There have been many recent studies elucidating the mechanism by which the 5S 
RNP is incorporated into the ribosome in yeast, however this mechanism appears to vary 
in humans. The data presented in this thesis determined that mimicking phosphorylation 
of RPL5 Y30 prevented 5S RNP incorporation into the ribosome. Furthermore, depletion of 
RPL7, RPL18, and RPL21 resulted in large subunit biogenesis defects and abrogated 5S RNP 
incorporation into the ribosome.  
Previous studies have suggested that SRSF1 and PRAS40 may be involved in the 
regulation of p53 via RPL5 and RPL11 respectively. In congruence with this, the data 
presented here showed SRSF1 interacts with the 5S RNP. Furthermore, depletion of SRSF1 
results in reduction in 5S RNP-dependent p53 activation, mis-localisation of RPL11, and 
reduction in 5S RNP integration. Collectively, these data suggest that SRSF1 may be 
important for both ribosome production and p53 regulation. The role of PRAS40, however, 
still remains unclear. Despite not interacting with the 5S RNP, depletion of PRAS40 
appeared to abrogate 5S-RNP mediated p53 induction.  
In summary, this work has provided a basis for studies into how the 5S RNP is 
recruited into the ribosome and provides evidence to suggest that SRSF1 is a component 
of the 5S RNP complex to activate p53.  
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CHAPTER ONE: INTRODUCTION 
1.1 The ribosome  
Ribosomes are highly conserved complexes involved in translating mRNA into proteins 
through peptide bond formation. Ribosomes are conserved throughout all domains of 
life, although their composition varies. The mature eukaryotic ribosome (80S) consists 
of two subunits, the large (60S) subunit and the small (40S subunit). They are thus 
named the 80S, 60S and 40S due to their sedimentation coefficient.  The structure of 
the ribosome has been solved in several eukaryotic organisms including S.cerevisiae, 
H.sapien, and T.thermophila, showing the organisation of the rRNAs and ribosomal 
proteins (Khatter et al., 2015, Ben-Shem et al., 2010, Klinge et al., 2011). The small and 
large subunits are composed of ribosomal RNA (rRNA) and ribosomal proteins. The 
small subunit is involved in the decoding function of the ribosome whilst the large 
subunit contains the peptidyl transfer centre (Lafontaine and Tollervey, 2001, Jones et 
al., 2008). The small subunit contains around 32 ribosomal proteins and the 18S 
ribosomal RNA (rRNA) whilst the large subunit consists of 3 ribosomal RNAs (rRNAs), 
the 28S (25 in S. cerevisiae), 5.8S and 5S rRNAs as well as approximately 46 ribosomal 
proteins (Wilson and Doudna Cate, 2012).  
The rate of ribosome production dictates cell growth, differentiation and proliferation 
(Rudra and Warner, 2004, Warner, 1999b, Sulic et al., 2005, Thomas, 2000). 
Furthermore, ribosome production is down-regulated during differentiation (Villunger 
et al., 2003) and up-regulated during cancer (Ruggero and Pandolfi, 2003). As ribosome 
biogenesis is so energy costly to the cell, the regulation of this process is highly 
important and errors in ribosome biogenesis have been reported in a number of 
genetic diseases known as ribosomopathies (Danovi et al., 2004).  
1.2 Ribosome biogenesis 
Eukaryotic ribosome biogenesis is an extremely complex and tightly regulated pathway 
that involves the coordination of all 3 RNA polymerases as well as more than 200 
different ribosome assembly factors (Henras et al., 2008). Ribosome biogenesis is 
extremely energy consuming. In yeast 60% of the total transcription is dedicated to 
ribosomal RNA (Warner, 1999a) and thus  this process has to be tightly regulated.  
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1.2.1 The nucleolus 
Ribosome biogenesis occurs in the nucleolus, a nuclear sub-compartment formed 
around the nucleolar organiser regions (NORs) at the end of mitosis. The NORs are 
stretches of DNA containing the rRNA genes (McStay and Grummt, 2008). There are 
about 150 copies of the rDNA genes in yeast that are found in tandem repeats on 
chromosome 12 (Kobayashi et al., 1998). In humans, there are around 400 tandem 
repeats of the rDNA genes located in NORs on the short arms of acrocentric 
chromosomes (Chromosomes 13, 14, 15, 21 and 22) (Heliot et al., 1997).  In humans, 
not all of the NORs are active, however those that are not active are believed to be 
important for nucleolar organisation and chromatin structure (Sanij and Hannan, 
2009).    
Although the nucleoli are not membrane-bound organelles, they are organised into 
three different compartments- the fibrillar centres, the dense fibrillar component 
(DFC), and the granular component (GC) (Derenzini et al., 1990) (Figure 1.1). 
Depending on the cell type and stage, the arrangement of the nucleoli can vary as their 
morphology can change in response to altered demands (Hernandez-Verdun, 2006). 
The FC consists of a network of 4-5nm thick fibrils where components of the 
transcription machinery are localised whereas the DFCs are composed of 3-5nm thick 
densely packed fibrils is where rRNA processing occurs (Schwarzacher and Wachtler, 
1993). The GC contains 15nm granules and functions as a storage component.  
The 47S pre-rRNA precursor is transcribed by RNA polymerase I at the FC/DFC border 
of mammalian nucleoli (Puvion-Dutilleul et al., 1997, Cheutin et al., 2002) before the 
RNAs move into the DFC during the elongation process (Cheutin et al., 2002). In the 
DFC, the initial cleavage steps are thought to occur (Derenzini et al., 1990) before the 
movement to the GC and subsequent processing takes place (Gerbi and Borovjagin, 
1997). Finally, the pre-rRNAs exit the nucleoli and enter the nucleoplasm before being 
exported to the cytoplasm (Lei and Silver, 2002). 
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The nucleolus has many functions including regulation of RNA and RNP biogenesis, 
organisation of the epigenome, and modulation of cellular stress responses (Quin et 
al., 2014). Several studies have demonstrated that ribosome biogenesis is up-regulated 
in cancer tissues, believed to be caused by a loss of tumour suppressor function  (As 
reviewed in Montanaro et al. (2008)). This prompts the notion that the nucleolus may 
play roles in coordinating the cell cycle and cell death in stress situations, and the 
formation and maintenance of cancers. Furthermore, expression of dominant negative 
mutants of the nucleolar protein, BOP1 results in p53-mediated cell cycle arrest 
(Pestov et al., 2001b). 
1.2.2 rRNA processing  
The transcription and processing of the ribosomal rRNA is a key step in the formation 
of ribosomes. In eukaryotes, the 18S, 5.8S and 28S (25S in yeast) rRNAs are transcribed 
as a single polycistronic precursor by RNA polymerase I in the nucleolus (Leary and 
Huang, 2001, Nazar, 2004) whilst the 5S rRNA is transcribed by RNA polymerase III in 
the nucleoplasm. The eukaryotic rRNA precursor is 13kb long and has a sedimentation 
value of 47S (35S in yeast). The 47S pre-rRNA undergoes a series of processing steps in 
order to produce the mature ribosomal rRNAs. During transcription of the rDNA, the 
nascent transcripts emerge from the rDNA template in a “Christmas tree”-like manner 
known as Miller spreads (Miller and Beatty, 1969). The terminal knobs at the ends of 
the transcripts correspond to the rRNA processing complexes containing precursors to 
 
Figure 1.1 The structure of the nucleolus. Immunogold labelling detection of rRNAs from 
mouse ELT cells.showing the three nucleolar compartments: fibrillar centers (FC), dense 
fibrillar component (DFC) and granular component (GC). Figure modified from Cheutin et al. 
(2002).  
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the mature ribosomal subunits (Bernstein et al., 2004, Dragon et al., 2002, Grandi et 
al., 2002). Many of these factors are recruited as part of a large complex called the 
small subunit (SSU) processome which associates with the pre-rRNA during 
transcription (Osheim et al., 2004) and is involved in processing, assembly and 
maturation of the small subunit. These processing steps, whilst similar, vary between 
organisms. 
1.2.2.1 rRNA processing in S. cerevisiae 
Most of the current understanding of rRNA processing has been gleaned from studies 
in yeast and are summarised in Figure 1.2. The sites A2, A3 and an internal transcribed 
spacer (ITS1) are important for separating small subunit rRNA (18S) from the large 
subunit rRNAs (25S and 5.8S rRNAs).  
The 35S pre-rRNA undergoes B0 cleavage in the 3’ ETS by Rnt1 (Kufel et al 1999). This is 
followed by cleavages at A0, A1 and A2 which requires processing by several snoRNPs 
(Lafontaine and Tollervey, 1995, Venema and Tollervey, 1995, Morrissey and Tollervey, 
1993). Two further proteins have been proposed to be involved in the cleavage of sites 
A1 and A2. Bleichert et al. (2006) suggested that Utp24 may be responsible for the 
endonucleolytic cleavages at A1 and A2 whilst Site A2 has also been proposed to be 
cleaved by Rcl1 (Horn et al., 2011).  
Removal of the 5’ external transcribed spacer (5’ ETS1) and cleavage in the internal 
transcribed spacer, ITS1 is performed by the small subunit (SSU) processome complex 
(Phipps et al., 2011). The 20S precursor is then transported to the cytoplasm where 
cleavage at site D by the endonuclease Nob1 then removes the remainder of ITS1 at 
the 3’ end of the 18S rRNA to produce the mature 18S rRNA (Lamanna and Karbstein, 
2009, Pertschy et al., 2007).  
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There are then two different pathways in yeast for the processing of the large subunit 
rRNAs. In the majority of cases, RNAse MRP, an RNA-protein complex, is required for 
cleavage at A3 (Lygerou et al., 1996, Schmitt and Clayton, 1993) along with Nop4 (Sun 
and Woolford, 1994) and a component of the SSU processome, Rrp5 (Venema and 
Tollervey, 1996).  The 5’ to 3’ exonucleases, Xrn2/Rat1 (Petfalski et al., 1998) and 
Rrp17 (at the B1S site) (Oeffinger et al., 2009, Henry et al., 1994) as well as the A3 
cluster of proteins (Granneman et al., 2011, Sahasranaman et al., 2011) are involved in 
processing the 5’ end of the 5.8S rRNA. However, in around 20% of cases, the 27SA2 is 
produced by cleavage at A2. The B1L site is endonucleolytically processed, by an 
unknown RNase. The two pathways then follow a similar route, however the minor 
pathway produces the 5.8SL whilst the major pathway produces the 5.8SS (Henry et al., 
1994).  
Exonucleolytic cleavage at Site C2 in the nucleus produces 7S and 27SBS/27SBL (Michot 
et al., 1999). Exonucleases Rat1 and Rrp17 then process the mature 5’ end of the 25S 
(Oeffinger et al., 2009). The 5.8S containing precursor generated by cleavage at C2 is 
processed by the exosome to produce 5.8S with 30 nucleotide 3’ extension (5.8S+30). 
Exonucleases act in both directions following C2 cleavage and require Las1 
(Schillewaert et al., 2012). The 5.8S +30 precursor is cleaved to 6S by Rrp44 and Rrp6 
of the exosome (Schillewaert et al., 2012). The mature 3’ end of the 5.8SS and 5.8SL are 
formed in the cytoplasm by Rex1, Rex2 and Ngl2 exonucleases (Faber et al., 2002) The 
Mature 3’ of 25S is produced by exonuclease Rnt1 (Oeffinger et al., 2009).  
1.2.2.2 rRNA processing in mammals 
In direct contrast to yeast, mammalian ribosome biogenesis is much less studied and 
thus less is known about the factors involved. The human rRNA precursor transcript is 
47S compared to the yeast 35S and has many of the same features including the 
internal and external spacer regions as shown in Figure 1.3B. Furthermore, the 
mammalian rRNA processing pathway has multiple different alternative processing 
pathways (Figure 1.3A).  
In mammalian pre-rRNA processing, there are two cleavage steps in the 5’ ETS of the 
47S transcript at sites A’ and A0 (Hadjiolova et al., 1993, Mullineux and Lafontaine, 
2012). The A’ cleavage occurs co-transcriptionally and generates the 45S (Mullineux 
and Lafontaine, 2012). This cleavage relies on UTP-A, XRN2 and MTR4. However, in the 
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absence of XRN2 but not MTR4, A0 cleavage becomes the first cleavage in the 5’ ETS 
(Sloan et al., 2014). 
 
After A’ processing, cleavage at site 2 produces the 30S and 32S precursors and 
separates the large and small subunit rRNAs. The 5’ETS is removed from 30S to 
generate 21S. At this stage, there are two potential pathways. Either A0 and site 1 are 
cleaved simultaneously, or if A0 is cleaved before site 1, via a 26S intermediate 
(Bowman et al., 1981, Hadjiolova et al., 1993). The order at which these steps occur 
can vary and ITS1 cleavage can occur after cleavages to remove the 5’ETS. This 
generates the 41S which is cleaved at site 2 to produce the 21S and 32S. ITS2 contains 
two cleavage sites known as 3’ and 4a. Cleavage at the 3’-region of ITS2 results in the 
generation of the 12S pre-rRNA (Hadjiolova et al., 1993) and further cleavage at site 4a 
results in a 7S pre-rRNA (Farrar et al., 2008). The mature 3’ end of the 5.8S is 
generated by exonucleolytic processing involving the exosome (Wang and Pestov, 
2011). Exonucleolytic processing is required for the formation of the 5’ and 3’ ends of 
the 28S.  
The production of the 18S in mammals is known to be slightly more complicated than 
that in yeast. Site 2 cleavage was shown to be the initial cleavage in ITS1 in humans 
(Mullineux and Lafontaine, 2012) and the efficiency of site 2 cleavage is insensitive to 
defects in the cleavage of A0 and site 1 and depends on PES1, BOP1, NOL2, RPL15 and 
RPL26 (Lapik et al., 2004, Preti et al., 2013, Sloan et al., 2013b). 
 
Figure 1.3 rRNA processing in mammals. (A) The rRNA processing pathways in mammals from (Sloan et al., 
2013b). The major pathway is represented by black text and arrows whilst the minor pathway is shown with 
grey text and arrows. The mature rRNAs are shown in orange (large subunit) and blue (small subunit). (B) 
Schematic representation of the rRNA cleavage events in mammals depicting the full length 47S transcript 
with the key cleavage sites (A’, A0, 1, 3, 2a, 2, 4a and 3’) and spacer regions (ITS1, ITS2, 5’ETS, 3’ETS) 
mapped. The bars represent the rRNAs whilst the lines represent the transcribed spacer regions. The 
processed intermediates are shown below the full length transcript and are processed into the mature 18S, 
5.8S and 28S rRNAs as shown at the bottom.  
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Furthermore, it has been demonstrated that there are two pathways for the 
processing of ITS1 in human cells, the major and the minor pathways. In the major 
pathway, site 2 is cleaved and the 5’ end of 5.8S and site 2a is processed by 
exonucleases to produce the 18SE precursor (Preti et al., 2013, Sloan et al., 2013b). 
After nuclear export site 3 is processed by NOB1 to produce the mature 18S (Preti et 
al., 2013, Sloan et al., 2013b). The minor pathway is triggered when 18SE production is 
blocked, resulting in an endonucleolytic cleavage at sites 2 and 2a. RRP6, a component 
of the exosome then processes to site 2a (Sloan et al., 2013b). Recently, hUTP24 has 
been demonstrated to be essential for the processing of the 5'-end of the 18S rRNA 
(Tomecki et al., 2015).  
1.2.2.3 rRNA modifications 
In addition to the processing events, pre-rRNAs also undergo co-transcriptional and 
post-transcriptional covalent modifications (Kos and Tollervey, 2010) which are 
mediated by small nucleolar RNPs (snoRNPs). There are two different modifications 
that take place; 2’-O-methylation and the conversion of uridine to pseudouridine 
(pseudouridylation). Many of the modifications take place in functionally important 
domains and are thus extremely crucial for ribosome function (Decatur and Fournier, 
2002, Ofengand, 2002, Liang et al., 2007, Baudin-Baillieu et al., 2009).   
These two modifications are mediated by two different sub-classes of snoRNPs. The 
first class are BOX C/D snoRNPs that are responsible for 2’-O-methylation whilst the 
second class are BOC H/ACA snoRNPs  involved in pseudouridylation (Watkins and 
Bohnsack, 2012). 2’-O-methylation is important for stabilising base pairing and RNA 
folding whilst pseudouridylation is important for maintaining secondary structures and 
the interactions between rRNA and ribosomal proteins (Helm, 2006, Decatur and 
Fournier, 2002, Decatur and Fournier, 2003).  It has also more recently been shown 
that snoRNPs may have other important roles such as regulating gene expression by 
alternative spicing and gene silencing, and mediating stress responses (Bratkovic and 
Rogelj, 2011, Bratkovic and Rogelj, 2014). 
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1.2.3 Small and large subunit processing and assembly in yeast 
In yeast, after A2 cleavage to separate the large and small subunits, many of the factors 
involved in 60S maturation are assembled onto the pre-rRNA (Grandi et al., 2002, 
Schafer et al., 2003, Tschochner and Hurt, 2003).  The 40S particles contain most 
of the small subunit ribosomal proteins (Ferreira-Cerca et al., 2007) as well as some 
40S biogenesis factors. The 40S particle, in conjunction with the biogenesis factors, is 
exported rapidly to the cytoplasm to complete maturation (Schafer et al., 2003).  
Maturation of the 60S, however, requires more processing prior to its export and final 
maturation in the cytoplasm. There are around 80 factors thought to be involved in the 
maturation of the 60S subunit. One of the main factors involved in the maturation of 
the 60S subunit is the A3 cluster of proteins consisting of Nop7, Erb1, Ytm1, Rlp7, 
Nop15, Nsa3/Cic1 and Rrp1 (Pestov et al., 2001a, Oeffinger et al., 2002, Oeffinger and 
Tollervey, 2003, Fatica et al., 2003, Miles et al., 2005, Wu et al., 2001, Granneman et 
al., 2011, Sahasranaman et al., 2011). Erb1, Nop7 and Ytm1 form a scaffold onto which 
other A3-cluster proteins, exonucleases and ribosomal proteins assemble 
(Sahasranaman et al., 2011, Tang et al., 2008). The A3 cluster of proteins is linked to 
the processing of 27S A3 pre-rRNA which acts to complete the maturation of the 5' end 
of the 5.8S rRNA. Furthermore, most of the A3 factors bind within the pre-rRNA at sites 
close to the 5’ region of the 25S rRNA or the 3’ end of the 5.8S rRNA (Granneman et 
al., 2011). The release of the A3 factors is believed to trigger a conformational change 
within ITS2, triggering further maturation events (Sahasranaman et al., 2011, 
Granneman et al., 2011).  
The dynein-related AAA-ATPase, Rea1 is involved in removing factors from the 60S 
subunit at many steps as it matures and it contacts the pre-ribosome through its ring 
structure (Ulbrich et al., 2009, Nissan et al., 2004). Ytm1, Nop7 and Erb1, all A3 cluster 
proteins, are removed at this stage (Bassler et al., 2010), however Rsa4 and Rea1 
dissociate at a later stage (Ulbrich et al., 2009) after aiding in the recruitment and 
rearrangement of the 5S RNP (Bassler et al., 2015).  
Both the 40S and 60S subunits require transporting to the cytoplasm (see 1.2.3 for 
detail) to finalise their maturation process. After export, the pre-40S and pre-60S 
particles undergo a series of final maturation steps. Once in the cytoplasm, the 
ribosomal protein RPS3 is incorporated into the pre-40S particle whilst Ltv1 and Enp1, 
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ribosomal biogenesis factors, dissociate (Schafer et al., 2006). Most of the factors 
involved in the later stages of 40S maturation have had their binding sites identified 
and it has been proposed that these factors prevent premature association of the 
translation machinery and joining of the subunits (Strunk et al., 2011, Granneman et 
al., 2010).  
The cleavage of the 20S pre-rRNA to the 18S rRNA is one of the final maturation steps 
of the 40S precursor and is mediated by Nob1 (Lamanna and Karbstein, 2009). This 
step is initiated by Fun12, the yeast equivalent of the eIF5b translation initiation factor 
(Lebaron et al., 2012), and involves the general translation termination factors Rli1 and 
Dom34 (Strunk et al., 2012).  
The maturation of the 60S subunit also involves many factors acting in coordination. 
When the pre-60S is exported, all of the ribosomal proteins associate but the non-
ribosomal assembly factors dissociate and are recycled to the nucleus (Hedges et al., 
2005, Hung and Johnson, 2006, Zemp and Kutay, 2007). The AAA-ATPase Drg1 
removes the shuttling proteins Nog1 and Rlp24 (Kappel et al., 2012, Pertschy et al., 
2007). Removal of the RPL24-like protein rlp24 allows for the incorporation of RPL24 
which, in turn, recruits Rei1. Rei1 and Jjj1 promote the release and recycling of factors 
Arx1 and Alb1 (Demoinet et al., 2007). Arx1 is a protein that is found at the ribosome 
exit tunnel and acts to inhibit the association of translation factors (Bradatsch et al., 
2012) and thus removal of this protein is important for the creation of mature 
ribosomes. 
The removal of Tif6 is also an important step in the maturation of the 60S subunit as 
Tif6 (eIF6 orthologue) inhibits ribosomal subunit joining (Gartmann et al., 2010). The 
removal of Tif6 is mediated by Efl1 and Sdo1 and is known to require Arx1 removal 
(Senger et al., 2001, Menne et al., 2007). In order for Efl1 to be able to remove Tif6, 
the formation of the 60S stalk is required which requires the incorporation of the 
ribosomal protein P0 (Lo et al., 2009). The final step is the removal of Nmd3 by Lsg1 
and Rpl10 which requires the prior removal of Tif6 (Hedges et al., 2005). The fully 
matured subunits are then free to join together and translate mRNA into protein.  
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1.2.4 Nuclear export 
For successful export, the subunits have to interact with the hydrophobic channel of 
the nuclear pore complex. Export of both subunits involves the exportin, Xpo1/Crm1, 
several nuclear pore components, and the RanGTPase system. In higher eukaryotes, 
export of the pre-60S complex can occur independently of Crm1 through the export 
factor, Exportin 5 (Wild et al., 2010).  
Crm1 mediates export by recognising molecules with a leucine rich nuclear export 
signal (NES) and is recruited to the 60S subunit via Nmd3 (Ho et al., 2000). The NES 
sequences are found in each pre-ribosome on adapter molecules (Fukuda et al., 1997, 
Zemp and Kutay, 2007). In the nucleus, Crm1 binds to RanGTP and translocates to the 
cytoplasm through a nuclear pore complex. RanGTP is hydrolysed, causing dissociation 
and subsequent release of the pre-ribosomal complexes into the cytoplasm (Zemp and 
Kutay, 2007, Guttler and Gorlich, 2011).  
Other factors have also been thought to be implicated in this process, for example, in 
yeast, Mtr2p, Mex67 and Rrp12 have also been suggested to be involved in the export 
of both subunits (Faza et al., 2012, Oeffinger et al., 2004, Santos-Rosa et al., 1998) 
whilst Arx1, Ecm1, Bud20, and Npl3 have been implicated in the export of the 60S 
subunit (Bassler et al., 2012, Bradatsch et al., 2007, Yao et al., 2010, Hackmann et al., 
2011). 
1.2.5 The 5S RNP recruitment and rearrangement 
One important assembly intermediate of the large subunit is a ribonucleoprotein 
complex (RNP) called the 5S RNP which consists of the 5S rRNA complexed with two 
large subunit ribosomal proteins, RPL5 and RPL11.   
The 5S rRNA is the smallest ribosomal RNA species, the structure of which is generally 
highly conserved throughout most organisms and is found in most ribosomes apart 
from some mitochondrial ribosomes (Bhat et al., 2004). A significant proportion of the 
5S rRNA in the cell is not associated with ribosomes  (Knight and Darnell, 1967, Sloan 
et al., 2013a) and 5S is the only rRNA that forms a pre-ribosomal complex with 
ribosomal proteins prior to integrating into the ribosome (Ciganda and Williams, 2011). 
The 5S RNP is a major component of the ribosome central protuberance, although the 
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5S rRNA is not a component of the peptidyltransferase, decoding or elongation factor 
binding centres and, instead, acts to connect all of these components (Dinman, 2009). 
The biosynthesis of the 5S rRNA depends upon interactions with TFIIIA in the 
cytoplasm to the 5S gene in Xenopus, but it has also been demonstrated that 5S rRNA 
can bind TFIIIA itself (Szymanski et al., 2003, Sloan et al., 2013a). In some organisms, 
the binding of the 5S rRNA and TFIIIA forms the 7S RNP (Layat et al., 2013). In Xenopus 
oocytes, the 7S RNP is stored in the cytoplasm and TFIIIA acts to protect the rRNA from 
degradation (Allison et al., 1991). After transcription, the 5S rRNA contains a 2-3 3’ 
nucleotide extension, which is processed and removed to form the mature 5S rRNA. 
This processing step involves several exonucleases in yeast (Rex1p, Rex2p, and Rex3p) 
(van Hoof et al., 2000) and, more recently, Sloan et al. (2013a) demonstrated that RPL5 
was also essential for this maturation step in humans. 
The integration of the 5S RNP into the ribosome is not yet fully understood but is 
known to require Rrs1 and Rpf2 in yeast. Morita et al. (2002) demonstrated a role for 
Rpf2 and Rrs1 in yeast ribosome biogenesis by showing interactions between Rpf2 and 
Rrs1 and also demonstrating that Rpf2 interacted with RPL11 in the pre-60S ribosome 
particles. Depletion of Rpf2 resulted in a defect in 60S ribosomal subunit assembly 
based on polysome profiling and it was concluded that Rpf2 and Rrs1 were implicated 
in the processing of the 27SB to the 25S rRNA.  
Furthermore, it was shown that Rrs1 and Rpf2 were responsible for the integration of 
the 5S RNP into 90S pre-ribosomes containing the 35S pre-rRNA (Zhang et al., 2007). 
Zhang et al. (2007) further demonstrated that Rpf2, Rrs1, RPL5, RPL11 and the 5S rRNA 
formed a complex in yeast and that depletion of Rpf2 and Rrs1 resulted in a lack of 
integration of the 5S RNP into pre-ribosomes. It was also demonstrated that depletion 
of Rpf2/Rrs1 prevented Rpl10 association with pre-ribosomes. This data suggested an 
essential role of the Rpf2/Rrs1 complex in 5S RNP recruitment.  
Recently, the crystal structure of Rrs1 and Rpf2 complex has been solved in Aspergillus 
nidulans (Asano et al., 2014, Kharde et al., 2015) and yeast (Madru et al., 2015) leading 
to a greater understanding of the role of the Rpf2/Rrs1 complex in 5S RNP recruitment 
in these organisms. Kharde et al. (2015) and Madru et al. (2015) demonstrated that 
Rpf2 interacts with the 5S rRNA but that Rrs1 does not, whilst the whole complex also 
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interacts with RSA4. This interaction with Rsa4 occurs at the UBL domain, which, 
crucially, is involved in the recruitment of Rea1, a dynein-related AAA-ATPase (Ulbrich 
et al., 2009).  
RPL5 and RPL11 are delivered to the nucleus and probably assembled onto the 5S 
rRNA by the symportin, Syo1 (Calvino et al., 2015) to form the 5S RNP. The 5S RNP 
docks onto helix 84 of the 25S rRNA (Rhodin et al., 2011). When the 5S RNP is recruited 
into the ribosome, it is locked into conformation by the C-terminal tail of Rpf2, Rsa4 
and Nsa2 to prevent any rotation (Kharde et al., 2015, Bassler et al., 2015). 
Interestingly, the conformation of the 5S RNP in pre-ribosomes is not the same as that 
found in mature ribosomes (Leidig et al., 2014). Rea1 releases Rsa4 from the 5S RNP 
and rotates the structure by 180o (Bassler et al., 2015, Leidig et al., 2014). This allows 
for the correct formation of the central protuberance (Leidig et al., 2014) and is an 
important step in ribosome formation.  
Whilst Rrs1 and Rpf2 are crucial for the recruitment of the 5S RNP into ribosomes in 
yeast, the role of the human homologues, RRS1 and BXDC1, in human ribosome 
assembly appears to be different. Sloan et al. (2013a) demonstrated that RRS1 and 
BXDC1 do not contact the 5S RNP outside of ribosomes and showed that depletion of 
RRS1 or BXDC1 resulted in a reduction of RPL5 in the nucleolus whilst only depletion of 
BXDC1 had the same effect on RPL11. However, depletion of both proteins increased 
the nucleoplasmic localisation of RPL5 and RPL11. Cross-linking experiments revealed 
that RRS1 and BXDC1 both directly contact the 5S rRNA suggesting that RRS1 and 
BXDC1 directly contact the 5S RNP complex to regulate its nucleolar localisation. 
Interestingly, it was also found that depletion of PICT-1 (also known as Glioma tumour 
suppressor candidate region gene – GLTSRC2), the human homologue of the yeast 60S 
ribosome biogenesis factor, Nop53,  (Thomson and Tollervey, 2005), had a more 
profound effect than depletion of RRS1 or BXDC1 on 5S rRNA ribosomal recruitment. 
PICT-1 was demonstrated to directly contact the 5S rRNA and be required for the 
integration of the 5S rRNA into the ribosome. Unlike RRS1 and BXDC1, PICT-1 had a 
lesser effect on localisation of RPL5 and RPL11, only increasing the levels of 
nucleoplasmic RPL11. This suggested that RRS1 and BXDC1 may not be as important 
for recruitment of the 5S RNP into human ribosomes as they are in yeast, but instead 
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be an important factor for the localisation of the 5S RNP whilst PICT-1 is an important 
integration factor. 
1.2.6 Quality control of ribosome biogenesis 
As ribosome biogenesis is such an energy costly process, ribosome assembly is 
monitored in order to prevent the formation of defective ribosomes. Aberrant or 
stalled pre-ribosomes are picked up by a surveillance system and targeted for 
degradation. It is thought that biogenesis factors are assembled onto the pre-
ribosomal complexes much earlier than they are required in order to provide a quality 
control system. For example, Dim1 is recruited early and its presence, rather than 
dimethylation activity, is required for A0 and A1 cleavages (Lafontaine et al., 1998).  
When ribosome biogenesis is disrupted, pre-RNAs do not accumulate very significantly, 
suggesting that they are unstable and targeted for degradation rapidly (Houseley and 
Tollervey, 2009). Pre-ribosomes that accumulate in the nucleus are degraded by the 
exosome complex (Allmang et al., 2000, Mitchell et al., 1997). Furthermore, a co-factor 
of the exosome, the TRAMP complex, targets the exosome to substrates that are 
destined for degradation (Dez et al., 2006).  
Defective ribosomal subunits that escape the initial degradation and are present in the 
cytoplasm are also targeted for degradation. Ribosomes with mutations in important 
sites such as residues within the peptidyl transfer centre of the large subunit or the 
decoding centre of the small subunit results in the degradation of the RNA 
components by non-functional rRNA decay (NRD) (Cole et al., 2009, LaRiviere et al., 
2006). 
1.3 The tumour suppressor, p53 
The tumour suppressor p53 is a protein that was first identified in 1979 as a protein 
linked to the transformation of cells (Linzer and Levine, 1979, DeLeo et al., 1979). It 
wasn’t until ten years later that p53 earned its title as a tumour suppressor gene 
(Baker et al., 1989, Finlay et al., 1989). It has since become well established for its role 
in malignancy as it is mutated in the majority of cancers (Muller and Vousden, 2013), 
and its involvement in malignancy development earned the protein the title, ‘guardian 
of the genome’ (Lane, 1992). Introduction of mutated p53, which abrogated cell cycle 
arrest activity but retained apoptosis activity, into p53-/- mice demonstrated resistance 
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to spontaneous tumour development compared to p53-/- counterparts (Toledo et al., 
2006). However, mice harbouring a P172R mutation in p53 are deficient in p53-driven 
apoptosis but were still protected from cancer (Liu et al., 2004). This demonstrates the 
versatility of p53 as a tumour suppressor as it exerts its activity by triggering pathways 
such as apoptosis and cell cycle arrest. 
1.3.1 The p53 family of proteins 
p53 belongs to a family of proteins which includes two structural homologs of p53- p63 
and p73. The overall domain structure of the three proteins is conserved (Figure 1.4). 
All three proteins contain a transactivational domain (TAD), proline rich domain (PRD), 
DNA binding domain (DBD) and the oligomerisation domain (OD) (Levrero et al., 2000). 
p63 and p73 also contain an additional sterile alpha motif (SAM) domain, although, 
unlike other SAM domains, these are not involved in homo- or hetero-dimerisation 
(Chi et al., 1999). As p63 and p73 are structural homologues of p53, they are able to 
form oligomers, bind DNA, and transactivate p53 responsive genes much like p53 (Zhu 
et al., 1998, Jost et al., 1997, Yang et al., 1998, De Laurenzi et al., 1998, Melino et al., 
2004, Keyes et al., 2005). However, both p63 and p73 also regulate genes that are not 
targets of p53 (Harms et al., 2004).  
 
Both the TP63 and TP73 genes have two separate promoters, the P1 promoter yields 
the full length proteins with the TAD. The P2 promoter, located in intron 3, yields N-
terminal truncation proteins lacking the TAD, which are referred to as ΔNp63 and 
ΔNp73 (Yang et al., 1998, Senoo et al., 2001). Furthermore, 5’ exon splicing within the 
P1 transcripts of TP73 results in additional isoforms of p73 lacking the TAD known as 
 
Figure 1.4 The domain structure of the p53 family of proteins is highly conserved. Schematic 
representation of the domain structure of p53, p63 and p73. All three proteins contain a transactivational 
domain (TAD), proline rich domain (PRD), DNA binding domain (DBD) and the oligomerisation domain (OD). 
The longest forms of p63 and p73 also contain an additional PRD and a sterile alpha motif (SAM).  
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ΔN’p73, Δex2p73 and Δex2/3p73.(Fillippovich et al., 2001, Stiewe and Putzer, 2002, 
Ishimoto et al., 2002).  
Mutations in TP63 and TP73 are rare in cancers (Nomoto et al., 1998, Park et al., 2000). 
However, ΔN isoforms of p73 and p63 are overexpressed in many different cancer 
types (Uramoto et al., 2006, Uramoto et al., 2004, Dominguez et al., 2006, Wager et 
al., 2006, Park et al., 2000). ΔNp63 and ΔNp73 proteins function as dominant-negative 
inhibitors of the p53 family of proteins by competing for p53 DNA binding sites and 
forming complexes with p63 and p73 over p53 (Stiewe and Putzer, 2002, Chan et al., 
2004, Yang et al., 1998, Grob et al., 2001). Therefore, it is possible that the ΔN isoforms 
of p63 and p73 act as proto-oncogenes by negatively regulating the p53 family of 
tumour suppressors.   
1.3.2 Regulation of p53 via MDM2 and MDMX/MDM4 
The main regulator of p53 is Mouse Double Minute 2 (MDM2- HDM2 in humans), an 
ubiquitin ligase which promotes the ubiquitination and degradation of p53 by targeting 
it to the 26S proteasome (Honda and Yasuda, 1999). Loss of function of MDM2 is 
embryonic lethal in mice due to p53-induced apoptosis (Itahana et al., 2007), thus 
showing the importance for MDM2 in suppression of p53. Furthermore, MDM2 is also 
involved in the suppressing the transactivation potential of p63 and p73 without 
promoting their degradation (Kadakia et al., 2001, Zeng et al., 1999). 
In addition to its involvement in the degradation of p53, MDM2 is responsible for the 
nuclear export of p53 through concealment of  its nuclear localisation signal (Boyd et 
al., 2000) and, furthermore, the binding of MDM2 to p53 also conceals p53’s 
transactivation domain (Kussie et al., 1996). In stressed conditions such as DNA 
damage or chromosomal aberrations, MDM2 is suppressed and leads to the 
stabilisation and activation of p53 (Michael and Oren, 2003). Furthermore, MDM2 is 
regulated at the transcriptional level by a p53 responsive element in its second intron, 
meaning that MDM2 serves as a negative feedback regulator of p53 (Wu et al., 1993).  
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MDMX is a protein that was first identified through its ability to bind to p53 from a 
mouse cDNA library screen (Shvarts et al., 1996). It is homologous to MDM2, most 
notably in its p53 binding domain where both proteins are able to inhibit p53s 
transcriptional activation function (Figure 1.5). However, MDMX, most importantly, 
lacks the E3 ubiquitin ligase activity of MDM2, due to an inactive ring domain and thus 
cannot target p53 for degradation. This means that MDMX has the ability to prevent 
p53 activity without promoting p53 degradation (Jackson and Berberich, 2000). 
Together with the evidence that MDMX-p53 interactions are also far less susceptible 
to treatment with the small molecule inhibitor Nutlin-3 (which blocks interactions 
between MDM2 and p53), it was suggested that the two proteins work through 
different mechanisms (Joseph et al., 2010).  
Initially there were two separate models for the suppression of p53 via MDM2 and 
MDMX; one is whereby the two work in conjunction as a heterodimer, whilst the other 
states that the two proteins have separate, specific roles. In fact, it appears that the 
proteins work both alone and in conjunction with one another to suppress p53.  
1.3.2.1 MDM2 and MDMX working in conjunction  
There is a lot of evidence to suggest that MDM2 and MDMX work together to inhibit 
p53 and that they are dependent on one another for function. Using siRNA 
knockdowns of MDM2 and MDMX, it was found that MDM2 is dependent on MDMX 
for stabilisation whilst MDMX requires MDM2 for shuttling to the nucleus (Gu et al., 
2002).   
MDM2 and MDMX interact with one another through their RING (Really Interesting 
New Gene) finger domains (Tanimura et al., 1999) and are able to form heterodimers 
 
Figure 1.5 The structure of the homologous proteins, MDM2 and MDMX.  A schematic 
representation of the MDM2 and MDMX structure as described in (Wade et al., 2010, Makitie et al., 
2004).  
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as well as homodimers. It was shown that this RING-RING interaction is required for 
the E3 ubiquitin ligase activity of MDM2, suggesting that MDMX is crucial for MDM2s 
main mechanism of action against p53 (Kawai et al., 2007).   
1.3.2.2 MDM2 and MDMX as distinct mechanisms 
MDM2 and MDMX whilst clearly acting in co-operation, have many mechanistic 
differences. MDM2 inhibits p53 mainly through its E3 ubiquitin ligase activity, targeting 
p53 for degradation (Honda et al., 1997) whereas MDMX inhibits p53 by binding to its 
transactivation domain (Danovi et al., 2004).  
Whilst both proteins were found to be crucial for development, it was shown that 
MDM2 deletion in mice lead to apoptosis whilst deletion of MDMX resulted in p53-
dependent cell cycle arrest suggesting alternative mechanisms of action of each 
protein (Chavez-Reyes et al., 2003). There is also a difference between different cell 
types whereby one can be deleted but not the other (Boesten et al., 2006, Grier et al., 
2006). 
1.3.3 Activation of p53 
Several pathways have been identified that lead to p53 activation as summarised in 
Figure 1.6. One such pathway involves activation of p53 through DNA damage such as 
ionising radiation through ataxia telangiectasia mutated (ATM) kinase and the 
checkpoint kinase, CHK2. CHK2 works downstream of ATM and is able to 
phosphorylate p53, preventing MDM2 binding and allowing for p53 activation 
(Vogelstein et al., 2000).  
Another pathway is initiated by growth signals produced by the expression of 
oncogenes such as c-Myc and Alternative Reading Frame (ARF).  ARF, which in humans 
produces a 14kDa protein, p14ARF, is a negative regulator of MDM2 and binds to, 
inactivates and promotes degradation of MDM2, the main suppressor of p53 (Zhang et 
al., 1998), thus inducing p53. Interestingly, p53 provides a feedback loop and has the 
ability to inhibit the transcription of the ARF  gene (Jin and Levine, 2001). Furthermore, 
ARF is activated by c-Myc, an oncogene frequently translocated in Burkitt Lymphoma 
and overexpressed in multiple myeloma (Dang, 2012).  
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The final way that p53 can be activated is by chemotherapeutic drugs and U.V. light 
through interactions with Ataxia Telangiectasia Related (ATR) and casein kinase II (CK2) 
through the phosphorylation of serine 37 of p53, enhancing its transcriptional ability 
(Meek, 1999). 
1.3.4 Transcriptional activation via p53 
Under cellular stress such as DNA damage, oncogene activation, hypoxia, nucleolar 
stress or changes in cellular metabolism, p53 is activated and leads to DNA repair, 
autophagy, senescence, cell cycle arrest or apoptosis through a variety of signalling 
pathways (Ko and Prives, 1996, Timofeev et al., 2013, Sperka et al., 2012, Sugikawa et 
al., 1999, Vogelstein et al., 2000, Vousden and Lane, 2007, Vousden and Prives, 2009).  
1.3.4.1 p53 in the regulation of apoptosis 
One of the main roles that p53 is most commonly known for is its ability to regulate 
apoptosis in cells. Apoptosis is a process often referred to as ‘programmed cell death’ 
and results in cellular death without the loss of membrane integrity (Kerr et al., 1972).  
There are two apoptotic pathways- the extrinsic (death receptor pathway) or the 
intrinsic (mitochondrial pathway) (Elmore, 2007). Both pathways result in the 
activation of molecules known as caspases. Caspases are selective proteases that 
 
Figure 1.6 Pathways for activating p53. A schematic representation of various pathways involved in 
the activation of p53. Ionising radiation leads to activation of ATM kinase which phosphorylates and 
activates CHK2. CHK2, in turn, phosphorylates p53 and activates it. When onocogenes such as Myc 
or ARF are activated, ARF inactivates MDM2, the negative regulator of p53. This allows p53 to be 
active. In U.V damage, ATR activates CK2 which phosphorylates p53 at two sites, leading to 
activation.  
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organise all steps of the apoptotic process (Fan et al., 2005). Caspases exist in the cell 
in an inactive form known as pro-caspases but, when active, break down cellular 
molecules and DNA, and condense chromatin (Cohen, 1997). p53 has been implicated 
in the regulation of both pathways.  
The extrinsic pathway is activated by Tumour Necrosis Factor (TNF) family of proteins 
(Locksley et al., 2001) that activate death receptors resulting in the activation of the 
cell surface Fas receptor (Apo-1 or CD95). Fas interacts with FADD (Fas-associated 
death domain), forming the DISC complex (Death inducing signalling complex).The 
DISC complex activates caspases 3 and 7, resulting in apoptosis (Wajant, 2002, Kischkel 
et al., 1995). The extrinsic pathway can be activated via p53 transcriptional 
upregulation. p53 initiates transcription of Fas (Muller et al., 1998) and the death 
receptor gene, DR5 (Wu et al., 1997). 
 
The intrinsic pathway is a slightly more complex pathway and is also known as the 
mitochondrial pathway as it involves cytochrome c release from the mitochondria 
through the action of the BCL-2 family of proteins. The BCL-2 family of proteins 
contains both pro-apoptotic and anti-apoptotic members. The anti-apoptotic members 
 
Figure 1.7. The intrinsic apoptosis pathway. In normal cells, the anti-apoptotic gene, BCL-XL binds 
to the pro-apoptotic gene, BAX and inhibits its activity. During apoptosis, BAD can bind to BCL-XL, 
displacing BAX. Displaced BAX undergoes a conformational change and binds to the mitochondrial 
membrane, permeabilising it. This allows for the release of cytochrome C from the mitochondria, 
triggering the caspase cascade.  
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inhibit apoptosis and include proteins such as Bcl-2, Bcl-W, Bcl-XL and Mcl-1. The pro-
apoptotic BCL-2 family members can be further subdivided into two groups- the BAX 
family (e.g. BAX, BAK, BOK) and the BH3-only family (e.g. BID, BAD, BIK, PUMA, NOVA) 
(Tsujimoto, 1998).  
In normal cellular conditions, the anti-apoptotic BCL-2 family members are found in a 
complex with the pro-apoptotic BAX family proteins in order to inhibit their function 
and prevent apoptosis. For example, when apoptosis is triggered, BAX (BAX family 
member) is displaced from Bcl-XL by BAD (BH3-only family member) (Yang et al., 
1995). This causes a conformational change in BAX and it is incorporated into the outer 
membrane of the mitochondria (Liu et al., 2003). Once within the mitochondrial 
membrane, BAX increases the permeability of the membrane, releasing cytochrome c. 
This process is summarised in Figure 1.7. Unlike BAX, BAK is always found within the 
mitochondrial membrane but changes conformation during apoptosis to allow for 
permeability (Lindsay et al., 2011).  
Cytochrome C binds to Apoptotic protease activating factor 1 (APAF-1), forming the 
apoptosome, a three-dimensional protein structure formed during apoptosis (Acehan 
et al., 2002). The apoptosome activates procaspase 9 which, in turn, activates caspases 
3 and 7, leading to a caspase cascade and apoptosis (Hill et al., 2004).  
Stabilised p53 regulates the expression of many of the pro-apoptotic genes involved in 
both the intrinsic and extrinsic pathways such as BAX (Miyashita and Reed, 1995), 
NOXA (Oda et al., 2000), PUMA (Nakano and Vousden, 2001), BID (Sax et al., 2002) and 
APAF-1 (Moroni et al., 2001). Aside from its ability to transcriptionally upregulate 
important apoptosis regulatory genes, p53 can also directly influence apoptosis. During 
apoptosis, p53 is also able to migrate to the mitochondrial membrane and can interact 
with Bcl-XL, freeing BAX from the complex. This allows BAX to relocate to the 
mitochondria and trigger cytochrome C release (Wolff et al., 2008).  
Whilst apoptosis is an important anti-tumourigenic mechanism, it is not the main form 
of defence. p53-upregulated modulator of apoptosis (PUMA) is a BCl-2 homology 
domain 3 protein that induces apoptosis through the mitochondrial pathway. PUMA 
was identified for its ability to be activated by p53 in cells undergoing p53-induced 
apoptosis (Nakano and Vousden, 2001, Yu et al., 2001). PUMA null mice showed that 
22 
 
PUMA is required for the apoptotic response to p53 in many tissues (Jeffers et al., 
2003). However, PUMA null mice do not spontaneously develop cancer (Michalak et 
al., 2008) supporting the theory that apoptosis is not the main form of defence against 
cancer and that p53 acts through a diverse range of different pathways to protect cells 
from transformation.  
1.3.4.2 p53 as a cell cycle regulator 
One further way that p53 protects the cells from cancer is through the regulation of 
the cell cycle. Early on it was discovered that p53 had a pivotal role in controlling cell 
cycle progression by transcriptionally activating the cyclin dependent kinase inhibitor, 
p21 (el-Deiry, 1998), Growth Arrest and DNA Damage 45 (GADD45) (Carrier et al., 
1994) and 14-3-3 sigma (Hermeking et al., 1997) as summarised in Figure 1.8. 
 
The cyclin dependent kinase inhibitor, p21 is regulated at the transcriptional level by 
both p53 dependent and independent mechanisms (Gartel and Tyner, 1999). p21 
expression is induced by low levels of p53  (el-Deiry, 1998, el-Deiry et al., 1993) and 
p21 is known to play a pivotal role in growth arrest after DNA damage (Dulic et al., 
1994, Brugarolas et al., 1995) but is not required for p53-mediated apoptosis (Deng et 
al., 1995). The p21 promoter contains two binding sites for p53, at least one of which is 
required for p53 responsiveness after DNA damage (el-Deiry et al., 1995). However, 
p21 can also be upregulated independently of p53 by proteins such as Signal 
transducer and activator of transcription 1 (STAT1), Specificity proteins 1 and 3 (Sp1 
and Sp3) and activator protein 2 (Ap2) (Chin et al., 1996, Gartel and Tyner, 1999). 
 
Figure 1.8 Cell cycle regulation by p53. p53 transcriptionally upregulates the genes encoding 
GAD45, p21 and 14-3-3. GADD45 expression induces G2 arrest by inhibiting Cdc2/cyclin B complexes 
and also induces G1 arrest by interacting with p21. p21 inhibits CDKs to induce G1 arrest. GADD45 
and p21 also bind to PCNA to induce DNA repair pathways. Finally, 14-3-3 induces G2 arrest by 
inhibiting Cdc2.  
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Furthermore, MDM2 is able to negatively regulate p21 by targeting it for degradation, 
independently of p53 (Zhang et al., 2004).  
Early on it was shown that over-expression of p21 leads to a G1, G2 or an S-phase 
arrest (Niculescu et al., 1998, Ogryzko et al., 1997), suggesting a role for p21 in cell 
cycle progression. p21 is a member of the Cip/Kip family of Cyclin-dependent kinase 
(CDK) inhibitors which inhibit the action of cyclin dependent kinases required for cell 
cycle progression. The Cip/Kip family specifically block  transition from G1 phase to S-
phase (Perez-Sayans et al., 2013). If cell cycle arrest is required, expression of p21 
occurs in early to mid G1 and p21 is incorporated into cyclin D-CDK 4/6 complexes to 
inhibit their activity (Sherr and Roberts, 1999). Furthermore, p21 can bind to 
Proliferating cell nuclear antigen (PCNA) (Xiong et al., 1992), a protein involved in DNA 
replication and repair (Warbrick, 2000). The interaction between p21 and PCNA results 
in a block in DNA synthesis via DNA polymerase δ (Waga et al., 1994, Flores-Rozas et 
al., 1994) meaning that p53-regulated p21 induction can also block DNA synthesis as 
well as promote cell cycle arrest.  
Furthermore, p53 transcriptionally upregulates GADD45 (Figure 1.8). GADD45 is 
proposed to have a role in halting the cell cycle arrest at G1 to S-phase transition 
possibly via p21 (Liebermann and Hoffman, 2008). GADD45 interacts with Cdc2 
(CDK1)/Cyclin B complex, causing it to dissociate. The dissociation of the complex halts 
cell cycle progression (Liebermann and Hoffman, 2008). Furthermore, GADD45 
competes with p21 to interact with PCNA to promote DNA repair (Smith et al., 1994, 
Chen et al., 1995).  
p53 has also been shown to interact with the scaffold protein, 14-3-3 (see Figure 1.8) 
to regulate cell cycle (Hermeking et al., 1997). Activation of 14-3-3 also causes G2 
arrest as it prevents the activation of the Cdc2/Cyclin B complex required for G2/M 
phase transition. The checkpoint protein kinases, CHK1 and CHK2 phosphorylate the 
cell cycle protein, Cdc25, allowing it to bind to the scaffold protein, 14-3-3. This binding 
sequesters Cdc2 to the nucleus and prevents G2-M transition (Peng et al., 1997, 
Furnari et al., 1999). Whilst 14-3-3 is transcriptionally upregulated by p53, 14-3-3 can 
directly interact with p53 upon DNA damage to enhance its expression and activity via 
a positive feedback loop (Yang et al., 2003). Furthermore, 14-3-3 over-expression also 
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blocked MDM2-mediated p53 ubiquitination and thus 14-3-3 also regulates p53 
stability (Yang et al., 2003).  
1.3.4.3 p53 and autophagy 
Finally, p53 also plays a role in the regulation of autophagy in cells. Autophagy is a 
process by which dysfunctional or old proteins and organelles are delivered to the 
lysosome for degradation and acts to recycle the cellular components. One way that 
p53 can positively regulate autophagy is through the inhibition of the mammalian 
Target of Rapamycin (mTOR).  
AMP-activated kinase (AMPK) is a negative regulator of mTOR and is activated by p53 
(Feng et al., 2007). AMPK activates a subunit of the tuberous sclerosis complex, 
Tuberous Sclerosis Complex 2 (TSC2) which negatively regulates mTOR (Inoki et al., 
2003). Furthermore, p53 can positively regulate autophagy by transactivating pro-
autophagic genes such as the damage-regulated autophagy modulator (DRAM) (Liu et 
al., 2013). Interestingly, the pro-apoptotic genes upregulated by p53 such as BAX, BAD 
and PUMA have also been shown to play a role in the upregulation of autophagy (Yee 
et al., 2009, Maiuri et al., 2007). Conversely, it is also believed that inactivated, 
cytoplasmic p53 can inhibit autophagy (Tasdemir et al., 2008).  
1.4 The role of the ribosome in p53 signalling 
As the rate of ribosome biogenesis dictates the proliferation rate of the cell, it is 
extremely important to tightly regulate this process. Many studies have shown a link 
between defects in ribosome biogenesis and the activation of p53 (Fumagalli and 
Thomas, 2011). The dysregulation of p53 has been reported in a number of diseases 
known as ribosomopathies. 
1.4.1 Ribosomal proteins and p53 signalling 
Many ribosomal proteins have been shown to bind to MDM2 including RPL23 (Jin et 
al., 2004), RPL26 (Ofir-Rosenfeld et al., 2008), and RPS7 (Chen et al., 2007). All 
ribosomal proteins, apart from RPL11, have been shown to interact with the acidic 
domain of MDM2 as shown in Figure 1.9.  
Immunoprecipitations using over-expressed MDM2 revealed interactions between 
MDM2 and RPL5, RPL11 and RPL23 (Jin et al., 2004). Further to this, it was found that 
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RPL23 binds to MDM2 in a region distinct to that which binds RPL11, thus suggesting 
they do not compete with one another and may act in coordination.  
It was demonstrated by Chen et al. (2007) that, using in vitro pull down assays in yeast, 
RPS7 could directly bind to MDM2 with the absence of any co-factors and that this 
binding occurred at amino acids 180-298 of the MDM2 protein. However, this has 
been debated as the binding site has also been mapped to 273-339 of MDM2 (Zhu et 
al., 2009). It was shown that over-expression of RPS7 in U2OS cells resulted in p53 
stabilisation and activation. Furthermore, Zhu et al. (2009) showed that RPS7 was a 
target for MDM2 ubiquitination, whilst also being able to inhibit the E3 ligase activity 
of MDM2.  Ubiquitination of RPS7 was demonstrated to be able to prevent MDM2-
mediated degradation of p53 and promote apoptosis much more strongly than RPS7 
alone. This suggested that RPS7 ubiquitination via MDM2 is an important regulator of 
p53.  
RPL26 has been shown to function in a slightly different manner. RPL26 binds to the 5’ 
untranslated region of p53 mRNA and is able to control p53 translation after DNA 
damage (Takagi et al., 2005). Furthermore, Ofir-Rosenfeld et al. (2008) established 
 
Figure 1.9 Ribosomal protein binding sites in MDM2. Schematic representation of the MDM2 
protein domain structure showing the location of the p53 binding domain (p53 BD), the nuclear 
localisation signal (NLS), the Nuclear export signal (NES), the acidic domain (AD), the Zinc finger 
domain (Zn) and the RING domain. Ribosomal proteins such as RPL5, RPL23 and RPS7 have been 
shown to interact with the acidic domain of MDM2 whilst RPL11 interacts with the zinc finger 
domain. p53 binds to the p53 binding domain whilst MDMX interacts with the RING domain. Figure 
adapted from Kim et al. (2014).  
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RPL11 (284-374)
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that, using a yeast two-hybrid screen and immunoprecipitations from HEK293 cells, 
RPL26 interacted with MDM2. This MDM2 interaction was found to prevent RPL26 
from binding to p53 mRNA and thus inhibit p53. Interestingly, it was also shown that 
MDM2 was able to polyubiquitinate RPL26 and target it for proteasomal degradation.   
It has since been demonstrated that RPS7, RPL26, or RPL23 were not required for p53 
responses after Actinomycin D (ActD) treatment but that RPL5 and RPL11 were (Bursac 
et al., 2012). ActD is a drug that activates p53 by selectively preventing transcriptional 
elongation of RNA polymerase I (Sobell, 1985) and thus induces ribosomal stress to 
cells without affecting 5S rRNA transcription. As RPL5 and RPL11 were crucial for this 
response and not the other ribosomal proteins, this suggests that it is the 5S RNP 
pathway that is crucial upon ribosomal stress.  One reason that many ribosomal 
proteins interact with MDM2 is that ribosomal proteins are basic in their structure 
(Warner, 1977) and thus may naturally interact with the acidic domain of MDM2. This 
may mean that all of the ribosomal proteins seen to interact with MDM2 are not 
necessarily involved in p53 signalling.  
1.4.2 The 5S RNP and MDM2/p53 
A link between RPL5 and p53 was first established more than 20 years ago. Marechal 
et al. (1994) showed in 3T3DM cells, with immunoprecipitations, an interaction 
between RPL5, MDM2, and p53. Whilst this was an important observation, it was not 
yet clear what the purpose of this complex was. It soon became clear that RPL5 and 
RPL11 were binding partners of MDM2 that could suppress the E2 ligase activity and 
promote p53 activation (Dai and Lu, 2004, Lohrum et al., 2003). 
 
 
Figure 1.10 The 5S RNP interacts with MDM2 to promote p53 signalling. Schematic representation of the 
5S RNP-p53 pathway. The 5S RNP is a complex of RPL11 (maroon), RPL5 (red) and the 5S rRNA (black line). 
Non-ribosomal 5S RNP binds to MDM2 (green), blocking its E3 ubiquitin ligase activity, activating p53 (blue). 
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Initial studies demonstrated that over-expression of RPL5 or RPL11 resulted in the 
stabilisation of p53 (Dai and Lu, 2004, Horn and Vousden, 2008), however it was also 
suggested that the two proteins could also work in co-ordination to activate p53 (Horn 
and Vousden, 2008). Furthermore, RPL11 or RPL5 depletions were able to counteract 
the effects on p53 of ActD treatment to cells (Bhat et al., 2004, Bursac et al., 2012, Dai 
and Lu, 2004). These studies suggested that RPL5 and RPL11 were important for the 
activation of p53 in ribosomal stress situations. However, as RPL5 and RPL11 form a 
sub-complex with the 5S rRNA (the 5S RNP) prior to incorporation into the ribosome 
(Zhang et al., 2007), it was suggested that the 5S RNP complex, rather than RPL5 and 
RPL11 alone, may be involved in the stabilisation of p53 (Fumagalli et al., 2012). The 5S 
rRNA involvement in p53 activation was shown in more recent studies by two 
independent groups (Donati et al., 2013, Sloan et al., 2013a). Like RPL5 and RPL11, the 
5S RNA directly contacts MDM2 and depletion of the 5S RNA was able to reduce the 
p53 response after ActD treatment (Sloan et al., 2013a). Furthermore, these data 
showed that when ribosome biogenesis was blocked by depletion of ribosomal 
proteins or ribosome biogenesis factors, the entire 5S RNP accumulates in the 
nucleoplasm and binds to MDM2 in order to stabilise p53 as demonstrated in Figure 
1.10. Furthermore, it has recently been demonstrated that the 5S RNP is involved in 
maintaining p53 homeostasis in unstressed cells (Sloan et al., 2013a).  
The outcome of 5S-RNP-mediated p53 activation appears to be variable.  Depletion of 
ribosomal proteins, apart from RPL11 and RPL5, in human cell lines results in p53-
dependent cell cycle arrest (Fumagalli et al., 2012), presumably through the 5S RNP 
pathway. Furthermore, RPL5 overexpression in U2OS cells was shown to promote p53-
dependent cell cycle arrest (Dai and Lu, 2004), however in p53 null Saos2 cells, RPL5 
overexpression induces p73-mediated apoptosis (Zhou et al., 2015). SRSF1-RPL5-
MDM2 interactions (described in section 1.5.2) were implicated in inducing cellular 
senescence (Fregoso et al., 2013). In addition, apoptosis in red blood cells, as a result 
of ribosome biogenesis defects and p53 activation, have been implicated in disease 
pathogenesis (described in section 1.6.1)(Danilova et al., 2014). More recently RPL5 
and RPL11 have been shown to be involved in coordinating the regulation of nutrient 
stress with lipid metabolism through p53 signalling (Liu et al., 2014). All these data 
together show the complexity of the 5S RNP-MDM2-p53 pathway.  
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1.4.2.1 Interactions between the 5S RNP and MDM2 
Recently, the crystal structure of RPL11 in a complex with MDM2 has been solved, 
showing the binding regions between the two proteins (Zheng et al., 2015). It was 
revealed that MDM2 binds to RPL11 in the same region that RPL11 binds to the 28S 
rRNA in the ribosome and that MDM2 interacts with RPL11 through an acidic domain 
and two zinc fingers. This supports the work by Zhang et al. (2011) who had previously 
demonstrated that RPL11 binds to distinct regions of the zinc finger domain of MDM2. 
RPL5, however, binds to the acidic domain of MDM2 (Dai and Lu, 2004).  
Furthermore, it has been shown that the 5S rRNA also directly contacts MDM2 but not 
mutant MDM2 that can no longer interact with RPL5 or RPL11 (Sloan et al., 2013a). In 
addition, the interaction between the 5S rRNA and MDM2 was significantly stronger 
when ribosome biogenesis was disrupted.  These data together demonstrate that all 
three components of the 5S RNP directly bind to MDM2 to co-ordinate p53 
stabilisation.  
1.4.3 The 5S RNP and MDMX 
Despite the similarities between MDM2 and MDMX, there have been no reported 
interactions between MDMX and the 5S RNP complex. However, it was shown that 5S 
rRNA binds to MDMX via its RING domain and acts as an inhibitor of MDMX 
degradation by Mdm2 (Li and Gu, 2011).  
p53 activation by ribosomal stress involves degradation of MDMX in an MDM2-
dependent manner (Gilkes et al., 2006). RPL11-MDM2 interactions result in MDMX 
ubiquitination and degradation (Gilkes et al., 2006), suggesting a role for RPL11 in 
regulating p53 via MDMX. In light of recent findings that the 5S RNP binds to MDM2 as 
a whole (Donati et al., 2013, Sloan et al., 2013a), this suggests a more intricate 
pathway for regulation of p53 via the 5S RNP involving MDMX as summarised in Figure 
1.11.  
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1.4.4. The 5S RNP and p73 
As MDM2 is also involved in the regulation of the p53 isoforms, p63 and p73 (Kadakia 
et al., 2001, Zeng et al., 1999), it is unsurprising that the 5S RNP has also been 
implicated in the activation of p73. However, no interactions between p63 and the 5S 
RNP have yet been described.  
Zhou et al. (2015) demonstrated that RPL5 and RPL11 directly bound to p73 
independently of MDM2, preventing MDM2-p73 interactions. Furthermore, the 
authors showed that depletion of RPL5 and RPL11 resulted in a decrease in p73 
activity. As this occurs independently of MDM2, it is unclear whether this involves the 
5S RNP complex or RPL5 and RPL11 proteins independently. However, given that the 
5S rRNA/RPL5 complex is found in high proportions in the cell (Sloan et al., 2013a) and 
ribosomal proteins are generally unstable (Lam et al., 2007), these data taken together 
suggest a role for the 5S RNP in regulating p73.  
 
Figure 1.11 Regulation of MDMX and MDM2 via the 5S RNP. In normal cells, the 5S rRNA binds to the 
RING domain of MDMX and protects it from MDM2-mediated degradation. Upon nucleolar stress, the 5S 
RNP binds to MDM2 and prevents its inhibition of p53, thus activating p53. Furthermore, the binding of 
the 5S RNP to MDM2 results in the polyubiquitination of MDMX via MDM2, resulting in the degradation 
of MDMX. As MDMX is an inhibitor of p53, this activates p53.  
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1.4.5 The 5S RNP-p53 pathway is linked to the expression of 
oncogenes and tumour suppressors 
The 5S RNP-p53 pathway (Figure 1.12) has also been linked to the expression of 
oncogenes and tumour suppressors such as c-Myc and ARF. ARF is able to down-
regulate ribosome biogenesis whilst c-Myc up-regulates it (Stumpf and Ruggero, 2011).  
ARF is a 14kDa protein that is induced by the expression of oncogenes (Zindy et al., 
1998, Palmero et al., 1998). ARF binds to, and inhibits, MDM2, allowing for p53 
activation (Honda and Yasuda, 1999). Furthermore, ARF is able to sequester MDM2 in 
the nucleolus and inhibits the nucleolar export of both MDM2 and p53 (Tao and 
Levine, 1999). The region in which RPL11 and RPL5 contact MDM2 is also a region 
important for ARF binding although the two binding regions do not overlap (Zhang et 
al., 2011) . This suggested that RPL5 and RPL11 may act in a similar way to ARF. 
However, ARF has since been shown to bind to RPL11 (Dai et al., 2012) and RPL11 has 
been shown to be important for ARF-mediated MDM2 suppression. When ARF is 
induced in U2OS cells, p53 and p21 are induced in a 5S RNP-dependent manner (Sloan 
et al., 2013a). This suggests that the entire 5S RNP, including the 5S rRNA, is important 
in ARF signalling to p53. 
 
 
Figure 1.12 The 5S RNP-p53 pathway. A schematic representation of 5S-RNP mediated p53 
regulation. When ribosome biogenesis is disrupted, the 5S RNP is not incorporated into the 
ribosome. It can bind to MDM2 and inhibit its E3 ubiquitin ligase activity, preventing ubiquitination 
of p53 and causing p53 activation. The 5S RNP can also interact with ARF in order to further inhibit 
MDM2.  
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Interestingly, the 5S RNP pathway also has links with the oncogene, c-Myc. When 
investigating the links between RPL11 and MDM2, one important mutation, MDM2 
C305F, was identified from cancer patients, as being able to block RPL11 binding 
(Lindstrom et al., 2007, Zhang et al., 2011). Disruptions in ribosomal protein (RP)-
MDM2 interaction accentuated the p53-mediated response to ribosomal stress and 
caused an increase in c-Myc induced lymphomagenesis (Macias et al., 2010). This is 
interesting as it suggests that the 5S RNP is able to inhibit the oncogene c-Myc and 
that this pathway may also be an alternative protective pathway against c-Myc 
oncogenesis from the canonical ARF-MDM2-p53 pathway. Interestingly, RPL11 is 
involved in a feed-back loop with c-Myc. c-Myc is able to upregulate the transcription 
of RPL11 whilst over-expression of RPL11 inhibits c-Myc induced transcription and 
prevents proliferation of the cell (Dai et al., 2007). More recently, it has been 
demonstrated that RPL5 and RPL11 are able to co-operatively inactivate c-Myc via the 
RNA-induced silencing complex (RISC) (Liao et al., 2014). All these data together 
implicate the 5S RNP in the repression of c-Myc.  
1.5 Regulation of the 5S RNP-p53 pathway 
Regulation of the 5S RNP-p53 signalling pathway is not yet fully understood. It has 
been demonstrated that 5S RNP accumulates in the nucleoplasm upon ribosomal 
stress and it was suggested that any proteins found to affect 5S RNP formation, 
localisation or integration into the ribosome may have a significant role in p53 
regulation via the 5S RNP  (Sloan et al., 2013a).  
Several proteins have been shown to interact with either RPL5 or RPL11 and affect 
their ability to induce p53, but it is not yet understood how this interplays with the fact 
that the whole 5S RNP is required to activate p53 (Donati et al., 2013, Sloan et al., 
2013a). Two proteins have been shown to inhibit p53 signalling via RPL11, PICT-1 (also 
known as GLTSRC2- Glioma tumour suppressor candidate region gene) and PRAS40 
(the proline-rich Akt Substrate of 40kDa) whilst SRSF1 (Serine-Arginine Rich Splicing 
Factor 1) has been demonstrated to be required for p53 activation via RPL5.  
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1.5.1 PICT-1 
One of the potential candidates for regulating the p53 response to ribosomal stress is 
PICT-1. PICT-1 is the human homologue of the yeast protein, Nop53 which is a 60S 
ribosome biogenesis factor (Thomson and Tollervey, 2005). Furthermore, PICT-1 is a 
nucleolar protein that regulates the phosphorylation and stability of Phosphatase and 
Tensin Homologue (PTEN) (Okahara et al., 2004).  PTEN, like p53, is a tumour 
suppressor that is frequently altered in cancer and, when depleted in cells, promotes 
p53 activation (Song et al., 2012). PICT-1 itself has been linked to many different 
cancers such as glioblastoma (Kim et al., 2008), skin carcinomas (Kim et al., 2013), lung 
cancer (Okamura et al., 2014) and breast cancer (Moon et al., 2013).   
Over-expression of PICT-1 has been demonstrated to induce apoptosis in a caspase 
and mitochondrial independent manner (Yim et al., 2007). PICT-1 is frequently located 
in the nucleolus but moves into the nucleoplasm in ribosomal stress situations where it 
is proposed to stabilise p53. PICT-1 achieves this by binding p53 but, crucially, in an 
ARF-independent manner (Lee et al., 2012). As ARF is often down-regulated in cancers, 
this could be an alternative pathway for p53 activation in tumour cells.  
 
In contrast, Sasaki et al. (2011) showed that PICT-1 depletion in cells activated p53.  
PICT-1 was shown to interact with RPL5 and RPL11 but that only RPL11 depletion was 
 
Figure 1.13 The regulation of RPL11-mediated p53 induction via PICT-1. (A) PICT-1 binds to 
nucleolar RPL11, preventing RPL11’s exit from the nucleolus. MDM2 can polyubiquitinate p53 and 
promote its degradation. (B) In the absence of PICT-1, RPL11 can exit the nucleolus and bind to 
MDM2, activating p53 
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able to counter-act the p53 induction after PICT-1 depletion. This suggested that PICT-
1 and RPL11 interaction was important for p53 signalling. PICT-1 depletion also caused 
loss of RPL11 nucleolar localisation, suggesting that PICT-1 sequesters RPL11 to the 
nucleolus as summarised in Figure 1.13. Furthermore, (Uchi et al., 2013) found that 
PICT-1 depletion in a gastric cancer cell line caused p53 activation by preventing p53 
ubiquitination. Cells depleted of PICT-1 were found to arrest in the cell cycle at G1 and 
showed decreased cell growth and an increase in apoptosis markers, all correlating 
with p53 induction.  
As described in Section 1.2.5, it has recently been shown that PICT-1 directly binds to 
the 5S rRNA and facilitates 5S RNP integration into the ribosome (Sloan et al., 2013a, 
Donati et al., 2013). Interestingly, Sloan et al. (2013a) also demonstrated that PICT-1 
was an essential ribosome biogenesis factor. This, combined with the role of PICT-1 in 
integration of the 5S RNP into the ribosome may offer an explanation as to why PICT-1 
was previously shown to retain RPL11 in the nucleolus.  
1.5.2 SRSF1 
SRSF1 (also Alternative Splicing Factor- ASF) is a 28kDa member of the SR protein 
family of splicing factors which are involved in constitutive and alternative splicing as 
well as being involved in mRNA nuclear export, mRNA translation and nonsense 
mediated decay, an RNA surveillance pathway to eliminate mRNAs containing 
premature stop codons (Long and Caceres, 2009).  
SRSF1 was shown to interact with translating ribosomes when SRSF1 is 
hypophosphorylated in the RS domain (Sanford et al., 2004, Sanford et al., 2005) and it 
has since been shown that SRSF1 can enhance translation via the mammalian Target of 
Rapamycin (mTOR) signalling. Michlewski et al. (2008) demonstrated that SRSF1 
interacts with mTOR and Protein Phosphatase 2 (PP2A), two regulators of the 
Eukaryotic translation initiation factor 4E binding protein (4E-BP). 4E-BP is a 
competitive inhibitor of cap-dependent translation (Pause et al., 1994) and thus 
suppression by SRSF1 via mTOR and PP2A results in increased translation. 
Furthermore, SRSF1 regulates alternative splicing of the ribosomal protein S6 kinase 
(S6K). The alternative splicing of S6K produces short isoforms which bind to mTORC1 
and enhance 4E-BP phosphorylation, increasing translation initiation (Karni et al., 
2007, Ben-Hur et al., 2013). Finally, SRSF1 is able to interact with the mTORC1 
34 
 
complex, increasing the phosphorylation of S6K and 4E-BP to enhance translation 
efficiency (Michlewski et al., 2008). 
SRSF1 is upregulated in many cancers such as breast cancer (Anczukow et al., 2012) 
which could possibly be attributed to its ability to be upregulated by c-Myc (Das et al., 
2012). As c-Myc is often up-regulated in cancers and may lead to apoptosis, it could 
potentially do this through interaction with SRSF1. Interestingly, c-Myc is also involved 
in up-regulating ribosome biogenesis by targeting many of the factors involved in 
ribosome biogenesis (Ruggero and Pandolfi, 2003).  
Fregoso et al. (2013) demonstrated a role for SRSF1 in p53 signalling via RPL5. 
Interactions were shown between RPL5 and SRSF1, whereas there was no evidence of 
the involvement of RPL11 or the 5S rRNA. SRSF1 was also found to bind to MDM2 and 
thus it was suggested that RPL5, MDM2 and SRSF1 form a complex to activate p53. 
Furthermore, it has been demonstrated that SRSF1 depletion was able to counteract 
the p53 induction from ActD treatment Fregoso et al. (2013). ActD, at concentrations 
below 10nM is able to stimulate p53 in a specifically 5S-RNP dependent manner and 
thus this suggested that SRSF1 was important for p53 induction via ActD. In addition, it 
was shown that when SRSF1 was over-expressed in human foreskin BJ-TT cells, p53 
was induced in an RPL5 dependent manner. This p53 response resulted in senescence.  
Donati et al. (2013) and Sloan et al. (2013a) both demonstrated that RPL5, RPL11 and 
the 5S RNP were all required for p53 activation in response to ribosomal stress, this 
raises the question as to how SRSF1 is involved. It is possible that the 
SRSF1/RPL5/MDM2 complex forms a distinct complex free from RPL11 and the 5S 
rRNA, as suggested by Fregoso et al. (2013), or that SRSF1 forms a part of the 5S-RNP 
mediated p53 regulation pathway. Further investigation into the role of SRSF1 is 
required to answer this question.  
1.5.3 PRAS40 
 PRAS40 (also known as AKT1S1) is a protein that was first identified as an Akt 
substrate that, when phosphorylated by Akt, is able bind to the scaffold protein 14-3-3 
to activate mTORC1 (Kovacina et al., 2003). PRAS40 is involved in signalling elicited by 
the presence of growth factors, as summarised in Figure 1.14.  
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One of the major pathways that PRAS40 is important for is the regulation of mTORC1. 
mTORC1 is a complex of mTOR, Raptor and Mammalian lethal with SEC13 protein 8 
(mLST8) that promotes cell growth in response to growth signals (Kim et al., 2003, Kim 
et al., 2002, Fonseca et al., 2007). As cell growth is an important process in cells, 
regulation of pathways responding to growth factors is extremely important. One way 
that mTORC1 is regulated is via Rheb, a small GTPase that enables mTORC1 to be in the 
active configuration (Avruch et al., 2006). Akt promotes mTORC1 by inhibiting TSC2, a 
GTPase activating protein that regulates Rheb (Huang and Manning, 2009). This 
inhibition of TSC2 allows Rheb to remain GTP bound and activate mTORC1. mTORC1 
activates many downstream pathways including translation by inhibiting the 
translation inhibitor 4E-BP and activating S6K (Burnett et al., 1998). 
 
 
Figure 1.14. Summary of the role of PRAS40 in the Akt/mTOR and p53 pathways. Non-
phosphorylated PRAS40 binds to raptor, a component of mTORC1, inhibiting the kinase activity. 
Upon growth factor stimulation, Akt can inhibit the action of TSC2, allowing for Rheb-mediated 
activation of mTORC1 leading to increased cell proliferation. Growth signals also promote the 
phosphorylation of PRAS40 by Akt and mTORC1, dissociating it from raptor, activating mTORC1. 
Phosphorylated PRAS40 can bind RPL11, inhibiting its interaction with MDM2. MDM2 
polyubiquitinates p53 and targets it for degradation, therefore growth arrest is inhibited.  
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Another regulator of mTOR via Akt is through PRAS40. Non-phosphorylated PRAS40 
binds to Raptor, a component of mTORC1, and inhibits the kinase activity of mTORC1. 
When growth factors are present, PRAS40 is phosphorylated by mTORC1 and Akt. This 
phosphorylation leads to PRAS40 dissociating from raptor and binding to the scaffold 
protein, 14-3-3 (Thedieck et al., 2007, Fonseca et al., 2007). This then allows for mTOR 
signalling to occur (Figure  1.14).   
Havel et al. (2015) demonstrated, using immunoprecipitations, that nuclear PRAS40 
was able to bind RPL11 and that this binding was dependent upon the phosphorylation 
of PRAS40 via mTORC1 and AKT at residues S221 and T246. Due to the nuclear nature 
of this binding, it was suggested that PRAS40-RPL11 complex does not occur within 
ribosomes. 
Further to this, it was shown that PRAS40 depletion in the human osteosarcoma cell 
line, U2OS, resulted in an increase in p53 protein levels as well as an increase in its 
downstream targets p21 and BAX. This p53 induction upon PRAS40 depletion was 
RPL11 dependent. When ActD was used at levels that increase p53 via the 5S-RNP 
pathway in conjunction with PRAS40 depletion, PRAS40 knockdown was found to have 
an additive effect suggesting that the two pathways were linked. It was hypothesised 
that PRAS40 may inhbit RPL11-mediated p53 signalling (Figure 1.14) by blocking RPL11 
translocation from the nucleoli to the nucleoplasm and thus prevents its interaction 
with MDM2 (Havel et al., 2014), similar to what was hypothesised for PICT-1 (Sasaki et 
al., 2011).    
Interestingly, the complex containing RPL11 and PRAS40 was found to have a high 
molecular weight of between 300-700kDa and thus it was hypothesised that this could 
contain other unidentified proteins. Questions, therefore, arise as to whether these 
proteins could be the other 5S RNP components or, indeed, PICT-1 which appears to 
have a similar role.  
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1.5.4 Post-translational modifications 
1.5.4.1 NEDDylation 
Post-translational modifications are important regulators of proteins in Eukaryotic 
organisms. One such post-translational modification important in regulation of the 5S 
RNP is NEDDylation. NEDDylation is a process that is similar to ubiquitination 
(Liakopoulos et al., 1998), and involves the protein, NEDD8, which shares 60% of 
sequence similarity with ubiquitin (Kumar et al., 1993) and was found, initially, to 
target cullin proteins. E1, E2 and E3 ligases conjugate NEDD8 to lysine residues on 
target proteins (Jentsch and Pyrowolakis, 2000, Brown and Jackson, 2015). 
NEDDylation has been implicated in the regulation of many important cellular 
processes such as apoptosis, DNA damage responses and cell proliferation (Brown et 
al., 2015, Chairatvit and Ngamkitidechakul, 2007, Nagano et al., 2012). 
In a study into finding targets of NEDD8, 36 ribosomal proteins were identified, 
including RPL11. It was discovered that in these ribosomal proteins, NEDDylation acts 
to stabilise the proteins and protect them from degradation and whilst RPL5 was 
identified in this study initially, it was found to show no evidence of NEDDylation 
(Xirodimas et al., 2008).. Interestingly, RPL5 has a greater level of stability than the 
other ribosomal proteins (Lam et al., 2007) and, therefore, may not require this level of 
protection from NEDDylation.  
Further investigations showed a more crucial role in regulation of RPL11 via 
NEDDylation. Sundqvist et al. (2009) showed that, in addition to protecting RPL11 from 
destabilisation, NEDDylation was shown to control the localisation and mobility of 
RPL11 and that prolonged lack of NEDDylation leads to the decrease in RPL11 levels. 
Interestingly, MDM2 is able to promote NEDDylation of RPL11 and protects RPL11 
from destabilisation. ActD treatment was found to decrease NEDDylation of RPL11 and 
cause relocalisation of RPL11 to allow for interaction with p53.  
Further to this, Mahata et al. (2012) demonstrated that RPL11 and NEDD8 were both 
required for acetylation of K832 of p53, resulting in the activation of p53, upon 
ribosomal stress. It was demonstrated that RPL11 is recruited to promoter sites of p53 
regulated genes upon ribosomal stress and that this requires NEDDylation by NEDD8. 
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This, together with the previous reports, indicated the importance of NEDDylation in 
p53 activation via the 5S RNP.  
Zhang et al. (2014) showed that lack of NEDDylation of RPS14 reduced stability of the 
protein and caused mislocalisation, preventing it from interacting with MDM2 and 
activating p53. The NEDDylation of RPS14 could be inhibited by human coilin-
interacting nuclear ATPase protein (hCINAP) which suggested that hCINAP regulated 
p53 signalling via RPS14. No such regulator has yet been discovered for the 
NEDDylation of RPL11, but if found it could have a profound impact on diseases caused 
by 5S RNP signalling defects.  
1.5.5.2 Phosphorylation 
One other important post-translational modification commonly found in cells is 
phosphorylation. Phosphorylation plays a key role in the regulation of p53 signalling as 
described in Section 1.3.4. Furthermore, MDM2 and MDMX are also phosphorylated to 
mediate p53 signalling. Phosphorylation of MDM2 by ATM and C-Abl inhibits p53 
degradation upon DNA damage (Goldberg et al., 2002, Maya et al., 2001). 
Furthermore, DNA damage results in phosphorylation of MDMX via Chk1, Chk2 and 
ATM, activating p53 (Jin et al., 2006, Chen et al., 2005). Some ribosomal proteins such 
as RPS3, RPS6, RPS14 and RPL5 have been found to be phosphorylated (Ruvinsky and 
Meyuhas, 2006, Kim et al., 2009, Lee et al., 2010, Park and Bae, 1999, Bialik et al., 
2008, Ventimiglia and Wool, 1974).  
Phosphorylation of RPS6 by the ribosomal protein S6 kinase (S6K) has been shown to 
regulate glucose metabolism, cell size and is important for the translation of 5’ 
terminal oligopyramidine tract (TOP) mRNAs (Ruvinsky and Meyuhas, 2006). Despite 
RPS6 being shown to be involved in the activation of p53 (Fumagalli et al., 2009), it has 
since been demonstrated that depletion of RPS6 results in 40S ribosome biogenesis 
defects (Fumagalli et al., 2012) and presumably this results in 5S RNP-mediated p53 
activation. However, phosphorylation of RPS6 has also been shown to be present in 
higher levels in pancreatic cancer and mice deficient for RPS6 phosphorylation were 
found to have increased p53 levels (Khalaileh et al., 2013), suggesting that 
phosphorylation may play a role in p53 signalling via ribosomal proteins.  
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Several phosphorylations have been reported in RPL5 and RPL11, according to 
Phosphosite (http://www.phosphosite.org). RPL5 has 17 reported phosphorylation 
sites whilst there are 8 reported for RPL11 (Figure 1.15). Park and Bae (1999) 
demonstrated that RPL5 could be phosphorylated by Casein Kinase 2 (CK2), a highly 
conserved serine/threonine kinase that is involved in cell cycle control and DNA repair 
(St-Denis and Litchfield, 2009). Using the yeast two-hybrid system, Park and Bae (1999) 
demonstrated that RPL5 was able to interact with the β-subunit of CK2, which is 
responsible for substrate binding. By expressing and purifying human RPL5 in E.coli, 
phosphorylation of RPL5 was observed upon the addition of purified CK2 protein. 
Further analysis revealed that the phosphorylations by CK2 were exclusively serines in 
the regions of amino acids 142-200 and 272-297 of the RPL5 protein. Interestingly, 
RPL5 that had been incubated with CK2 and ATP prior to binding to the 5S rRNA 
showed a reduced binding efficiency for the 5S rRNA, suggesting that these 
phosphorylations block the formation of the 5S RNP.  
 
RPL5 was also shown to interact with other kinases and phosphatases although their 
role in the regulation of RPL5 is unclear. RPL5 was demonstrated to interact with 
Death-associated protein kinase (DAPk) using high throughput screening from HeLa 
cell extracts (Bialik et al., 2008). Whilst phosphorylations occurred when DAPk and ATP 
were incubated with RPL5, it was concluded that RPL5 was a weak substrate and thus 
was not able to be studied further. Furthermore, RPL5 has also been shown to interact 
with a phosphatase, Protein Phosphatase Type 1 (PPI) in yeast two-hybrid screening 
(Hirano et al., 1995) although it remains unclear as to the importance of this 
interaction. As phosphorylation plays a key role in p53 signalling (Meek, 1999, 
 
Figure 1.15 Phosphorylation sites reported in RPL5 and RPL11. (A) A schematic representation of the 
tyrosine (blue), serine (red) and threonine (black) phosphorylation sites reported in RPL5 on 
Phosphosite (http://www.phosphosite.org). (B) As in A, showing the phosphorylation sites reported in 
RPL11.  
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Goldberg et al., 2002, Maya et al., 2001) (Jin et al., 2006, Chen et al., 2005), it is 
possible that phosphorylation of RPL5 or RPL11 may play a role in p53 regulation.  
1.6 Diseases as a result of aberrant ribosome biogenesis 
Defective ribosomes and, consequently, the activation of p53, can lead to diseases 
known as ribosomopathies which have increased cancer risk levels. The clinical 
features of ribosomopathies can be variable although many patients exhibit anaemia 
and a predisposition to cancer. 
 
Some examples of well-characterised ribosomopathies include Diamond Blackfan 
Anaemia, 5q-syndrome and Treacher Collins Syndrome but ribosomal defects not 
resulting in ribosomopathies have also been implicated in cancer such as acute 
myeloid leukaemia (AML).  
 
Disease Gene defect Cancer risk References 
Diamond 
Blackfan Anaemia 
RPS19, RPS24, RPS17, RPL36, 
RPL35A, RPL5, RPL11, RPS7, 
RPS15, RPS27A 
Osteosarcoma, 
MDS, AML 
(Cmejla et al., 2009, 
Gazda et al., 2008, 
Delaporta et al., 2014) 
5q-syndrome RPS14 AML 
(Barlow et al., 2010, 
Boultwood et al., 2007) 
Schwachman-
Diamond 
Syndrome SBDS MDS, AML 
(Shammas et al., 2005, 
Elghetany and Alter, 
2002) 
Dyskeratosis 
Congenita DKC1 
AML, Head and 
neck tumours (Zhang et al., 2012) 
Treacher Collins 
syndrome TCOF1 None reported 
(Wise et al., 1997, 
Jones et al., 2008) 
Autism RPL10 None reported 
(Klauck et al., 2006, 
Chiocchetti et al., 2011, 
Gong et al., 2009) 
Hereditary 
Hypotrichosis 
simplex RPL21 None reported (Zhou et al., 2011) 
X-linked 
microcephaly RPL10 None reported (Brooks et al., 2014) 
X-linked 
syndromic 
intellectual 
disability RPL10 None-reported (Thevenon et al., 2015) 
 
Table 1.1 Diseases of ribosome biogenesis dysfunction 
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1.6.1 Diamond Blackfan Anaemia 
Diamond Blackfan Anaemia (DBA) is characterized by a severe reduction in erythroid 
precursor cells due to apoptosis or a failure to differentiate (Quarello et al., 2010b). 
These patients are also predisposed to cancers such as leukaemia, osteogenic sarcoma 
and myelodysplastic syndrome (Lipton et al., 2001). 40% of DBA patients also present 
with growth defects and congenital abnormalities and solid tumours (Lipton et al., 
2006).  
Many of the mutations found in patients with DBA have been in the genes encoding 
ribosomal proteins, including the ribosomal proteins RPS7, RPS19, RPS27, RPS26, 
RPL27, RPL5, RPL11 (Smetanina et al., 2015, Wang et al., 2015, Mirabello et al., 2014, 
Konno et al., 2010). 50-70% of all DBA patients present with a mutation in ribosomal 
proteins and 25% of all cases have mutations in RPS19 (Horos and von Lindern, 2012, 
Pereboom et al., 2014).  
As the most common ribosomal protein defect found in DBA patients, RPS19 has been 
studied in detail. RPS19 knockdowns lead to a block in ribosome biogenesis and 
activation of p53 through the 5S RNP (Choesmel et al., 2007, Flygare et al., 2007). It 
has also been demonstrated that disruption of ribosomal proteins is associated with 
decreased translation in many different cell types (Gazda et al., 2006, Avondo et al., 
2009), which may account for why the symptoms of the disease can be so variable.   
Mutations in RPL5 and RPL11 are associated with distinct symptoms in DBA (Gazda et 
al., 2008, Quarello et al., 2010b). RPL5 mutations have been linked to cleft palate 
whilst RPL11 has been linked to thumb abnormalities (Gazda et al., 2008). In one study, 
half of all of the patients with RPL5 mutations were found to have multiple severe 
abnormalities, whereas patients with RPL11 or RPS19 mutations were rarely found to 
have such severe symptoms (Gazda et al., 2008).  
The pathogenesis of DBA was originally thought to be due to the fact that red blood 
cell precursors proliferate rapidly (Lajtha and Oliver, 1961) and thus require rapid 
production of ribosomes during their proliferation and differentiation. Therefore, if 
there is a reduction in ribosome synthesis, this will affect the erythroid precursors 
quite drastically (Zhang et al., 2011). However, since defects in ribosomal proteins or 
ribosome biogenesis factors result in p53 activation (Sloan et al., 2013a), it has also 
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been proposed that these defects are due to accumulation of p53 and thus cell-cycle 
arrest and apoptosis in these erythroid cells (Dai and Lu, 2004, Danilova et al., 2014). 
Interestingly, Kummalue et al. (2015) found that RPL11 expression in erythroleukaemic 
cells caused activation of STAT5 and resulted in the cells being able to proliferate in the 
absence of erythropoietin, a growth factor involved in red blood cell development 
(Ridley et al., 1994). Signal Transducer and Activator of Transcription 5 (STAT5) is part 
of the STAT family of proteins and acts as promoter of angiogenesis (Yang and Friedl, 
2015) and, subsequently, is associated with a range of cancers (Tan and Nevalainen, 
2008). This suggested that RPL11 is able to increase erythroid cell proliferation and 
may give some explanation as to why deficiencies in ribosomal proteins often result in 
blood disorders.  
There is need for a greater understanding of the pathogenesis of DBA as there are few 
effective treatments available apart from blood transfusions and bone marrow 
transplants. One current treatment for DBA is treatment with glucocorticoids (Vlachos 
et al., 2008). Loss of the glucocorticoid receptor in mice resulted in anaemia (Bauer et 
al., 1999) and p53 was able to block glucocorticoid-induced proliferation in erythroid 
precursors, hinting that p53 may play a pivotal role in the effectiveness of this 
treatment in DBA patients. Recently, Sjogren et al. (2015) showed that in RPS19 
deficient mice, glucocorticoid treatment counteracted p53 activation and supported 
the idea that glucocorticoids act in DBA to dampen down the p53 response and 
promote proliferation in erythroid cells.  
One other promising treatment of DBA is treatment with L-leucine. As DBA results in 
translational defects (Cmejlova et al., 2006) and L-leucine has been shown to regulate 
translation through mTOR (Kimball and Jefferson, 2006), L-Leucine was trialled as a 
potential therapeutic for DBA. Initial tests in zebrafish and mouse models of DBA show 
improvement in their anaemia upon L-leucine treatment (Boultwood et al., 2013, 
Jaako et al., 2012, Payne et al., 2012). Furthermore, it was shown in a mouse model for 
DBA that L-leucine treatment reduced p53 levels (Jaako et al., 2012). In patient trials, it 
appeared to be an effective treatment and within 6 months the patient tested became 
transfusion independent and showed increased erythroid differentiation (Pospisilova 
et al., 2007). This is interesting as leucine is known to trigger the mTOR pathway which 
has recently been closely linked to the 5S RNP via PRAS40 (Havel et al., 2014).  
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Investigation of this link may further the understanding of the regulation of the 5S RNP 
and make treatment of DBA more effective. 
1.6.2 5q-syndrome 
5q-syndrome is a myelodysplastic syndrome that shares many similarities with DBA 
such as anaemia, decreased erythroid precursors and a predisposition to AML 
(Vardiman et al., 2002). Like DBA, 5q syndrome has also been linked with ribosome 
defects as cells from the bone marrow of patients with 5q syndrome showed rRNA 
processing defects (Ebert et al., 2008).  
5q-syndrome is a very distinct form of myelodysplastic syndrome characterised by 
deletion of the long arm of chromosome 5 (Van den Berghe et al., 1974). One of the 
proteins affected by this deletion is RPS14. Boultwood et al. (2007) detected 
haploinsufficiency of RPS14 in a group of patients with 5q syndrome using micro-array 
based gene expression profiling of CD34+ bone marrow cells from 5q syndrome 
patients compared to healthy individuals. This suggested that RPS14 may be an 
important gene in the pathogenesis of 5q syndrome. Subsequently, depletion of RPS14 
in CD34++ haematopoietic stem cells was shown to mirror the defects seen in 5q-
syndrome, which could be rescued by over-expression of RPS14 (Ebert et al., 2008). 
This was supported by the evidence of a mouse model for the disease, whereby RPS14 
is disrupted (Barlow et al., 2010).  
An effective treatment for 5q-syndrome is the drug Lenalidomide (Messingerova et al., 
2015, Wei et al., 2013). Lenalidomide is commonly used as a treatment for multiple 
myeloma and is known to promote erythroid differentiation (Narla et al., 2011) as well 
as promoting degradation of p53 (Wei et al., 2013). Lenalidomide has been shown to 
inhibit two phosphatases involved in G2-M checkpoint control, Protein Phosphatase 2A 
catalytic subunit α (PP2Acα) and Cell division cycle 25 (CDC25C), which are located on 
5q and deleted in many patients with 5q-syndrome (Wei et al., 2009). The ability of 
Lenalidomide to suppress p53 and specifically target phosphatases already 
downregulated in 5q syndrome (PP2Acα and CDC25C) explains the selective toxicity 
seen in just the 5q deleted cells. However, Tehranchi et al. (2010) reviewed 7 patients 
with 5q syndrome that had responded well to Lenalidomide treatment and found that 
most patients developed Lenalidomide resistance over time and relapsed. This 
suggested that new therapies or a combination of therapies were needed.  
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Similar to Diamond Blackfan Anaemia, treatment with L-leucine has had some 
promising results in the treatment of 5q-syndrome. In CD34+ cells with RPS14 
depletion and cells from 5q syndrome patients, L-leucine treatment resulted in 
increased differentiation and proliferation of the cells (Yip et al., 2012). Furthermore, 
zebrafish models of 5q syndrome showed improvement in red blood cell count after 
treatment with L-leucine (Payne et al., 2012). However, whilst L-leucine treatment has 
initially proven to be successful in DBA patient trials, its efficacy in treating 5q 
syndrome in human trials seems less successful. Steensma and Ebert (2013) treated 
three 5q syndrome patients with L-leucine for 3 months and found that whilst there 
were no adverse effects, their symptoms were not alleviated. In fact, two of the 
patients only found relief from blood transfusions after Lenalidomide treatment. 
Lenalidomide, as previously explained, has some adverse effects and patients taking 
the drug often relapse. Therefore, it is important that the role of the 5S RNP-signalling, 
which may provide the crucial link between L-leucine and ribosomopathies, is better 
understood.  
1.6.3 Treacher Collins Syndrome 
Treacher Collins syndrome (TCS) is a rare autosomal dominant disease, affecting 
around 1 in 50,000 births (Fazen et al., 1967, Rovin et al., 1964), which is characterised 
by aberrant neural crest cell development (Ross and Zarbalis, 2014) resulting in 
craniofacial defects. Neural crest cells are the cells that give rise to cartilage, nose, and 
connective tissue in the face and head.  They are almost stem-cell like in nature due to 
their ability to differentiate into a range of different cell types and their self-renewal 
properties (Ross and Zarbalis, 2014). There are a wide range of developmental 
abnormalities seen in TCS patients, including alterations to the size, shape and position 
of the external ears, dental malocclusion, cleft palate and ophthalmic abnormalities 
(Trainor et al., 2009). 
The most common defect found in TCS patients is in the gene Treacher-Collins-
Franceschetti syndrome 1 (TCOF1) which encodes for a protein called treacle (Wise et 
al., 1997). Treacle is a nucleolar phosphoprotein that is involved in rRNA transcription 
through interactions with the upstream binding factor, UBF and RNA polymerase I 
(Valdez et al., 2004). Mutations in TCOF1 have been shown to lead to ribosome 
biogenesis defects, p53 stabilisation and thus cell cycle arrest at G1 (Jones et al., 2008). 
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Interestingly, mutations have also been found in genes that encode for subunits of the 
RNA polymerases I and III. Dauwerse et al. (2011) found that patients deficient for 
TCOF1 mutations often had mutations in the POLR1D gene that encodes for a subunit 
for RNA polymerases I and III. The 5S rRNA is transcribed by RNA polymerase III and 
the other rRNAs are transcribed as a single precursor by RNA polymerase I, suggesting 
that all rRNA synthesis is affected in these patients and not just the 28S, 5.8S and 18S 
as with TCOF1 mutations.  
Unlike DBA and 5q syndrome, Treacher Collins syndrome does not present with blood 
related symptoms or cancer predisposition. The main treatments for TCS have been 
surgical in order to reconstruct the facial abnormalities (Trainor et al., 2009) and may 
result in several surgeries throughout the patient’s life. A greater understanding of the 
pathogenesis of ribosomopathies in general may help to lead to more treatment 
options in the future.  
1.6.4 Cancers 
As ribosome biogenesis defects result in aberrant p53 signalling, it is not surprising 
that ribosome biogenesis defects have been linked to cancer as p53 is mutated or lost 
in around half of cancers (Vogelstein et al., 2000).  
Both Diamond Blackfan Anaemia and 5q-syndrome result in a predisposition to cancers 
such as leukaemia (Khanna-Gupta, 2013). Furthermore, mutations in both RPL5 and 
RPL10 were described in patients with T-cell acute lymphoblastic leukaemia (T-ALL). 
Keersmaecker et al. (2013) described a common mutation, R98S, in RPL10 in five 
patients. Expressing these mutants in yeast resulted in ribosome biogenesis defects 
and a decrease in proliferation, suggesting a role for RPL10 in ribosome biogenesis. 
This raised the question as to why this mutation that decreases cellular proliferation 
could result in cancer which is characterised by an overgrowth of cells. Further 
investigation into this mutation revealed that the mutation resulted in a late-stage 60S 
ribosome biogenesis defect resulting in a decrease in proliferation, especially in rapidly 
dividing cells such as blood cell precursors (Sulima et al., 2014).  However, after time, it 
was seen that the cells were subjected to selective pressure, favouring cells that 
harboured mutations in proteins involved in ribosome quality control. This resulted in 
the rapid proliferation of cells with defective ribosomes without quality control 
mechanisms in place. This research was pivotal in understanding how ribosomopathies 
46 
 
result in cancer and may lead to prevention of cancer in ribosomopathy patients in the 
future.  
Interestingly, mutations in RPL22 have also been described in T cell acute 
lymphoblastic leukaemia (T-ALL) (Rao et al., 2012). Loss of RPL22 was shown to 
accelerate the development of lymphoma in a mouse model, suggesting a link 
between RPL22 and transformation of cells. However, the emergence of a role of 
ribosomal proteins in cancer is fairly recent and thus very little is currently known 
about whether targeting these proteins could act as a potential therapeutic.    
1.6.4.1 The nucleolus and cancer 
Large and abnormal nucleoli were observed very early on in cancer cells by the Italian 
pathologist Giuseppe Pianese (Pianese, 1896) and since then a strong correlation has 
been made between nucleolar morphology and cancer (Figure 1.16). In some cases, 
nucleolar size is used as a marker for clinical outcome- with larger nucleoli indicating a 
poor prognosis (Derenzini et al., 1986, Derenzini et al., 1989). Furthermore, changes in 
nucleolar morphology help to indicate a patient’s response to chemotherapeutic drugs 
(Derenzini et al., 1998).  
 
One nucleolar protein, NPM (nucleophosmin/B23, encoded by the gene NPM1) is 
mutated in several different cancers, including gastric, colon, ovarian and prostate 
carcinomas (Tanaka et al., 1992, Nozawa et al., 1996, Shields et al., 1997, Subong et al., 
1999), Anaplastic Lymphoma Kinase (ALK)+ Anaplastic Large Cell Lymphoma (ALCL), 
 
Figure 1.16 Nuclear morphology in cancer.  Electron micrographs showing changes in nucleolar 
morphology in wild type mouse prostate cells (A) or in a mouse model for prostate cancer (B). 
Arrows indicate the nucleoli. Adapted from (Koh et al., 2011).  
A B
Wild type Prostate cancer
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(Morris et al., 1995) and AML (Falini et al., 2005). NPM has been shown to be involved 
in ribosome biogenesis, the nucleolar export of the RPL5/5S rRNA complex, protein 
chaperoning and centrosome duplications (Yu et al., 2006, Feuerstein et al., 1988, 
Kondo et al., 1997, Okuda et al., 2000, Okuwaki et al., 2001). Furthermore, NPM is 
involved in p53 signalling. ARF and NPM co-localise to the nucleolus (Gallagher et al., 
2006) where NPM protects ARF from degradation (Colombo et al., 2005) and maintains 
basal ARF levels in the nucleolus (Sherr, 2006). Under cellular stress conditions, NPM 
and ARF exit the nucleoli and MDM2 and NPM compete for ARF binding. The 
formation of ARF-MDM2 and NPM-MDM2 results in the activation of p53 (Lee et al., 
2005, Kurki et al., 2004). In addition, NPM is able to directly bind to p53 to promote 
p53 stabilisation and activation (Colombo et al., 2002).  
NPM1 mutations exist in around 30% of adult AML cases leading to an increase in 
mutant cytoplasmic NPM (Falini et al., 2005, Falini et al., 2007b). In a mouse model, 
overexpression of cytoplasmic mutant NPM resulted in a proliferative advantage of 
myeloid lineage cells (Cheng et al., 2010), whereas in D. rerio, expression of the 
cytoplasmic mutant NPM resulted in the expansion of hematopoietic cells (Bolli et al., 
2010), suggesting that, in AML, NPM1 mutations contribute to the pathogenesis of the 
disorder. In 85% of ALK+ ALCL cases, a translocation exists between the ALK and NPM1 
genes causing constitutive expression of a the NPM-ALK fusion kinase (Falini et al., 
2007a, Morris et al., 1995).  
One other nucleolar protein thought to be involved in the activation of p53 is Myb-
binding protein 1a (MYBBP1A), a predominantly nucleolar transcription factor involved 
in p53 acetylation and stabilisation (Kumazawa et al., 2015, Ono et al., 2014). 
MYBBP1A translocates to the nucleoplasm during ribosomal stress to activate p53 in 
an RPL5 and RPL11 dependent manner (Kuroda et al., 2011, Ono et al., 2014). This, 
therefore, suggests a link between the 5S RNP and MYBBP1A.  
1.6.5 Other diseases as a result of aberrant ribosome biogenesis  
Ribosomal proteins have also been implicated in other diseases such as Schwachman-
Diamond Syndrome, Dyskeratosis congenita (DC), Parkinson’s disease, Autism 
spectrum disorder, X linked microcephaly, X-linked syndromic intellectual disability and 
hereditary hypotrichosis simplex.  
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Schwachman-Diamond Syndrome is a rare disorder characterised by haematological 
abnormalities, exocrine pancreatic insufficiency, decreased neutrophils in the blood, 
and an increased cancer risk (Myers et al., 2013). Approximately 90% of Schwachman-
Diamond Syndrome patients have mutations in the Shwachman-Bodian-Diamond 
syndrome (SBDS) gene. The SBDS protein, which binds to NPM, has been implicated in 
ribosome biogenesis (Austin et al., 2005, Ganapathi et al., 2007, Finch et al., 2011), 
suggesting that ribosome biogenesis plays a role in the pathogenesis of the disease. 
Furthermore, aberrant p53 expression has been demonstrated in Schwachman-
Diamond Syndrome patients (Elghetany and Alter, 2002) although no links to the 5S 
RNP have yet been made.   
One other ribosomopathy is DC which is a highly heterogeneous disease characterised 
by bone marrow failure, predispositions to cancer, reticular skin pigmentation and 
immune deficiencies (Alter et al., 2009, Mason and Bessler, 2011).There are many 
different modes of inheritance of DC, the X-linked form of DC is linked to rRNA 
processing defects and arises from mutations in the DKC1 gene (Heiss et al., 1998, 
Knight et al., 1998) whilst autosomal dominant DC is linked to defects in the 
telomerase, TERT (Vulliamy et al., 2001, Basel-Vanagaite et al., 2008). The DKC1 gene 
encodes dyskerin, a component of the telomerase complex (Brault et al., 2013) and 
part of the H/ACA snoRNP complex involved in pseudouridylation. The p53 status in DC 
remains unclear. Mouse models for DC have shown reductions in p53 levels (Bellodi et 
al., 2010), whereas studies in D. rerio have shown that p53 is activated when dyskerin 
levels are reduced (Ying Zhang et al., 2012). There is much debate about the 
pathogenesis of DC and it remains unclear whether DC is caused by defects in telomere 
maintenance or ribosome biogenesis due to the different complexes that dyskerin is 
involved in. However, due to the phenotypic similarities between DC and 
ribosomopathies such as DBA and 5q-syndrome, it is likely that ribosome biogenesis 
defects play a role in the pathogenesis of DC.  
Although no ribosome defects have not been reported in Parkinson’s disease directly, 
altered RPS6 expression has been reported in brains of patients with Parkinson's 
disease (Papapetropoulos et al., 2006). Furthermore, it was shown that the bacterial 
homologue of the parkinsonism-associated protein DJ-1 was related to translation 
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defects and resulted in the aggregation of many ribosomal proteins (Kthiri et al., 2010), 
suggesting a link between ribosomes and Parkinson’s disease.  
Finally, mutations in the large subunit ribosomal protein, RPL10, have been linked to 
several neuronal diseases such as autism (Klauck et al., 2006, Chiocchetti et al., 2011, 
Gong et al., 2009), X-linked microcephaly (Brooks et al., 2014), and X-linked syndromic 
Intellectual Disability (Thevenon et al., 2015). Furthermore, RPL21 mutations have 
been reported in hereditary hypotrichosis simplex (Zhou et al., 2011). However, the 
link to p53 in these diseases has not been characterised. 
1.7 Project aims and objectives 
The links between the ribosomal proteins and MDM2 have been established for some 
time. However, it is only recently that it has been elucidated that the 5S RNP-MDM2 
interaction is crucial for p53 activation when ribosome biogenesis is disrupted (Donati 
et al., 2013, Sloan et al., 2013a). Furthermore, it has been shown that the 5S RNP is 
involved in maintaining normal p53 homeostasis (Sloan et al., 2013a). Ribosome 
biogenesis defects and subsequent p53 activation has been implicated in a number of 
diseases known as ribosomopathies (Fumagalli and Thomas, 2011) and, therefore, 
understanding how the 5S RNP signalling pathway is regulated may lead to novel 
treatments for these diseases.  
As only non-ribosomal 5S RNP can activate p53, integration into the ribosome is a 
crucial step in the regulation of the 5S RNP. In yeast it is known that Rrs1 and Rpf2 are 
required for integration of the 5S RNP into the ribosome (Kharde et al., 2015, Morita et 
al., 2002, Zhang et al., 2007). It has been shown that the 5S RNP docks onto the 
25S/28S rRNA and is subsequently rotated 180o in order to form the central 
protuberance (Leidig et al., 2014). However, it has been recently demonstrated that 5S 
RNP recruitment may differ in human ribosomes as the human Rpf2/Rrs1 homologues 
BXDC1/RRS1 do not interact with the 5S RNP outside of pre-ribosomes and were 
shown to be less important in 5S RNP recruitment (Sloan et al., 2013a). Therefore, it is 
important to further explore the factors involved in 5S RNP recruitment as it appears 
to differ between humans and yeast.  
One way that the 5S RNP recruitment may be regulated is through post-translational 
modifications. Post-translational modifications such as ubiquitination, acetylation and 
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phosphorylation are common in p53 signalling and thus it follows that the 5S RNP may 
be modified in a similar way. Indeed, RPL11 has been shown to be NEDDylated by 
MDM2 to protect it from degradation. Furthermore, RPL11 and RPL5 both have 
multiple phosphorylation sites which may affect 5S RNP-mediated p53 signalling by 
blocking 5S RNP incorporation into the ribosome.  
Finally, two proteins, SRSF1 and PRAS40, were shown to interact with the 5S RNP 
components to regulate p53 signalling. In light of the recent findings that the 5S RNP is 
required to activate p53 (Donati et al., 2013, Sloan et al., 2013a), it is possible that 
these proteins regulate the 5S RNP-mediated p53 pathway. Interestingly, SRSF1 and 
PRAS40 are both involved with the regulation of the mTOR signalling pathway. One of 
the successful treatments for the DBA, has been leucine treatment which activates 
mTOR and thus investigation of SRSF1 and PRAS40 may help to uncover the 
mechanism by which leucine treatment is successful.  
Therefore, this project aimed to:  
 Further elucidate the factors involved in 5S RNP recruitment into the ribosome 
in human cells.  
 Determine the role of RPL5 phosphorylation in 5S RNP-mediated p53 signalling.  
 Evaluate the role of SRSF1 and PRAS40 in the regulation of p53 signalling via 
the 5S RNP.   
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CHAPTER TWO: METHODS 
2.1 Reagents 
All reagents for buffers were purchased from Sigma Aldrich unless stated otherwise.  
2.2 DNA methods 
2.2.1 Plasmid purification 
Minipreps were carried out using the Promega Wizard® Plus SV Minipreps DNA 
Purification System according to the manufacturer’s instructions and eluted in 50µl 
H2O.  
2.2.2 PCR  
2.2.2.1 PCR and cloning 
PCR reactions were used to amplify target sequences from vectors or cDNA. All PCR 
reactions were carried out using Phusion Polymerase (New England Biolabs) to create 
blunt-ended PCR products.  
 
Reactions were carried out using the primers in Table 2.1 using the explained reaction 
conditions (Table 2.2) using the detailed thermal cycling conditions as per the 
manufacturer’s protocol.  
 
Gene Direction 
Restriction 
site Sequence 
PRAS40 
Forward BamHI GATCGGATCCATGGCGTCGGGGCGCCCCGAGG 
Reverse XhoI GATCCTCGAGTCAATATTTCCGCTTCAGCTTCTGG 
SRSF1 
Forward BamHI GATCGGATCCATGTCGGGAGGTGGTGTGATTCGTGG 
Reverse XhoI GATCCTCGAGTTATGTACGAGAGCGAGATCTGC 
Table 2.1 Primers used for cloning. 
Volume Component 
10 µl 5X Phusion HF Buffer 
1 µl 10 mM dNTPs 
0.5 µl 100 µM Forward Primer 
0.5 µl 100 µM Reverse Primer 
1 µl 200 ng/µl Template 
0.5 µl Phusion Polymerase 
36.5 µl Nuclease free water 
Table 2.2. The PCR conditions used for cloning.  
52 
 
The PCR products were then cloned into the CloneJET PCR Cloning Kit (Life 
Technologies) followed by restriction digests to extract the clone of interest for further 
cloning into the desired vectors. 
2.2.2.2 RT-PCR 
RNA was treated with Turbo DNAse (Life technologies) for 1 hour at 37oC using the 
appropriate buffer. 10 pg -500 ng RNA was added to 200µM dNTPs, 2nM of oligo dT 
primer in order to extend all of the poly-A tailed mRNA sequences. This reaction was 
heated to 65oC for 5 minutes to anneal the primer (Table 2.3) before placing on ice.  
 
The extension of the primer was then performed by adding a final concentration of: 1X 
First strand buffer (Life technologies), 5mM DTT, 200U SuperScript III reverse 
transcriptase (Life Technologies) and 30U Recombinant RNasin ribonuclease inhibitor 
(Promega). The reaction was incubated at 55oC for 1 hour followed by 70oC for 15 
minutes to inactivate the enzymes. The PCR reactions were carried out using Go Taq 
G2 (Promega) with the conditions outlined in the manufacturers protocol using the 
thermal cycling conditions detailed in Table 2.4.  
 
2.2.2.3 Site directed mutagenesis 
Stratagene Quikchange site directed mutagenesis kit was utilised to mutate sites in 
plasmids. The reactions were set up as follows: 1X Pfu buffer, 200 ng DNA, 100 ng of 
Gene Primer direction Sequence 
RPL7 
Forward GGTTCCTGCTGTGCCAGAAAC 
Reverse CCTCAGCATGTTAATCGAAGCC 
RPL10 
Forward CAAGCCGTACCCAAAGTCTCG 
Reverse CTCCTTGTTCTGCAGCTTGGTG 
RPL21 
Forward GGAAAGAGGAGAGGCACCCG 
Reverse GCTGGCGCTTTAGTTGAACC 
RPL18 
Forward CTACCTGAGGCTGTTGGTCAAG 
Reverse CGAAATGCCGGTACACCTCTC 
Table 2.3 List of primers used for RT-PCR 
Step Temperature (oc) Time 
Initial Denaturation 95 5 minutes 
25-35 cycles 95 
58-70 
72 
1 minute 
1 minute 
1 minute per kb 
Final Extension 72 5 minutes 
Hold 4  
Table 2.4. The PCR thermal cycling conditions for Go Taq G2 polymerase.  
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each primer, 200 nM dNTPs and 2.5U PFU Turbo (Stratagene) made up to 100 µl with 
water. The PCR reactions conditions were as per the manufacturer’s protocol.  The 
resultant PCR products were digested with 1U DpnI (New England Biosciences) for 1 
hour at 37oC to digest the parental strand as DpnI digests only methylated DNA. 5 µl 
was then transformed into DH5α competent cells. The list of primers used is shown in 
Table 2.5.  
 
2.2.3 Sequencing 
To ensure that the site directed mutagenesis and cloning had been successful, 
restriction digests and agarose gel electrophoresis were used to check size of inserts. 
This was followed by sequencing by GATC biotech using the appropriate primers to 
check for correct sequences 
2.2.4 Agarose gel electrophoresis 
Samples were diluted in 6X DNA loading dye (0.4 % orange G, 0.03 % bromophenol 
blue, 0.03 % xylene cyanol FF, 15 % Ficoll400, 10 mM Tris-HCl pH 7.5, 50 mM EDTA pH 
8.0)) to a final 1X concentration. Typically, 2% agarose (w/v)-TBE (TRIS/Borate/EDTA: 
90 mM Tris-HCl, 90 mM Boric acid, 2 mM EDTA, pH 8.0) gels were combined with 1X 
SYBRSafe (Invitrogen) and run in 1 X TBE buffer at 125v for 30 minutes. Gels were 
visualised using the SYBRSafe fluorescence setting on the Typhoon FLA 7000 (GE 
healthcare) or with U.V on the Biorad 1000 transilluminator.  
Gene 
Mutation 
desired 
Primer 
direction Sequence 
RPL5 
Y30F, 
Y31F 
Forward CGAGAGGGTAAAACTGATTTTTTTGCTCGGAAACGCTTGG 
Reverse CCAAGCGTTTCCGAGCAAAAAAATCAGTTTTACCCTCTCG 
Y31F 
Forward CGAGAGGGTAAAACTGATTATTTTGCTCGGAAACGCTTGG 
Reverse CCAAGCGTTTCCGAGCAAAATAATCAGTTTTACCCTCTCG 
Y30F 
Forward CGAGAGGGTAAAACTGATTTTTATGCTCGGAAACGCTTGG 
Reverse CCAAGCGTTTCCGAGCATAAAAATCAGTTTTACCCTCTCG 
Y30E 
Forward CGAGAGGGTAAAACTGATGAGTATGCTCGGAAACGCTTGG 
Reverse CCAAGCGTTTCCGAGCATACTCATCAGTTTTACCCTCTCG 
Y44F 
Forward GGTGATACAAGATAAAAATAAATTCAACACACCCAAATACAGG 
Reverse CCTGTATTTGGGTGTGTTGAATTTATTTTTATCTTGTATCACC 
Y44E 
Forward GGTGATACAAGATAAAAATAAAGAGAACACACCCAAATACAGG 
Reverse CCTGTATTTGGGTGTGTTCTCTTTATTTTTATCTTGTATCACC 
Table 2.5 List of primers used in mutagenesis PCR 
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2.2.5 Restriction digests 
0.5-2 µg DNA was digested with the 10U of enzymes (Promega) and the manufacturers 
recommended buffer to a final volume of 20 µl for 1hr at 37oC. 
2.2.6 Ligation 
PCR products were digested with the appropriate restriction enzymes before the 
addition of the vector in a 5:1 molar ratio. 0.3U T4 DNA ligase (Promega) and 1X T4 
DNA ligase buffer (Promega) were added to a final volume of 10 µl. The reactions were 
carried out at 18oC for 16 hours.   
2.2.7 Transformation into E.coli 
For the pcDNA5 constructs and cloning, competent DH5α cells were used. RPL5 and 
RPL11 pGEXgp1 plasmids were kindly provided by Katherine Sloan (Watkins Lab). 50 ng 
plasmid DNA or 5 µl ligation mixture was added to 50 µl competent cells and incubated 
on ice for 30 minutes. The mixture was then heat shocked at 42oC for 1 minute before 
being immediately placed back on ice for 5 minutes. 1 ml Lysogeny Broth (LB) was 
added and the cells incubated at 37oC for 1hr 30 with gentle agitation. The bacteria 
was then plated on LB-agar plates containing the relevant selection antibiotic and 
grown at 37oC overnight. Single colonies were selected and added to 5 ml LB with the 
relevant antibiotics and rotated overnight ready for plasmid purification.   
For the E.coli expression vectors, BL21 PlysS cells were utilised to allow high efficiency 
gene expression whilst maintaining a low level of basal expression. The BL21 PlysS cells 
were grown overnight on antibiotic-free agar plates. 2-4 colonies of BL21 PlysS cells 
were resuspended in 120 µl 50mM sterile CaCl2 before the addition of 1 µg of the 
plasmid and incubation on ice for 15 minutes. The cells were heat shocked at 42oC for 
90 seconds before placing back on ice. 120 µl LB was added and incubated at 37oC for 
5 minutes with gentle agitation before plating on selective plates.  
2.3 RNA methods 
2.3.1 RNA extractions 
2.3.1.1 Phenol-Chloroform extractions 
Phenol:chloroform:isoamylalcohol (25:24:1) solution was added to at a 1:1 ratio with 
the sample and then vortexed for 1 minute before centrifugation for 5 minutes at 
13,000rpm. The upper aqueous phase was transferred to a fresh tube and combined 
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with NaOAc pH 5.3 was added to a final concentration of 150 mM along with 1 ml 
ethanol. 50 µg/ml glycogen blue (Ambion) was added to help with the precipitation of 
the RNA before storage at 20oC overnight. The ethanol was removed by centrifugation 
for 20 minutes at 13,000 rpm and removing the liquid. The pellet was air-dried and 
resuspended in 10 µl H2O. 
2.3.1.2 TRI-Reagent extractions 
Cell pellets were resuspended in 500 µl TRI-reagent and incubated at room 
temperature for 5 minutes. 100 µl chloroform was added before shaking vigorously for 
15 seconds and then incubated for 2 minutes at room temperature and centrifuged at 
13,000rpm for 15 minutes. The upper aqueous phase was separated and combined 
with 250 µl isopropanol and incubated for 5 minutes at room temperature before 
centrifugation at 13,000 rpm for 10 minutes to pellet the RNA. The RNA pellets were 
washed in 500 µl 75% ethanol (v/v) and centrifuged as before for 5 minutes. The 
ethanol was then removed and the pellet resuspended in 10 µl H2O prior to being 
heated for 10 minutes at 55oC.  
2.3.2 Northern blot methods and probes 
2.3.2.1 Acrylamide Gels for 5S and 5.8S rRNAs 
Samples were combined with 2x RNA loading dye (80% formamide, 10 mM EDTA [pH 
8.0], 1 mg/ml xylene cyanol FF, 1 mg/ml bromophenol blue) in a 1:1 ratio and 
separated by electrophoresis using an 8% acrylamide, 7M urea gel in 1x TBE buffer at 
350V for 1-2 hours. RNAs were transferred from the gel onto Hybond N membrane 
(Amersham Biosciences) using a Trans-Blot ® Cell (BIO-RAD) in 0.5x TBE  buffer at 65V  
for 1.5 hours. RNA was cross-linked to the membrane using a Stratalinker UV 
crosslinker (Stratagene) using the auto-crosslinking setting of 120,000 
microjoules/cm2.  
2.3.2.2 Glyoxal Gels for larger RNAs 
Glyoxal Loading Buffer (61.2% DMSO (v/v), 20.4% glyoxal (v/v), 12.2% 1x BPTE buffer 
[30 mM Bis-Tris free acid [pH 7.0], 10 mM PIPES free acid, 1 mM EDTA], 4.8% glycerol 
(v/v), and 0.02 mg/ml ethidium bromide) was added to RNA samples at a 5:1 ratio. The 
samples were heated at 55oC for 1 hour.  
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The samples were loaded onto a gel containing 1.2% agarose / 1x BPTE and run in 1x 
BPTE for 3 hr 30 at 185 volts. The bands were then visualised using a U.V 
transilluminator (Biorad). The gel was then washed in order to fix the RNAs with 75mM 
NaOH for 20 minutes followed by 2x 15 minute washes with Tris-Salt buffer (0.5 M tris 
pH 7.4, 1.5 M NaCl) and a 20 minute wash in 6X SSC (0.9  M NaCl, 90 mM Na3C6H5O7 pH 
7.0).  
The RNA was transferred to a Hybond N Membrane (Amersham) overnight using 
capillary action with 6X SSC buffer. The RNA was cross-linked to the membrane using a 
Stratalinker U.V crosslinker (Stratagene) as described in section 2.2.2.1.  
2.3.2.3 Hybridisation and probes 
Northern blot probes are made as follows. 25-50 ng (approx 1 µl) of PCR template, 1 
mM ATP, 1 mM CTP, 1 mM GTP, 0.1 mM UTP, 1U RNasin, 1 µl T7 polymerase 
(Fermentas), 1x Transcription Buffer (Fermentas) and 2 µl 32P UTP in a 20 µl reaction. 
Incubated reaction at 37oC for 2 hours before the addition of 1 µl Turbo DNase 
(Ambion) to the reaction and a further incubation at 37oC for 30 minutes. Water was 
added to a final volume of 50 µl.  
 
The nylon membranes were pre-hybridised for 30 minutes in 20ml SES1 (0.5 M sodium 
phosphate pH 7.2, 7 % SDS (w/v), 1 mM EDTA).The labelled probe (Table 2.6) was then 
added to the pre-hybridisation buffer and incubated at 37oC with rotation overnight. 
The membranes were then washed twice in 1 x SSC, 0.1 % SDS (w/v) before being dried 
and exposed to a phosphorimager screen. Signals were then detected using the 
Typhoon FLA-7000 (GE healthcare).  
2.3.3 Labelling RNAs for interaction studies 
The 28S and 5S rRNA species were PCR amplified using Go Taq (Promega- see section 
2.1.2) from whole-cell cDNA samples using PCR primers containing T7 sites. The PCR 
products were transcribed into RNA and labelled with 32P UTP by the addition of T7 
Target Sequence 
ITS1  AGGGGTCTTTAAACCTCCGCGCCGGAACGCGCTAGGTAC 
5S CCGAGATCAGACGAGATCGGGCGCGTTCAGGGTGGTATGG 
5.8S CAATGTGTCCTGCAATTCAC 
Table 2.6 Probes used for northern blot hybridisation. 
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polymerase (Promega- see Table 2.7). This reaction was incubated at 37oC for 2 hours 
before the addition of 2U Turbo DNase (Life Technologies) for a further 1 hour at 37oC.  
 
T4 Polynucleotide kinase was used on the commercially bought RNA species in order to 
label them with 32P-γ-ATP (see Table 2.8). These were incubated at 37oC for 45 
minutes.  
 
After labelling, both the commercially bought RNA and the transcribed RNA were 
made up to a final volume of 50 µl with water before spinning in a G50 column (GE 
healthcare) to remove any unbound label.  
2.3.4 Quantification of RNA 
Protein quantification was carried out using 1 µl of RNA sample and analysed using 
Nanodrop (Thermo-Fisher) at 260 nm. Quantification of northern blots was carried out 
using ImageQuant software (GE healthcare).  
Component Volume 
Template 2 µl 
10mM low UTP NTPs 2 µl 
32P UTP 4.5 µl 
5X T7 buffer 4 µl 
1M DTT 2 µl 
T7 Polymerase (20U/µl) 0.5 µl 
Water 5 µl 
Table 2.7. Conditions for in vitro transcription. 
Component Volume used 
10µM RNA oligo 1 µl 
10X PNK buffer 2 µl 
Polynucleotide kinase (1U/µl) 1 µl 
32P ATP 4 µl 
Water 12 µl 
Table 2.8. Conditions for labelling RNAs. 
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2.4 Human Cell Culture 
2.4.1 Human Cell lines 
U2OS (Human Osteosarcoma), HEK 293 (Human embryonic kidney) and HeLa (cervical 
cancer) cells were routinely cultured in Dulbecco’s Modified Eagles Medium (D5796- 
Sigma Aldrich) supplemented with 10% (v/v) Foetal Bovine Serum (Sigma) and 100 
units/m penicillin and 100 µg/ml streptomycin. MCF-7 (Human breast cancer) cells 
were routinely cultured in Gibco™ DMEM/F12 media with Glutamax (10565-018- Life 
Technologies) supplemented with 10% (v/v) Foetal Bovine Serum (Sigma) and 100 
units/m penicillin and 100 µg/ml streptomycin. All cells were grown in a monolayer in 
a 37oC incubator with 5 % CO2. At 80% confluency, cells were detached using 1x Trypsin 
EDTA (Sigma Aldrich) in Phosphate Buffered Saline (Sigma Aldrich) and incubated for 5 
minutes at 37oC before resuspending in DMEM and reseeding at the required density. 
U2OS Flp-In™ T-REX™-cell line had been obtained from Neil Perkins.  This cell line 
contains a Flp Recombinase site contained within a stably integrated pFRT/lacZeo 
vector site from S. cerevisiae. The cell line also contains a pcDNA6/TR vector to allow 
for Blasticidin S resistance and constitutive expression from a tet-repressor under the 
control of the human CMV promoter to allow for tetracycline inducible cell lines. Cells 
were selected using 100 µg/ml hygromycin B at each passage and with 10 µg/ml 
Blasticidin S every third passage.  
U2OS luciferase reporter cell clones were kindly donated by George Schlossmacher. 
These cells contain the pGL4.38 [luc2P/p53 RE/Hygro] (Promega) plasmid allowing for 
p53-regulated luciferase expression. After transfection with the plasmid, individual 
colonies were selected and tested for luciferase expression. The cells were selected 
using 300 µg/ml hygromycin B and routinely cultured with hygromycin B at this 
concentration at each passage.  
All cell lines used were harvested using a swing bucket centrifuge at 900 rpm for 5 
minutes to pellet the cells. The media was removed and the pellets were snap frozen 
in liquid nitrogen and stored at -80oC or used immediately. To make stocks, cells from 
an 80% confluent flask were resuspended in 2 ml freezing media (DMEM, 10% DMSO, 
20% FBS) and cooling to -80oC in a freezing box to obtain gradual cooling.  
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2.4.2 RNAi 
Several proteins of interest were depleted using small interfering RNAs (siRNAs) 
targeting the specific mRNA sequences (Table 2.9). In all cases, a control siRNA 
targeting firefly luciferase mRNA (Elbashir et al., 2002) was used as none of the cell 
lines contain this mRNA.  
 
siRNAs SMARTpools (GE Dharmacon) were diluted to 20 µM in 1x annealing buffer 
(100 mM KOAc, 2 mM MgOAc, 20 mM HEPES-KOH (pH 7.4)). siRNAs purchased from 
Eurofins MWG Operon were resuspended in 1x Universal siRNA Buffer (Eurofins MWG 
Operon) to a concentration of 20 µM.  
Chemical siRNA transfection into U2OS cells was performed using Lipofectamine™ 
RNAiMAX transfection reagent (Invitrogen) using the reverse transfection method. 
Cells were harvested with trypsin as explained previously and resupended in antibiotic 
free DMEM and 1.5 x 104 cells in 2 ml seeded into each well. For a 6-well plate, 
150pmol siRNA was combined with 500 µl Opti-MEM Reduced serum media with L-
glutamine (Invitrogen) and 5 µl transfection reagent and incubated at room 
temperature for 10-15 minutes before addition to the cells. Cells were then usually 
grown for a further 48 hours before harvesting as described. 
2.4.3 Creation of pcDNA5 cell lines 
A modified pcDNA5/FRT/TO vector containing a tetracycline regulated CMV/TetO2 
promoter, a hygromycin B resistance gene with an FRT site in the 5’ coding region and 
2 FLAG tags was used to insert the gene of interest. The vector was co-transfected into 
Target Gene siRNA Sequence Source  Reference 
GL2 CGUACGCGGAAUACUUCGA Eurofins (Elbashir et al., 
2002) 
RPL5 UACUUUAAGAGAUACCAAG Eurofins (Fumagalli et al., 
2012) 
RPL11 GGUGCGGGAGUAUGAGUUA Eurofins (Bursac et al., 
2012) 
p53 GACUCCAGUGGUAAUCUAC Eurofins (Gu et al., 2004) 
RPL7 Smartpool GE Dharmacon  
RPL10 Smartpool GE Dharmacon  
RPL18 Smartpool GE Dharmacon  
RPL21 Smartpool GE Dharmacon  
PRAS40 Smartpool GE Dharmacon  
SRSF1 Smartpool GE Dharmacon  
Table 2.9 siRNA sequences used 
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Flp-In cells with pOG44, a plasmid encoding Flp recombination, in order to promote 
homologous recombination between the FRT sites and thus incorporation of the gene 
of interest and the Hygromycin B resistance into the host cell genome in frame. Cells 
with such insertions were then selected for by culturing in the presence of Hygromycin 
B. U2OS Flp-In cells were kindly provided by Neil Perkins.  
 
To generate the cell lines, the cells were grown at 37oC in growth medium in 6 well 
plates until 60% confluent. 9 µl per well of FuGene6 (Promega) was mixed with 91 µl of 
Opti-mem (Invitrogen) in an microfuge tube and incubated at room temperature for 5 
 
Figure 2.1 Schematic representation of the homologous recombination between the pcDNA5 
vector and Flp-In T-REX cells. The insert within the Flp-In host cells is shown at the top. With the 
addition of the poG44 plasmid, the FRT sites within the pcDNA5 vector (shown in the centre) 
recombines with the FRT sites (dotted line) within the host cell line to produce the insert as shown at 
the bottom. Shown are; SV40 promoter (pSV40), start codon (ATG), Flp Recombination sites (FRT), 
hygromycin resistance gene (hygromycin), origin of replication (pUC ori), Ampicillin resistance gene 
(Amp), CMV promoter (pCMV), Tetracycline operator sequence (2X TetO2), 2X FLAG Precission 
protease 6X His Tag (TAG), Gene of interest (GOI), BGH polyadenylation signal (BGH pA) and fusion 
gene of LacZ with Zeocin resistance gene (lacZ-zeocin). Based on a figure from Invitrogen.  
 
Constitutive expression of 
hygromycin resistance gene
Tetracycline-induced expression 
of tagged gene of interest
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minutes before the addition of 1.8 µg pOG44 and 0.6 µg pcDNA5 and a further 15 
minutes of incubation. The mixture was then added to the cells in a drop-wise manner.  
Cells were grown for a further 48 hours before the addition of Hygromycin B and 
Blasticidin S to a final concentration of 100 µg/ml and 10 µg/ml respectively. Colonies 
were allowed to form for up to a month before resuspension and testing for 
expression of the tagged proteins with the addition of 0-1mg/ml tetracycline for 48 
hours.  
2.4.4 Chemical treatments 
Human cells were chemically treated as shown in Table 2.10 before being harvested 
and used for further analysis.  
 
2.4.5 Whole Cell extracts 
Human cell lines were cultured as described, harvested with trypsin-EDTA and pelleted 
by centrifugation before snap-freezing in liquid nitrogen. For immunoprecipitation or 
gradient analysis, the cell pellets were resuspended in 0.5ml gradient buffer (20 mM 
HEPES-NaOH pH 8, 150 mM KCl, 0.5 mM EDTA, 1 mM DTT, 5% glycerol) and sonicated 
for two 20 second intervals at minimum power using a Bandelin Sonopuls HD2070 
ultrasonic homogeniser with a 2 mm MS72 titanium microtip. The lysate was 
centrifuged at 13,000 rpm at 4oc to remove insoluble material. To the lysate, Triton-
X100 (0.2% (v/v) was added. For the immunoprecipitations, 1.5 mM MgCl2 was also 
added and the glycerol concentration increased to 10% (v/v).  
2.4.6 Immunofluorescence 
HEK293 or U2OS cell lines were grown on 10 mm round coverslips for 48 hours to 
achieve around 80% confluence prior to immunofluorescence. For the pcDNA5 
transfected cell lines, cells were standardly treated with tetracycline for 48 hours prior 
to immunofluorescence. If RNAi was also required, cells were treated with tetracycline 
for 24 hours.  
Drug Concentration used Length of treatment 
ActD 5 nM 18 hours 
Nutlin 3A 5 µM 18 hours 
Deguelin 100 nM 24 hours 
Arginine 10 mM 12-48 hours 
L-Leucine 10 mM 12-48 hours 
Table 2.10. Final concentration of chemical treatments used in cell culture.  
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Coverslips were washed with PBS before incubation with PBS/4% Paraformaldehyde 
for 20 minutes at room temperature to fix the cells. Coverslips are then washed with 
PBS and incubated in PBS/0.1% Triton for 15 minutes at room temperature followed by 
4x PBS washes. They were then blocked for 1 hour at room temperature in PBS/10% 
FBS/0.1% Triton. Primary antibodies were then applied at the appropriate dilution 
(Table 2.11) in PBS/10%FBS (to prevent non-specific binding) /0.1% Triton for 1 hour at 
room temperature before 3 x quick and 3x 10 minute washes in PBS. Secondary 
antibodies were then applied at the appropriate dilution in PBS/10%FBS/0.1% Triton 
for one hour at room temperature before a repeat of the washes as per the primary 
antibody, with the addition of DAPI (0.1 µg/ml, Sigma Aldrich) in the penultimate 10 
minute wash.  
 
Coverslips were then immersed into water and ethanol before being dried and 
mounted using Moviol onto glass slides. Cells were analysed using a Zeiss Axiovert 
200M inverted microscope with a Plan-Apochromat, 100 x / 1.40 oil DIC, ∞ / 0.17 
objective (Zeiss).  The Zeiss filter sets used were: 02 (DAPI); 20 (Cy3); 26 (Cy5). 
2.4.7 Pulse labelling experiments 
After the desired treatment of the cells, the media was removed and replaced with 
phosphate free media (Sigma-Aldrich), supplemented with 10% dialysed FBS for 1 
hour. The phosphate free media was then removed and replaced with phosphate free 
DMEM supplemented with 10% dialysed FBS and 15µ Ci/ml 32P labelled inorganic 
phosphate for 1 hour. The cells were washed with FBS and the media replaced with 
normal DMEM containing 10% FBS for 3 hours. 6 hours was used for gradient analysis 
for studying 5S RNA incorporation. RNA was extracted from the cells using TRI-reagent 
and analysed by agarose-glyoxal gel electrophoresis as previously described. The 
membrane is then left to expose to a phosphorimager screen. Signals were detected 
using a Typhoon FLA 7000 (GE healthcare).  
Antibody Raised in Dilution for IF Source 
Alexa Fluor 555 anti-mouse Donkey 1 in 500 Invitrogen A31570 
Alexa Fluor 647 anti-rabbit Donkey 1 in 500 Invitrogen A31573 
FLAG Rabbit 1 in 500 Sigma F7425 
Fibrillarin Mouse 1 in 50 Michael Pollard/Ger Pruijn 
 
Table 2.11 Antibodies used in immunofluorescence 
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2.4.8 Glycerol Gradient analysis of 5S RNP components 
Gradients were used to separate ‘free’ ribosomal proteins from those integrated into 
the ribosome. Gradients were prepared by layering 2 ml of 40% glycerol solution (40% 
glycerol (v/v), 0.2% Triton-X100 (v/v), 1.5 mM MgCl2, 20 mM HEPES-NaOH [pH 7.9], 
150 mM KCl, 0.5 mM EDTA, 1mM DTT) underneath 10% glycerol solution (10% glycerol 
(v/v), 0.2% Triton-X100 (v/v), 1.5 mM MgCl2, 20 mM HEPES-NaOH [pH 7.9], 150 mM 
KCl, 0.5 mM EDTA, 1 mM DTT) in 4ml 11x60mm Ultra-clear tubes (Beckman) and 
spinning at 22 rpm, 83o for 70 seconds using a Gradient Master (BioComp). Gradients 
were then incubated at 4oC for 1 hour. Whole cell extracts were prepared as previously 
described and 400µl added to the top of the gradient after the removal of 400µl 
gradient mix. 100µl of the whole cell extract is stored for the total. Gradients were 
centrifuged in a Beckman Optima L8-80 ultracentrifuge using a SW60Ti rotor for 1.5 
hours at 52,000 rpm with slow acceleration and no brakes at 4oC. Gradients were 
fractionated into 200µl aliquots and snap-frozen in liquid nitrogen.  
2.4.9 Cell cycle analysis by flow cytometry 
Cells were harvested by centrifugation at 300g for 5 minutes before washing with PBS. 
The cell pellet was then resuspended in cold 70% ethanol while vortexing to ensure 
complete fixation of cells. Cells were either stored in ethanol at 4oC for a maximum of 
48 hours or used immediately. Cells were pelleted by centrifugation at 300g and 
followed by a PBS wash and a further centrifugation at 3000g to ensure maximal cell 
recovery. The cell pellet was then resuspended in 50 µl 100 µg/ml RNase A followed by 
200 µl Propidium Iodide (50 µg/ml). Cells were analysed for cell cycle using the 
FACSCanto II flow cytometer (BD Biosciences).  
2.5 Protein Methods 
2.5.1 SDS-PAGE 
Cells were harvested and pelleted by centrifugation before being heated to 95oc for 3 
minutes in protein loading dye (74 mM Tris-HCl [pH6.8], 1.25 mM EDTA, 20% glycerol, 
2.5% SDS, 0.125% bromophenol blue, 50mM DTT). The samples were vortexed before 
being loaded onto a denaturing 13% acrylamide SDS-PAGE gel with a 4% stacking gel. 
Gels were run for 45 minutes at 200V using the BioRad gel system in 1X Running buffer 
(25 mM Tris-HCl pH 8.3, 250 mM glycine, 0.1 % SDS (w/v)). For standard SDS-PAGE 
without western blot, proteins were visualised using Coomassie Blue Stain (0.1% 
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Coomassie Blue (w/v), 40% methanol (v/v), 10% aceitic acid (v/v)) for 16 hours 
followed by destaining in destain (40% methanol (v/v), 10% aceitic acid (v/v)).  
2.5.2 Western blotting 
Western blot was carried out after separation of proteins by SDS-PAGE. Proteins were 
transferred onto a nitrocellulose membrane (Protran, GE healthcare) in transfer buffer 
(25 mM Tris-HCl, 150 mM glycine, 10% methanol [pH 8.3]) using a BioRad Mini Trans-
Blot® Cell western blotting transfer tank for 1.5 hours at 65V. The membranes were 
then stained using Ponceau S solution to check for the presence of proteins before 
blocking for one hour in blocking solution (PBS, 0.1% Triton X100 (v/v), 2% Marvel 
skimmed milk powder (w/v)) to prevent non-specific binding.  
Antibodies were made up in blocking solution to the desired concentration (Table 
2.12) and incubated overnight at 4oC with gentle agitation. The membranes were 
washed (3 x 5 minutes) in wash buffer (PBS, 0.1% Triton X100 (v/v)) before the 
addition of the appropriate horseradish peroxidase (HRP)-conjugated secondary 
antibody diluted in blocking solution (Table 2.12). Membranes were incubated at room 
temperature in secondary antibody for 2-3 hours before washing (3x 5 minutes) with 
wash buffer. The western blots were then developed by enhanced chemiluminescence 
(ECL) solution (Pierce) and exposure to Hyperfilm (GE Healthcare) according to the 
Antibody Raised in Dilution for WB Source 
FLAG Rabbit 1 in 10,000 Sigma Aldrich- F725 
Goat Donkey 1 in 10,000 Santa Cruz- sc-2020 
Karyopherin Rabbit 1 in 500 Santa Cruz (H-300) 
MDM2 Mouse 1 in 100 Cal Biochem (Ab-1) OP46  
Mouse Donkey 1 in 10,000 Santa Cruz- sc-2314 
p21 Rabbit 1 in 1000 Santa Cruz- sc-397 
p53 Rabbit 1 in 1000 Santa Cruz- (FL-393) 
PRAS40 Rabbit 1 in 1000 Bethyl- A301-201A 
Rabbit Donkey 1 in 10,000 Santa Cruz- sc-2313 
RPL10 Rabbit 1 in 100 Abcam- ab128978 
RPL11 Goat 1 in 2000 Santa Cruz- sc-25931 
RPL5 Rabbit 1 in 5000 Bethyl-A303-933A  
RPL7 Rabbit 1 in 2000 Abcam- ab72550 
SRSF1 Mouse 1 in 1000 Santa Cruz- sc-33652 
α-Tubulin Mouse 1 in 10,000 Cell Signalling (DM1A) 
Table 2.12. List of antibodies used with the dilutions used in Western blotting.  
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manufacturer’s instructions. Quantification of western blots was carried out using 
ImageJ software.  
2.5.3 Phosphorylation gels 
Phos-tag™ Acrylamide (Wako) gels were made as per the manufacturers protocol with 
a 10% acrylamide gel for comparison. After running, the phos-tag gels were washed in 
transfer buffer (25 mM Tris-HCl, 150 mM glycine, 10% methanol [pH 8.3]) containing 1 
mmol/L EDTA for 10 minutes before a second wash in standard transfer buffer without 
EDTA. The western blot was then treated as normal.  
2.5.4 Luciferase assays 
Cells expressing luciferase were plated at 2x105 cells per well and incubated in growth 
medium at 37oC. After 48 hours the cells were harvested using the Promega luciferase 
assay kit per the manufacturer’s specifications with Cell culture lysis buffer (Promega). 
The luciferase measurements were taken using a Lumat 100 luminometer (Berthold).  
2.6 Over-expression and purification of GST-tagged proteins 
in E.coli cells 
2.6.1 Purification of GST-tagged proteins 
GST tagged proteins were expressed in E. coli BL21 cells and used to inoculate a litre of 
2X YT broth with the selective antibiotics. These cultures were grown at 37oc until an 
O.D600 of around 0.3. A final concentration of 1mM IPTG was added and the cultures 
grown for a further 3-18 hours at either 37oC or 18oC. The cells were harvested by 
centrifugation at 4,000 rpm, 4oC for 30 minutes. The supernatant was removed and 
the pellets resuspended in GST buffer (20 mM Tris-HCl pH 8, 5 mM MgCl2, 300 mM KCl, 
0.1% Tween 20, 10% glycerol) before adding ½ of a protease inhibitor tablet and THP 
to a final concentration of 0.5 mM. The samples were sonicated on ice for 3 minutes/5 
cycles/90% power to lyse the cells. The lysate was then collected by centrifugation at 
18,500 rpm for 45 minutes at 4oC for 45 minutes. The pellet was discarded. 1 ml 
glutathione-sepharose beads were equilibrated in GST buffer before being added to 
the clarified lysate. These were rotated at 4oC for 2 hours.  The beads were pelleted by 
centrifugation at 4,000 rpm at 4oC for 3 minutes before discarding the supernatant and 
resuspending in 50ml GST buffer and washing. After discarding the supernatant, the 
bead pellet was resuspended in 1.5ml GST buffer with 50 mM glutathione before 
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placing back on the wheel for 1hr at 4oC. The beads were pelleted by centrifugation 
before the supernatant containing the eluted GST-tagged proteins was taken and snap-
frozen in liquid nitrogen.  
2.6.2 Desalting 
To remove glutathione from the GST-tagged proteins, the purified proteins were 
passed through a HiTrap desalting column (GE) on the AKTA basic (GE life sciences). 
The column was equilibrated using GST buffer and samples were loaded via a loop. The 
resulting fractions were then collected and snap frozen in liquid nitrogen. To separate 
RNA from protein, the samples were loaded onto a 0.5ml injection loop and run 
through the AKTA basic using a Q-sepharose column, running a gradient from 100 mM 
NaCl to 1 M NaCl.  
2.7 Interaction studies 
2.7.1 Glutathione-sepharose protein-RNA pull downs 
Glutathione-sepharose beads were equilibrated in pull-down buffer (20 mM Tris-HCl 
pH 8, 5 mM MgCl2, 150 mM KCl, 0.1% triton, 10% glycerol, 0.5 mM DTT). Appropriate 
volumes of GST-tagged protein were added accordingly to the pelleted beads and the 
solution made up to 0.5ml with pull-down buffer. These were rotated at 4oC for 1 hour 
to bind the proteins. The beads were pelleted at 3,000 rpm for 3 minutes at 4oC before 
discarding the supernatant and washing in pull-down buffer. 0.5 ml pull-down buffer, 1 
µl tRNA and 1 µl 32P labelled RNA were added to the pelleted beads and rotated at 4oC 
for 1 hour. The beads were pelleted and washed before adding 0.5ml homogenisation 
buffer (1% SDS, 50 mM Tris HCl pH 7.6, 60 mM NaCl, 0.5 mM EDTA) to elute the bound 
protein-RNA complexes. A phenol-chloroform extraction and ethanol precipitation 
were performed to extract the RNA before running on 8% or 12% acrylamide urea gels 
at 160V for 40 minutes. The gel was fixed in 10% aceitic acid, 40% methanol before 
drying using a gel drier. A phosphorimager screen was then placed over the gel and left 
to expose overnight before scanning on the Typhoon FLA phosphorimager (GE).  
2.7.2 Immunoprecipitations 
10 µl protein G-Sepharose beads or ANTI-FLAG® M2 Affinity Gel (Sigma-Aldrich A2220) 
per immunoprecipitation were washed thrice in IP Buffer (20 mM HEPES-NaOH pH 8.0, 
150 mM NaCl, 3 mM MgCl2, 0.5 mM DTT, 10% glycerol (v/v), 0.1% Triton-X100 (v/v)) to 
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equilibrate the beads. The ANTI-FLAG® M2 Affinity gel was used directly whereas the 
protein G-sepharose beads were resuspended in IP buffer with 5 µl mouse anti-FLAG 
(Sigma- F3165) antibody or a bead-only control and gently rotated on a wheel at 4oC 
overnight before washing thrice in IP buffer. Whole cell extracts (as previously 
described in section 2.2.5) were added to the prepared resins after taking a 10% total 
of 100µl and rotated at 4oC for 2 hours before centrifugation and washing in IP buffer 
to remove un-bound proteins. RNA extractions were carried out with phenol-
chloroform as described previously.  
For western blots, the resin was resuspended in loading buffer without DTT (74 mM 
Tris-HCl [pH6.8], 1.25 mM EDTA, 20% glycerol, 2.5% SDS, 0.125% bromophenol blue) 
and heated to 95oC for 5 minutes. A final concentration of 50 mM DTT was added and 
western blots carried out as previously described.  
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CHAPTER THREE: UNDERSTANDING THE FACTORS 
INVOLVED IN RECRUITING THE 5S RNP INTO THE 
RIBOSOME 
3.1 Introduction 
The ribosome is a crucial complex within both eukaryotic and prokaryotic organisms. 
The production of ribosomes dictates cellular proliferation (Donati et al., 2012) and 
requires over 200 trans-acting factors and the coordination of all three RNA 
polymerases (Henras et al., 2008). Ribosome biogenesis occurs in the nucleolus, a 
nuclear body only present within the interphase nucleus. RNA polymerase I transcribes 
the 5.8S, 18S and 28S rRNA in a single precursor (47S) in the nucleolus which is then 
processed and modified into the three separate rRNAs through multiple cleavage 
events whereas the 5S rRNA is transcribed by RNA polymerase III in the nucleoplasm 
(Leary and Huang, 2001, Nazar, 2004). The 5S rRNA forms a complex with RPL5 and 
RPL11 known as the 5S RNP and is the only rRNA that forms a pre-ribosomal complex 
with ribosomal proteins prior to integrating into the ribosome (Ciganda and Williams, 
2011).  
Recently, ribosome biogenesis dysfunction has been closely linked to the activation of 
p53. The tumour suppressor, p53, is often referred to as the ‘guardian of the genome’ 
and is deleted or inactivated in the majority of cancers. In cellular stress situations, p53 
is activated and coordinates with a variety of signalling pathways that result in DNA 
repair, apoptosis, senescence or G1 cell cycle arrest (Ko and Prives, 1996, Timofeev et 
al., 2013, Sperka et al., 2012, Sugikawa et al., 1999). The main regulator of p53 is 
MDM2 which harbours E3 ubiquitin ligase activity, promoting the ubiquitination and 
degradation of p53 by targeting it to the 26S proteasome (Honda and Yasuda, 1999). In 
situations of cellular stress such as DNA damage or chromosomal aberrations, MDM2 
is suppressed and leads to the stabilisation and activation of p53 (Michael and Oren, 
2003). Many ribosomal proteins have been seen to interact with MDM2 such as RPL23, 
RPS7, RPL5, and RPL11 (Jin et al., 2004, Marechal et al., 1994, Lohrum et al., 2003, 
Chen et al., 2007) although it has been shown by two independent groups that the 5S 
RNP (consisting of RPL5, RPL11 and the 5S rRNA) is the critical factor in the 
maintenance of p53 homeostasis as well as being involved in the induction of p53 
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under ribosomal stress conditions (Sloan et al., 2013a, Donati et al., 2013) as 
summarised in Figure 3.1.  
Disruptions in translation or ribosome biogenesis have been implicated in many 
diseases known as ribosomopathies such as DBA and 5q-syndrome. Many of these 
diseases have links to p53 signalling as a result of a disruption in ribosome production 
(Fumagalli and Thomas, 2011). 
 
DBA and 5q-syndrome share many of the same symptoms such as anaemia, decreased 
erythroid precursors and a predisposition to cancers such as leukaemia (Quarello et al., 
2010b, Vardiman et al., 2002). Almost half of all DBA patients have mutations in genes 
encoding ribosomal proteins, including RPL11 and RPL5, and the pathogenesis of DBA 
is partly attributed to the rapid proliferation of red blood cell precursors requiring a 
high rate of ribosome production (Zhang et al., 2011). Furthermore, defects in 
ribosomal proteins may lead to accumulation of p53 and thus cell-cycle arrest and 
apoptosis in these erythroid cells (Dai and Lu, 2004). 5q-syndrome is a myelodysplastic 
syndrome characterised by the deletion of the long arm of chromosome 5 (Van den 
Berghe et al., 1974). This deleted region contains the gene encoding the ribosomal 
protein RPS14, a small subunit ribosomal protein (Ebert et al., 2008). 
Haploinsufficiency of RPS14 results in ribosome biogenesis defects (Cazzola, 2008, 
Galili et al., 2009) and activation of p53 (Barlow et al., 2010). Based on more recent 
findings that the 5S RNP regulates p53 upon disruption of ribosome biogenesis (Donati 
 
Figure 3.1. The 5S RNP-p53 pathway. In normal cells, p53 is targeted for proteasomal degradation 
by the E3 ubiquitin ligase, MDM2. The 5S RNP, consisting of RPL5, RPL11 and the 5S rRNA is 
incorporated into the pre-60S subunit which then forms part of the mature 80S ribosome. When 
ribosome biogenesis is disrupted, the 5S RNP is not incorporated into ribosomes and is able to bind 
to MDM2 and activate p53. p53 signals to various pathways inducing those involved in senescence, 
DNA repair or apoptosis.   
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et al., 2013, Sloan et al., 2013a), it is presumed that the 5S RNP contributes to the p53 
activation in 5q-syndrome.   
The regulation of the 5S RNP is therefore crucial to understanding the pathogenesis of 
these diseases and for the invention of novel treatment therapies. Sloan et al. (2013a) 
proposed that any proteins involved in the regulation of 5S RNP formation, localisation 
or integration were central in regulating MDM2 activity and, thus, p53 levels in the 
cell. However, the factors involved in 5S RNP recruitment into the ribosome are not 
fully understood. In yeast, RPL5 and RPL11 are delivered to the nucleus and probably 
assembled onto the 5S rRNA by Syo1, forming the 5S RNP.  Rpf2 and Rrs1 form a 
complex with the 5S RNP and are crucial for the recruitment of the 5S RNP into the 90S 
pre-ribosomes (Zhang et al., 2007, Morita et al., 2002). Upon joining the pre-ribosome, 
the 5S RNP docks onto helix 84 of the 25S rRNA (Rhodin et al., 2011) and is locked into 
conformation by the C-terminal tail of Rpf2, Rsa4 and Nsa2 to prevent any rotation 
(Kharde et al., 2015, Bassler et al., 2015). Rsa4 is then released from the 5S RNP by 
Rea1 and the 5S RNP structure is rotated by 180o in order to form the central 
protuberance (Bassler et al., 2015, Leidig et al., 2014).  
The human homologues of Rrs1 and Rpf2, RRS1 and BXDC1, are not as crucial for 5S 
RNP integration, however, depletion of both proteins increased the nucleoplasmic 
localisation of RPL5 and RPL11 (Sloan et al., 2013a) and thus it was suggested that in 
humans, these proteins were involved in localisation of the 5S RNP. Interestingly, it 
was also found that the nucleolar protein, PICT-1, directly contacted the 5S rRNA and 
depletion of PICT-1 had a more profound effect on than depletion of RRS1 or BXDC1 on 
5S rRNA ribosomal recruitment. This suggested that PICT-1 is a crucial factor for the 5S 
RNP recruitment into the ribosome in human cells. The differences between yeast and 
human 5S RNP ribosomal integration means that there could be many more factors 
involved in humans that have not yet been identified.  
The eukaryotic T. thermophila structure of the large subunit of the ribosome (Klinge et 
al., 2011) showed that several ribosomal proteins surround the 5S RNP within the 
ribosome (Figure 3.2A and B). These proteins were RPL7, RPL10, RPL18 and RPL21 and, 
as they appeared to form a ‘binding pocket’ for the 5S RNP, may be involved in the 
recruitment of the 5S RNP into the ribosome.  
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Interestingly, two of these proteins, RPL10 and RPL21 have been shown to mutated in 
disease. Mutations in RPL10 have been described in patients with T-cell acute 
lymphoblastic leukaemia (T-ALL) (Keersmaecker et al., 2013). Interestingly, the RPL10 
mutation found in T-ALL patients, Arg98Ser, appeared to cause ribosome biogenesis 
and proliferation defects in mammalian lymphoid cells. RPL10 mutations have also 
been linked to several neuronal diseases such as autism (Klauck et al., 2006, 
Chiocchetti et al., 2011, Gong et al., 2009), X-linked microcephaly (Brooks et al., 2014), 
and X-linked syndromic Intellectual Disability (Thevenon et al., 2015). RPL21 mutations 
have been reported in hereditary hypotrichosis simplex (Zhou et al., 2011). However, 
the link to p53 in these diseases has not been characterised.  
Currently, ways to combat ribosomopathies are limited, a more in-depth 
understanding of 5S RNP-p53 signalling and how the 5S RNP is integrated into the 
ribosome could unlock new targeted ways to treat patients. This chapter aimed to 
identify factors that may affect integration of the 5S RNP into the ribosome and thus 
p53 signalling through studying interactions between ribosomal proteins, rRNA and the 
5S RNP.  
 
Figure 3.2. The 5S RNP ‘binding pocket’. An image of the top of the T. thermophila crystal structure 
of the large ribosomal subunit (Klinge et al., 2011) showing the position of the RPL7 (green),  RPL18 
(brown), RPL10 (orange), RPL21 (blue) with (A) and without (B) the 5S RNP in situ. The grey 
represents the rRNA and other ribosomal proteins. The proteins surround the 5S RNP and form a 
’pocket’ that may be important for the recruitment of the 5S RNP. 
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3.2 Results 
3.2.1 Depletion of RPL7, RPL10, RPL18 and RPL21 in U2OS cells  
As RPL7, RPL18 and RPL21 appeared to form a binding pocket for the 5S RNP based on 
the T. thermophila crystal structure (Klinge et al., 2011) it was important to investigate 
whether depletion of these proteins would result in a block in 5S RNP recruitment. It 
was necessary to first establish that siRNA transfection was successful at reducing 
mRNA and protein levels in cells. Therefore, U2OS cells were cultured in growth 
medium at 37oC post-transfection with siRNA duplexes targeting the four protein’s 
mRNA sequences (20 µM RPL7 and RPL10 and 2 µM RPL18 and RPL21), or a control 
luciferase siRNA (20 µM GL2) for 48 hours. 
 
The RNA was extracted from the cells and reverse transcribed followed by PCR 
amplification using primers annealing to RPL7, RPL10, RPL18 or RPL21. GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) primers were used as a control. The 
mRNA of each protein was reduced in the knockdowns compared to the control 
(Figure 3.3A), suggesting that the knockdown had been successful. However, it should 
be noted that the RPL10 siRNA appeared to have less of an effect on its target mRNA 
levels than the other siRNAs.  It was not possible to obtain antibodies for all of the 
 
Figure 3.3. Treatment of cells with siRNAs for RPL7, RPL10, RPL18 and RPL21 results in a reduction 
of the relevant mRNA and protein levels. (A) U2OS cells were incubated at 37oC in growth medium 
post-transfection with siRNA duplexes targeting RPL7, RPL10 (20 µM), RPL18 and RPL21 (2 µM) for 
48 hours prior to harvesting, RNA extraction and RT-PCR using primers specific to the 4 ribosomal 
proteins and a housekeeping gene, GAPDH. The resultant PCR products were separated via agarose 
gel electrophoresis containing DNA stain and the cDNA signals visualised using the fluorescence 
setting on a Typhoon FLA imager. The signals were quantified using ImageQuant and the levels of 
each cDNA in both the control and the knockdowns was normalised to the GAPDH. (B+C) U2OS cells 
were depleted of RPL7 and RPL10 as in A. Whole cell extracts were separated by SDS-PAGE followed 
by western blotting using RPL7 and RPL10 antibodies alongside karyopherin as a loading control. 
Bars in A represent the mean ± the standard deviation of the mean, n=3. Statistical analysis 
determined by paired t-test. NS= non-significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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***
*
***
74 
 
proteins, however RPL7 and RPL10 antibodies were used to show the level of 
knockdown at the protein level. U2OS cells were incubated in growth medium at 37oC 
post-transfection with 20 µM siRNA duplexes targeting RPL7, RPL10 or the control GL2 
for 48 hours prior to harvesting. Whole cell extracts were separated by SDS-PAGE and 
western blotted using karyopherin (loading control), RPL7, or RPL10 antibodies (Figure 
3.3B). The siRNA treated cells showed a reduction in signal compared to the control 
when using the appropriate antibodies suggesting that the knockdowns had been 
successful.  
3.2.2 Depletion of RPL7, RPL18 and RPL21 affects integration of the 
5S rRNA into the ribosome. 
In order to determine the importance RPL7, RPL10, RPL18 and RPL21 on the 
recruitment of the 5S RNP into the ribosome, the proteins were depleted using RNAi 
and the 5S rRNA was analysed using glycerol gradients and northern blots.  
U2OS cells were incubated in growth medium at 37oC post-transfection with 20 µM 
siRNA duplexes targeting RPL11, RPL7 or RPL10 or 2 µM siRNA duplexes targeting 
RPL18 or RPL21 for 48 hours. In order to visualise just the newly synthesised 5S rRNA, 
the cells were depleted of phosphate by incubating in phosphate-free medium for 1 
hour and labelled using 32P orthophosphate-supplemented medium, followed by a 6 
hour chase with normal medium. The 6 hour chase period was selected for this 
experiment as 5S rRNA recruitment into the ribosome is slow  (Sloan et al., 2013a) and 
thus to visualise recruitment, a longer time is required.  
After depletion of the ribosomal proteins for 48 hours and pulse-labelling, cells were 
lysed and applied to a 10-40% glycerol gradient in order to separate the large and 
small complexes. After centrifugation, 20 fractions were taken. Based upon published 
data, (Sloan et al., 2013a) fractions 1-7 were combined for the smaller complexes that 
should contain the ‘free’ 5S rRNA whilst fractions 9-20 were pooled for the ribosome 
bound 5S rRNA. RNA was extracted from the pooled fractions and separated using an 
8% acrylamide-urea gel before transferring to a nylon membrane and exposing to a 
phosphorimager screen (Figure 3.4A).  
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In control cells, 45% of the 5S rRNA was shown in the ‘ribosomal’ fractions. Depletion 
of RPL11 resulted in a decrease in ribosomal 5S rRNA to less than 20%. Depletion of 
RPL7, RPL18 and RPL21 resulted in a similar reduction in 5S rRNA integration, with 
around 18-20% of the 5S rRNA in the ribosome fractions (Figure 3.4B). Depletion of 
RPL10, however, showed no reduction in 5S rRNA in the ribosome fractions. As the 
effect of depletion of RPL7, RPL18 and RPL21 was similar to that of RPL11, which is 
crucial for the 5S RNP recruitment into the ribosome (Sloan et al., 2013a), this 
indicated that RPL7, RPL18 and RPL21 may be required for integration of the 5S rRNA 
into the ribosome, but that potentially RPL10 is not.  
3.2.3 RPL7, RPL18 and RPL21 are crucial for ribosome biogenesis 
and RPL7 and RPL18 knockdowns lead to accumulation of the 36SC 
precursor 
Depletion of proteins that affect 5S RNP incorporation into the ribosome such as PICT-
1 have been shown to also result in ribosome biogenesis defects (Sloan et al., 2013a). 
As RPL7, RPL18 and RPL21 had reduced 5S rRNA incorporation into the ribosomes, the 
next step was to investigate whether they were also important for ribosome 
biogenesis.  
 
Figure 3.4. RPL7, RPL18 and RPL21 depletion results in accumulation of ‘free’ 5S rRNA. (A) Gradient 
centrifugation of siRNA treated cells followed by northern blot with a 5S rRNA probe  to reveal ‘free’ 
and ‘ribosome’ bound 5S rRNA. U2OS cells were incubated in growth medium post-transfection with 
siRNA duplexes targeting RPL7, RPL10 (20µM), RPL18 and RPL21 (2µM) for 48 hours prior to 
phosphate starving the cells in phosphate free medium. Cells were then incubated in 32P 
orthophosphate labelled medium for 1 hour before returning the cells to normal growth medium for 
6 hours at 37oC. All incubations were carried out at 37oC. Cells were harvested and RNA extracted. 
The RNA was separated by acrylamide gel electrophoresis before transferring to a nylon membrane 
and exposing to a phosphorimager screen. (B) Quantification of A using densitometry analysis to 
show the percentage of 5S from the ribosome fractions. n=1.   
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To investigate the role of these proteins in pre-rRNA processing, pulse-labelling was 
utilised whereby cells were phosphate starved with phosphate free medium before the 
addition of 32P orthophosphate labelled medium and a 3 hour chase period with 
normal phosphate medium. This method allows for the specific evaluation of newly 
synthesised rRNAs. The 3 hour chase period ensures that there is enough time for the 
rRNAs to be processed so that each precursor can be studied.  
U2OS cells were incubated at 37oC for 48 hours in growth medium post-transfection 
with 20 µM (RPL5, RPL7, RPL10) or 2 µM (RPL18, RPL21) siRNA duplexes. The cells were 
then grown in phosphate free medium for 1 hour, followed by 1 hour incubation with 
labelled medium. After a three hour chase with normal growth medium, RNA was 
extracted from the cells and separated by glyoxal-agarose gel electrophoresis (Figure 
3.5A- top panel) to separate the large rRNA precursors and acrylamide-urea gel 
electrophoresis (bottom panel) to separate the 5S and 5.8S rRNAs. The 18S rRNA from 
the U.V scan of the glyoxal-agarose gel (middle panel) was used as a loading control.   
In agreement with previously published data (Sloan et al., 2013a), depletion of RPL5 
resulted in a severe reduction in levels of the 28S rRNA. Depletion of RPL7 showed a 
slight reduction in 5S production but resulted in an almost complete loss of 28S as well 
as reductions in 32S, 47/45S and 5.8S. Similar, but more extreme, results were 
observed with the RPL18 and RPL21 knockdowns. The depletion of RPL18 resulted in 
an almost complete loss of 47/45S, 32S, 28S and 5.8S, with an additional reduction in 
18S production. RPL21 depletion resulted in reduction in 28S and 5.8S and an 
accumulation of 32S, suggesting a defect in cleavage of the 32S precursor into the 28S 
and 5.8S rRNAs.   
Furthermore, rRNA precursors were studied using cell extracts and northern blotting 
to see whether any further defects could be detected (Figure 3.5B). RNA from 
knockdown cells was extracted and separated via glyoxal-agarose gels before 
transferring to a nylon membrane. The northern blots were probed using an Internal 
Transcribed Spacer 1 (ITS1) probe (Figure 3.5C), which hybridises to small subunit 
precursors and early large subunit precursors.  In all of the northern blot analysis, the 
18S RNA, visible from U.V scanning of the gel prior to transfer, was used as a loading 
control.  
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Figure 3.5. RPL7, RPL18 and RPL21 knockdowns affect ribosome biogenesis. (A) Pulse-labelling of 
knockdowns. U2OS cells were incubated in growth medium containing RPL5, RPL7, RPL10 (20µM), 
RPL18 and RPL21 siRNA duplexes for 48 hours at 37oC before the addition of phosphate free medium 
for 1 hour. 32P orthophosphate labelled medium was then introduced into the cells for 1 hour before 
a 3 hour chase with normal media to allow for rRNA processing to occur. RNA was extracted and 
separated via Agarose-glyoxal (top panels) and acrylamide-urea (bottom panel) gels and transferred 
to nylon membranes. The membranes were exposed to phosphorimager screens and visualised via 
phopshorimaging. (B) Northern blot showing the effect of RPL7, RPL10, RPL18 and RPL10 
knockdowns in U2OS cells. Cells were in treated with siRNAs for 48 hours prior to harvesting, RNA 
extraction and separation of the RNAs with a glyoxal-agarose gel. The RNAs were transferred to a 
nylon membrane via northern blotting and incubated with the ITS1 probe to look at the large subunit 
rRNA precursors. (C) Schematic representation of the rRNA precursors showing the location of the 
where the ITS1 probe hybridises. The precursors that ITS1 probe hybridises to, seen in A are shown 
in black. N=3 
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The RPL18 and RPL21 knockdowns appeared to severely affect the cells, leading to 
reduced cell numbers and thus it was difficult to get RNA from these cells. Taking into 
account differences in loading, depletion of RPL7, RPL18 and RPL21 resulted in 
accumulation of the early precursors (47/45S, 41S and 36S). Interestingly, the RPL21 
knockdown showed a great increase in the 30S precursor whereas depletion of the 
other proteins did not. RPL7 and RPL18 depletion resulted in an accumulation of the 
36SC precursor, suggesting that the 36S is not properly cleaved into the 32S in the 
absence of RPL7 and RPL18. These results, taken in conjunction with the pulse-labelling 
data, imply that these proteins are required for rRNA processing.  
3.2.4 Knockdowns of RPL7, RPL18 and RPL21 but not RPL10 induce 
p53 via the 5S RNP 
The data presented in 3.2.3 highlighted the possibility that knockdown of RPL7, RPL18, 
or RPL21 may prevent integration of the 5S RNP into the ribosome. When the 5S RNP is 
not incorporated into ribosomes, it is free to contact MDM2 and thus stabilise p53, 
therefore the effect of knockdowns of the ribosomal proteins were investigated to 
determine whether they resulted in accumulation of p53 in a 5S RNP-mediated 
manner.  
U2OS cells were transfected with GL2, RPL7, RPL10, (20µM) RPL18 or RPL21 (2µM) 
siRNA duplexes alone or in combination with an RPL5 siRNA duplex. The cells were 
harvested after 48 hours, separated via SDS-PAGE and then western blotted (Figure 
3.6A). Antibodies raised against p53, p21, and MDM2 were utilised, and an α-Tubulin 
antibody was used as a loading control. The western blots revealed that depletion of 
RPL7, RPL18, or RPL21 increased the levels of p53 and its downstream target, p21 as 
well as MDM2. These inductions were abolished upon co-depletion of RPL5, suggesting 
that this p53 induction was 5S RNP dependent. RPL10 depletion showed little change 
in p53 levels.  
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Whilst the increase in p21 levels suggested an increase in p53 transcriptional activity, it 
was decided to analyse this further by directly measuring p53 transcriptional activity as 
p21 can be activated independently of p53 (Macleod et al., 1995). Therefore, U2OS 
cells stably expressing a p53-regulated luciferase reporter were utilised. As in Figure 
3.6A, the siRNA duplexes alone or in combination with RPL5 were transfected into 
U2OS cells. The cells were harvested after 48 hours, lysed, and analysed for luciferase 
activity (Figure 3.6B). As seen with the western blots, depletion of RPL7, RPL18, or 
RPL21 resulted in an increase in luciferase levels, which was decreased to near-basal 
 
Figure 3.6. Depletion of RPL7, RPL18 and RPL21 induces p53 in a 5S RNP-dependent manner. (A) 
Representative western blot from three independent experiments. U2OS cells were incubated in 
growth medium at 37oC post-transfection with RPL7, RPL10 (20 µM), RPL18 and RPL21 (2 µM) siRNAs 
alone or in conjunction with a 20µM RPL5 siRNA for 48 hours. Whole cell extracts were separated by 
SDS-PAGE before western blot analysis. α-Tubulin was used as a loading control. (B) U2OS cells 
containing a p53-regulated luciferase reporter were treated with siRNAs as in A before assaying for 
firefly luciferase reporters. Bars represent the means ± the standard deviation of the means, n=3. 
Statistical analysis determined by paired t-test. NS= non-significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 
0.001.  
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levels upon knockdown of RPL5, indicating that depletion of RPL7, RPL18, or RPL21 
resulted in an increase in p53 activity in an RPL5 dependent manner. RPL10 showed no 
significant increase in luciferase and thus did not result in an increase in p53 activity, 
thus suggesting that RPL10 depletion does not induce p53 via the 5S RNP.  
3.2.5 Depletion of RPL7, RPL18 and RPL21 result in an 
accumulation of cells in G1 in an RPL5-dependent manner.  
As RPL5-dependent p53 induction and activation of p21 upon knockdown of RPL7, 
RPL18 and RPL21 was observed, it was next important to establish whether this 
affected cell cycle progression. p21, also known as cyclin-dependent kinase inhibitor 1, 
is a cell cycle regulator that, when activated, often results in G1 arrest (Deng et al., 
1995, Waldman et al., 1995). RPL21 depletion resulted in too few cells for flow 
cytometric analysis and thus only RPL7 and RPL18 depletions were analysed.  
U2OS cells were incubated in growth medium post-transfection with 20 µM (RPL5, 
RPL7) or 2 µM (RPL18) siRNA duplexes before fixing in ice cold ethanol, staining with 
propidium iodide and analysing by flow cytometry, gating on the live population 
(Figure 3.7 A-F). Unfortunately, the RPL5 depletion and the RPL5/RPL18 co-depletion 
were toxic to cells and thus resulted in very low cell numbers (figure 3.7B and F). 
However, they resulted in consistent results over 3 experiments.  
The number of cells at each stage in the cell cycle were taken as a percentage and 
were represented in a graph (Figure 3.7G) which revealed that RPL7 and RPL18 
depletion resulted in an accumulation of cells at G0/G1. Interestingly, RPL5 depletion 
gave a small, but significant accumulation of cells in G2 (t test, p= 0.0281). When RPL5 
was co-depleted with RPL7 and RPL18, it was revealed that RPL5 depletion 
counteracted the G0/G1 arrest seen in the single knockdowns and, instead, resulted in 
a slight accumulation of cells in G2. This suggested that RPL5 was required for the 
accumulation of cells in G1 seen with the RPL7 and RPL18 depletions.  
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Figure 3.7. RPL7 and RPL18 knockdowns give an RPL5 dependent accumulation of cells in G1. (A-F) 
Cell cycle analysis using propidium iodide staining and flow cytometry in cells depleted of the 
ribosomal proteins.U2OS cells were incubated in growth medium containing 20µM (RPL5, RPL7) or 
2µM (RPL18) siRNA duplexes at 37oC for 48 hours. The cells were harvested and fixed in ice cold 
ethanol before the addition of propidium iodide and RNAse before flow cytometric analysis. The 
forward scatter (FSC) was plotted against the side scatter (SSC) and the live population of cells was 
gated on as shown in blue.  (G) Graphical representation of the proportion of cells at each stage of 
the cell cycle from E-F. Bars in G represent the means ± the standard deviation of the means, n=3. 
NS= non-significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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3.2.6 In vitro binding assays to show RPL11/28S rRNA interactions 
Integration of the 5S RNP into the ribosome in yeast requires the 5S RNP to dock onto 
helix 84 of the 25S rRNA (28S in humans) (Rhodin et al., 2011). From investigation into 
the crystal structure of T. thermophila (Klinge et al., 2011), it appeared that the region 
where RPL11 and 28S rRNA interaction occurred overlapped with the site of MDM2 
and RPL11 interactions. This raised questions as to whether RPL11 binding to this 
region of the 28S rRNA could block interactions between RPL11 and MDM2. Therefore, 
recombinant RPL11 and RPL5 were expressed in purified from E. coli cells and 28S 
rRNA fragments were transcribed in vitro in order to test the interactions between 
them.  
3.2.6.1 Creation of rRNA fragments 
There were two different rRNA species that were tested for binding to RPL5 and 
RPL11. As the 5S rRNA is part of the 5S RNP complex with RPL5 and RPL11, the 5S rRNA 
was used as a control rRNA. A full length transcript of the 5S rRNA was transcribed, 
using cDNA extracts from U2OS cells as a template, and labelled with 32P for use in 
pull-down experiments.  
The area of the 28S that appeared to contact RPL11 in the same region as MDM2 
consisted of helices 83-85 (Figure 3.8A). In order to test binding to RPL11, two 
different fragments of the helix 83-85 of the 28S rRNA were created (Figure 3.8B). One 
fragment contained helix 84, a small 20bp fragment (Figure 3.8-green), whilst the 
other was a larger 57bp fragment consisting of helices 83-85 (Figure 3.8- purple). Both 
fragments were transcribed in vitro using cDNA reverse transcribed, using U2OS cell 
RNA extracts as a template, and labelled with 32P for use in interaction studies.  
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3.2.6.2 Purification of RPL5 and RPL11 proteins to use in pull-down experiments 
E. coli cells were transfected with pGEX6p1 plasmids encoding GST-tagged RPL5 and 
RPL11 and grown in 2X YT broth at 37oC until an OD600 of 0.3. After the cells had grown 
to the desired density, a final concentration of 1mM IPTG was added for 18 hours at 
18oC. The cells were harvested, lysed and then purified using glutathione-sepharose 
beads. It was consistently found that RPL5 was more difficult to purify and generally 
gave a much less concentrated protein than RPL11 (Figure 3.9A). A much larger volume 
of culture was therefore required to purify usable amounts of RPL5 than RPL11.  
Anion-exchange chromatography was used to further purify the two proteins. Both 
proteins did not bind to the resin and were found in the flow-through as shown for 
RPL5 (Figure 3.9B) as the first peak. For RPL5, a second peak was seen, eluting at 
approximately 500 mM NaCl. As the 260nm level was greater than the 280nm level, it 
 
Figure 3.8. The 28S rRNA contacts RPL11 in the ribosome. (A) Cryo-EM structures from the human 
ribosome (Khatter et al., 2015) showing the helix 83-85 region of the 28S rRNA in contact with the 5S 
RNP. The two 28S fragments, 28S-1 and 28S-2 are denoted in green and purple, respectively.  (B) A 
diagrammatic representation of the 28S rRNA secondary structure denoting the 28S region of 
interest.  
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was presumed that this peak was RNA and suggested that RPL5 purified bound to E. 
coli RNA. RPL5 could not be suitably purified using this approach and was found to be 
unstable after being run through the anion exchange column (Figure 3.9D). It was 
previously reported that little or no RNA co-purified with X. laevis RPL5 over-expressed 
in E. coli when a much shorter induction time was used (Scripture and Huber, 1995). 
Therefore, E. coli cells expressing RPL5 were induced for 3 hours at 37oC before 
harvesting and purifying proteins. Anion exchange chromatography of the purified 
proteins revealed that RPL5 not retained on the column and eluted as the first peak. 
Furthermore, the second peak, eluting at approximately 500 mM NaCl was significantly 
reduced,(Figure 3.9C). This implied that significantly less RNA co-purified with RPL5 
and that this was a better approach for obtaining RNA-free RPL5.  Therefore, these 
methods were employed for purification of GST-RPL5 for further experimentation. The 
final resultant purified GST-RPL5 and GST-RPL11 can be seen in Figure 3.9E.  
 
Figure 3.9. Protein purifications of RPL5 and RPL11. (A) E.coli BL21 cells transformed with plasmids 
for GST-tagged RPL5 and RPL11 were induced with 1 mM IPTG for 18 hours at 18oc before harvesting 
the cells. The cells were lysed and the lysates incubated with glutathione sepharose to purify the 
GST-tagged proteins. Samples were taken pre- and post-IPTG induction and run on a 13% SDS-PAGE 
gel together with the final, purified protein.  (B) The chromatograph (254nm) of RPL5 from an anion 
exchange column. E. coli cells were grown and the proteins purified as in (A). The purified protein 
samples were applied to an anion exchange column. A large RNA peak can be seen with a fairly small 
protein peak. (C) As in B but the E. coli cells were grown for 3 hours at 37oc post-induction with IPTG. 
(D) Analysis of protein containing fractions from D on a coomassie stained SDS-PAGE gel. Fractions 
A2-A4 represent the first peak whilst B11-B7 represent the second. (E) The final purified products of 
RPL5 and RPL11 for use in interaction studies after anion exchange and then applying the sample to a 
desalting column. 
85 
 
3.2.7 RPL11 directly binds helix 83-85 of the 28S rRNA but not the 
5S rRNA  
In order to investigate whether RPL11 was able to directly bind the 5S rRNA, equal 
amounts of the purified GST-tagged RPL5 or RPL11 were bound to glutathione-
sepharose beads before the addition of the 32P labelled 5S rRNA, 28S-1 (helix 84)  or 
28S-2 (helix 83-85) fragments. 
TATA binding protein-interacting protein of 49kDa (Tip49) protein extracts were 
provided by Dr. Katherine Sloan and used as a control protein as Tip49 was previously 
demonstrated to not bind RNA (McKeegan et al., 2009). Bound RNAs were isolated and 
then analysed by polyacrylamide gel electrophoresis (8% acrylamide-urea gels (28S-2 
and 5S) or 12% acrylamide-urea gels (28S-1). The gels were fixed, dried and exposed to 
a phosphorimager screen. 
Tip49 did not bind the 5S rRNA, suggesting specificity of binding. RPL5 consistently 
showed direct binding to the 5S rRNA (Figure 3.5). However, RPL11 did not bind to the 
5S rRNA, suggesting that it is not able to directly bind to the 5S rRNA. This suggests 
 
Figure 3.10. RPL11 directly binds to helix 83-85 of the 28S rRNA. Protein-RNA interaction study 
using recombinant human proteins purified from E. coli. Tip49, RPL5 or RPL11-GST plasmids were 
transfected into E. coli BL21 cells. The cells were grown and induced with IPTG to induce expression 
of the GST-tagged proteins. After lysis, glutathione sepharose was incubated with the lysate to bind 
the GST-tagged proteins. The proteins underwent further purification via anion exchange and 
desalting. The purified proteins were bound to glutathione-sepharose. Three rRNA species (5S, 28S-1 
and 28S-2) were transcribed in vitro and labelled with 32P before incubating with the bead and 
protein mixture. Any unbound RNA was washed off before eluting the bound protein/RNA followed 
by RNA extraction. Denaturing acrylamide-urea gels were utilised to separate the proteins before 
drying the gels and exposing to phosphorimager screens.  
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that there may be an induced fit change in the structure of the 5S rRNA upon RPL5 
binding that then allows RPL11 to bind.  
RPL11 was bound to the full helix 83-85 (as described in Figure. 3.8) 28S-2, the larger of 
the two fragments but not the smaller (helix 84) fragment (Figure 3.5). This implied 
that either helix 84 did not contain the region for binding to RPL11 or that the small 
rRNA fragment did not fold correctly for binding- although it was not clear which.   
3.3 Discussion 
Understanding how the 5S RNP is recruited into the ribosome is vital to understanding 
p53 regulation. This chapter aimed to address this issue by looking at 4 ribosomal 
proteins and a fragment of the 28S rRNA to see how they interact with the 5S RNP and, 
in the case of the ribosomal proteins, how this affects p53 signalling in U2OS cells.  
Based on the crystal structure of the T. thermophila ribosome, RPL7, RPL10, RPL18, and 
RPL21 were identified as proteins that may be involved in 5S RNP recruitment into the 
ribosome due to their close proximity to the 5S RNP. Ribosomal proteins are known to 
be required for many different stages of rRNA processing (O'Donohue et al., 2010) 
although at present very little information is available on the roles of RPL10, RPL18 and 
RPL21 in ribosome biogenesis. However, in S. cerevisiae, depletion of RPL7 showed a 
decrease in the levels of 28S with an accumulation of the 45S and 41S rRNA 
precursors. Furthermore, it is thought that RPL7, along with RPL8, might be necessary 
for the association and function of the A3 assembly factors in yeast (Jakovljevic et al., 
2012). Therefore, in this chapter, knockdowns of RPL7, RPL10, RPL18, and RPL21 were 
performed and analysed by northern blot analysis and pulse-chase labelling to 
determine the rRNA processing defects and whether the same defects were shown as 
described previously. The data showed that depletion of RPL7, RPL18 and RPL21 
resulted in ribosome biogenesis defects (Figure 3.5). RPL7 and RPL18 depletion 
resulted in the accumulation of the 36SC precursor in the RPL7 and RPL18 knockdowns 
(Figure 3.5B). This precursor is not usually found in cells and indicates a defect in site 2 
cleavage (Sloan et al., 2013b), as shown in Figure 3.11. As site 2 in humans is thought 
to be equivalent to the A3 cleavage site in yeast (Sloan et al., 2013b), this supports 
previous findings that RPL7 is required for the functioning of the A3 factors (Jakovljevic 
et al., 2012).  Furthermore, the RPL21 knockdowns resulted in reduction in 28S and 
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5.8S but an accumulation in 32S (Figure 3.5). This could be attributed to a defect in 
ITS2 cleavage, resulting in a lack of cleavage between the 5.8S and 28S rRNAs (as 
shown in Figure 3.11). This supports recent findings in yeast that RPL7 and RPL18 are 
both involved early in ribosome biogenesis whilst RPL21 is a later acting factor 
(Gamalinda et al., 2014). Interestingly, depletion of RPL10 showed no rRNA processing 
defects. However, it was previously reported that the RPL10 mutation, R98S, caused 
ribosome biogenesis and proliferation defects in mammalian lymphoid cells 
(Keersmaecker et al., 2013). Therefore, further experimentation is required to fully 
understand the role of RPL10 in ribosome biogenesis.  
 
These data, taken together, suggest that RPL7 and RPL18 are required for site 2 
cleavage in ITS1 to separate the large and small subunit rRNAs, whilst RPL21 is 
required for cleavages in ITS2 to separate the 5.8S and 28S rRNAs.  This data provides a 
novel insight into the role of these ribosomal proteins in large subunit rRNA 
processing, helping to unravel the complicated human rRNA processing pathway.  
5S RNA incorporation into the ribosomes is an important step as disruptions to this 
process result in the activation of p53 (Sloan et al., 2013a). Currently it is known in 
yeast that Syo1 transports RPL5 and RPL11 into the nucleus and acts as an assembly 
platform for the 5S RNP (Calvino et al., 2015). Rpf2 and Rrs1 then chaperone the 
complete 5S RNP complex into the ribosome (Kharde et al., 2015, Madru et al., 2015, 
Morita et al., 2002, Zhang et al., 2007) where RPL11 docks onto the 25S rRNA (Rhodin 
et al., 2011) and the 5S RNP is locked into conformation by Rpf2, Rsa4 and Nsa2 to 
prevent any rotation (Kharde et al., 2015, Bassler et al., 2015). The final stage of 5S 
RNP incorporation relies on the removal of Rsa4 from the 5S RNP which allows for the 
rotation of the structure by 180o to produce the 5S RNP conformation found in mature 
 
 
Figure 3.11. rRNA processing defects in ITS1 and ITS2. Schematic representation of the rRNA 
precursors showing defects in cleavage of site 2 results in the 36SC precursor instead of the 32S 
precursor. Defects in ITS2 cleavage result in accumulation of the 32S precursor.  
ITS2
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ribosomes (Bassler et al., 2015, Leidig et al., 2014). However, in humans the 
homologues of Rrs1 and Rpf2, RRS1 and BXDC1, are not associated with the 5S RNP 
outside of pre-ribosomes and depletion of RRS1 and BXDC1 has little effect on 5S RNP 
recruitment (Sloan et al., 2013a). However it was shown that depletion of the 
nucleolar protein, PICT-1 had a much greater effect on 5S RNP recruitment (Sloan et 
al., 2013a). Therefore, this suggests that the 5S RNP recruitment into the ribosome 
differs between yeast and ribosomes and thus it was important to investigate this 
further. The data presented in this chapter offers the possibility that RPL7, RPL18 and 
RPL21, but not RPL10, are required for integration of the 5S rRNA into the ribosome 
(Figure 3.4). As these factors severely affect large subunit production (Figure 3.5), it 
was unsurprising that they resulted in a defect in 5S RNP recruitment into the 
ribosome. However, it had been previously demonstrated that factors involved in large 
subunit production do not all have the same effect on 5S rRNA incorporation into the 
ribosome. Depletion of PICT-1, RRS1, or RPL11 had a similar effects on large subunit 
production but depletion of RPL11 and PICT-1 had a much stronger influence on 5S 
rRNA integration into the ribosome than that of RRS1 (Sloan et al., 2013a). As the data 
presented in this chapter showed that depletion of RPL7, RPL18, or RPL21 have a 
profound effect on large subunit production and have a similar effect on 5S rRNA 
incorporation into the ribosomes to that of RPL11, this suggests that these proteins 
may be affecting 5S RNP integration directly. Therefore, it is possible that the 5S RNP 
incorporation into the ribosome requires interactions with RPL7, RPL18, RPL21 and the 
28S rRNA as a binding pocket.  
Depletion of RPL7, RPL18 and RPL21, but not RPL10 resulted in RPL5-dependent p53 
accumulation in the cells. This suggests that accumulation of ‘free’ 5S RNP, as a result 
of the depletion of RPL7, RPL18 and RPL21, results in p53 activation. Furthermore, 
RPL7 and RPL18 depletion resulted in an accumulation of cells in G1/G0 which is 
consistent with p53 activation (Lin et al, 1992). The data in this chapter, therefore, 
suggests that depletion of RPL7, RPL18 and RPL21, by decreasing 5S RNP incorporation 
into the ribosome (Figure 3.4) and affecting ribosome biogenesis (Figure 3.5), induce 
p53, leading to a cell cycle defect with cells accumulating in G1.  
Interestingly, RPL5 depletion resulted in an accumulation of cells in G2. It was 
previously shown in yeast that depletion of ribosomal proteins leads to either G1 or G2 
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arrest (Thapa et al, 2013) whilst in mouse embryonic stem cells, haploinsufficiency of 
RPL5 resulted in delayed G2 progression (Singh et al., 2014). However this is conflicting 
with Teng et al. (2013) who demonstrated that depletion of RPL5 had no effect on cell 
cycle progression. The data in this study (Figure 3.7) is in agreement with Singh et al. 
(2014) that a reduction in RPL5 leads to delayed G2 progression, although the 
mechanisms behind this are, at current, unknown. Investigation of the factors involved 
in this G2 arrest could help to uncover new treatments for patients with mutations in 
RPL5 and RPL11.  
Whilst depletion of RPL7, RPL18, and RPL21 all affected 5S RNP integration into the 
ribosome and induced p53, depletion of RPL10 did not. RPL10 has been shown to be to 
be a late-acting ribosome biogenesis factor that is recruited in the cytoplasm in yeast 
(Johnson et al., 2002, Nguyen et al., 1998, Gamalinda et al., 2014) and it was 
demonstrated that depletion of Rpf2/Rrs1 prevented RPL10 association with pre-
ribosomes (Zhang et al., 2007) suggesting that RPL10 recruitment occurs after 5S RNP 
integration, which may offer an explanation for why RPL10 did not affect 5S RNP 
integration. Furthermore, the RPL10 knockdown (Figure 3.3) did not appear to be as 
efficient as the knockdown for RPL7, RPL18, and RPL21 and thus it must be taken into 
consideration that this may affect the downstream results. Therefore, if a more 
efficient knockdown could be attained and the same results were seen, this would help 
to support the findings in this chapter.  
The human ribosome structure has been solved during the course of this project 
(Khatter et al, 2015) and shows some differences in the binding pocket (Figure 3.12). In 
human ribosomes, RPL7 makes less contact with the 5S RNP, which may explain why 
the RPL7 depletions had less of an impact on p53 signalling than the RPL21 or RPL18 
depletions. RPL18 makes the most contact around the 5S RNP, possibly contributing to 
the larger impact on p53 levels. As it was also shown that, in yeast,  the 5S RNP rotates 
upon incorporation into the ribosome (Leidig et al., 2014) , this suggests that the 
position of the complex in the mature ribosome is not the same at the time of 
incorporation. However, despite this, the data presented in this chapter suggests that 
RPL7, RPL18 and RPL21 may play a role in recruitment of the 5S RNP, therefore 
suggesting that the 5S RNP requires contact with RPL7, RPL18, RPL21 and the 28S rRNA 
for its integration into the ribosome. It would be beneficial in the future to be able to 
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investigate whether RPL7, RPL18 or RPL21 are mutated in any diseases as this may 
implicate p53 in the pathogenesis of these conditions. Therefore, published array data 
could be analysed to detect any changes in the levels of those proteins in various 
conditions.  
 
The second part of this chapter investigated the ability of RPL11 to bind to the 28S 
rRNA. As previously described, the 5S RNP docks onto helix 84 of the 25S/28S rRNA 
upon integration into the ribosome (Rhodin et al., 2011). By analysis of the T. 
thermophila ribosome crystal structure (Klinge et al., 2011) it was noted that the 28S 
appeared to contact RPL11 in the same region that MDM2 binds (Zhang et al., 2011).  
Upon investigation, it was found that helices 83-85 of the 28S rRNA (Figure 3.8) bind 
directly to GST-RPL11 (Figure 3.10). Helix 84 alone did not bind to GST-RPL11, implying 
that it is either missing the crucial binding region or that it does not fold correctly. This 
could be an important finding as helix 83-85 could potentially be used therapeutically 
to block 5S RNP-mediated p53 induction. During the course of this project, the 
structure of the RPL11-MDM2 complex was solved (Zheng et al., 2015) and the authors 
demonstrated that the binding of the 28S rRNA to RPL11 and MDM2 was mutually 
exclusive (Figure 3.13), further supporting the data in this body of research.   
 
Figure 3.12 The cryo-EM structure of the human ribosome showing the RNP and the surrounding 
ribosomal proteins. Top view of the human ribosome structure showing the 4 ribosomal proteins, RPL7, 
RPL10, RPL18 and RPL21 with (A), or without (B), the 5S RNP. The 5S rRNA is shown in white, RPL5 in red and 
RPL11 in purple. RPL18 is brown, RPL7 is green, RPL21 is blue, RPL10 is orange and the 28S rRNA is in grey.  
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An interesting observation from this study was that GST-RPL11, under the conditions 
used, appeared to be unable to bind the 5S rRNA. However, GST-RPL5 was shown to 
bind the 5S rRNA. This suggested that, as RPL5 and RPL11 are both known to bind the 
5S rRNA in the RNP but not each other, RPL11 may require RPL5 binding first in order 
to bind the complex. This could be an important factor for the formation of the 5S RNP 
as there may be mechanisms in place to regulate these binding steps. Furthermore, it 
suggested that RPL5 may induce a conformational change in 5S upon binding that then 
allows for the binding of RPL11. Interestingly, it was demonstrated in X. laevis that the 
binding of RPL5 to the 5S rRNA caused structural changes in the region of the rRNA 
that binds RPL11 (Scripture and Huber, 2011) and thus my data may support these 
findings. 
This work has revealed many insights into how the 5S RNP is recruited into the 
ribosome and has laid a foundation for future research. It was shown that the helix 83-
85 of the 28S rRNA is able to bind to RPL11 and thus it would be interesting to test the 
hypothesis that this rRNA fragment can prevent RPL11 binding to MDM2 in vitro. In 
addition, introduction of this rRNA fragment into cells to attempt to block 
MDM2/RPL11 interactions could provide a novel way to prevent p53 induction in cells. 
Furthermore, the data presented in this chapter has shown that RPL7, RPL18 and 
RPL21 are ribosome biogenesis factors, involved in ITS1 and ITS2 processing 
respectively, that are required for integration of the 5S RNP into the ribosome.  
 
Figure 3.13 The binding of the 28S rRNA and MDM2 to RPL11 are mutually exclusive. (A) Interaction 
between the 5S RNP and MDM2. Cryo-EM structure from the human ribosome (Khatter et al., 2015) super-
imposed with the MDM2-RPL11 structure (Zheng et al., 2015). RPL5 is shown in red, RPL11 in purple and 
the 5S rRNA in white. MDM2 is shown in blue with the lighter shade representing the zinc finger domain 
and the dark blue the acidic domain. (B) As in A but with the 28S rRNA-5S RNP interaction in the ribosome. 
The 28S rRNA is shown in grey.  (C) A combination of A+B to show overlapping regions. 
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CHAPTER FOUR: INVESTIGATION INTO THE ROLE OF 
SRSF1 AND PRAS40 AS POTENTIAL REGULATORS OF THE 
5S RNP-P53 PATHWAY 
4.1 Introduction 
Ribosomes are essential for the translation of mRNA into proteins and the production 
of ribosomes dictates cell growth, proliferation and differentiation (Rudra and Warner, 
2004, Warner, 1999b, Sulic et al., 2005, Thomas, 2000). As ribosomes are crucial to the 
survival of cells, ribosome biogenesis is tightly regulated. When ribosome biogenesis is 
disrupted, one mechanism the cell has to protect itself is activation of the tumour 
suppressor, p53. Induction of p53 triggers pathways involved in DNA damage repair, 
cell cycle arrest, senescence, and apoptosis (Ko and Prives, 1996, Timofeev et al., 2013, 
Sperka et al., 2012, Sugikawa et al., 1999). In normal, unstressed cells, MDM2 
polyubiquitinates p53 and targets it for the degradation by the 26S proteasome 
(Honda and Yasuda, 1999). Furthermore, p53 is regulated by ARF which binds to, 
inactivates, and promotes degradation of MDM2 (Zhang et al., 1998), thus inducing 
p53. 
One component of the large subunit, the 5S RNP (Figure 4.1A), has been shown to play 
a crucial role in the regulation of p53 in cells. The 5S RNP has been shown to activate 
p53 through interaction with MDM2 and ARF, the process of which is summarised in 
Figure 4.1B. Many ribosomal proteins have been shown to bind to MDM2 (Zhang and 
Lu, 2009). However, it has since been established that the 5S RNP-MDM2 interactions 
are crucial for p53 regulation. Depletion of any of the 3 components of the 5S RNP 
were able to counteract the effects on p53 as a result of Actinomycin D (ActD) 
treatment to cells (Bhat et al., 2004, Dai and Lu, 2004, Sloan et al., 2013a, Bursac et al., 
2012, Donati et al., 2013). ActD is a drug that activates p53 by selectively inhibiting Pol 
I transcription, preventing transcriptional elongation (Sobell, 1985) and thus induces 
ribosomal stress to cells as RNA Pol I transcribes the 5.8S, 18S and 28S ribosomal RNAs 
but, crucially, not the 5S rRNA. As the 5S RNP components were crucial for ActD-
induced p53 activation, this suggested that the 5S RNP is involved in activating p53 in 
ribosomal stress situations. Furthermore, it has recently been demonstrated that the 
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5S RNP is crucial for the normal homeostasis of p53 (Sloan et al., 2013a) as well as for 
the activation of p53 during ribosomal stress (Donati et al., 2013, Sloan et al., 2013a). 
In addition to activating p53 by interacting with MDM2, one other way that the 5S RNP 
regulates p53 signalling is through the tumour suppressor, ARF. ARF binds to and 
inhibits MDM2, allowing for p53 activation (Honda and Yasuda, 1999) and it has been 
recently shown that 5S RNP is essential for the full activity of ARF (Sloan et al., 2013a). 
As ARF expression inhibits ribosome biogenesis (Bertwistle et al., 2004, Itahana et al., 
2003), this suggested that ARF is able to activate p53 by both directly binding to 
MDM2 and also by increasing the amount of non-ribosomal 5S RNP by disrupting 
ribosome biogenesis. All of these data taken together showed the 5S RNP to be a vital 
link between cell proliferation and ribosome production.   
 
Defective ribosome production and, consequently, the activation of p53, can lead to 
diseases known as ribosomopathies and so a greater understanding of 5S RNP 
signalling may lead to potential new therapies for these diseases. One ribosomopathy 
is Diamond Blackfan Anaemia (DBA) which is characterized by a severe reduction in 
erythroid precursor cells due to apoptosis or a failure to differentiate (Quarello et al., 
2010a). Almost half of all DBA patients have haploinsufficiency mutations in the 
ribosomal protein genes of which some of these are in RPL11 or L5. 70% of patients 
 
Figure  4.1 The role of the 5S RNP in p53 signalling (A) The surface view of the structure of the 5S RNP from 
the human ribosome cryo-EM structure (Khatter et al., 2015). The 5S RNP is composed of the 5S rRNA 
(white) with the ribosomal proteins RPL5 (red) and RPL11 (purple). (B) The current proposed pathway for 
the interactions between the 5S RNP and p53. Ribosome defects lead to accumulation of the 5S RNP which 
can bind to MDM2. MDM2 is a negative regulator of p53 but in the presence of the 5S RNP, the suppression 
is lost and p53 activated. ARF is a suppressor of MDM2 that can also be activated by the 5S RNP to further 
activate p53.  
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with physical malformations carry RPL5 and RPL11 mutations. Generally, RPL5 
mutations are linked to very severe forms of DBA and can lead to thumb defects, cleft 
lip and/or palate which are not seen with other DBA mutations (Quarello et al., 2010a, 
Gazda et al., 2008). 
One explanation for the pathogenesis of DBA is that defects in ribosomal proteins may 
lead to accumulation of p53 and thus cell-cycle arrest and apoptosis in erythroid cells 
(Dai and Lu, 2004). However, the mechanisms behind the pathogenesis of DBA with 
patients harbouring RPL5 and RPL11 mutations is less understood. It has been 
demonstrated that RPL11 expression in erythroleukaemic cells caused activation of 
STAT5 which acts as a promoter of angiogenesis (Kummalue et al., 2015). This 
suggested that RPL11 may be involved in the regulation of erythroid cell proliferation. 
However there is a need for a greater understanding of the pathogenesis of DBA as 
there are few effective treatments available apart from blood transfusions and bone 
marrow transplants.  
One further treatment of DBA is with L-leucine. L-leucine was suggested due to the 
links with ribosome production defects and translational inefficacy in DBA patients as 
amino acids have been shown to regulate translation through mTOR signalling (Kimball 
and Jefferson, 2006). Initial tests in zebrafish and mice models of DBA resulted in an 
improvement in their anaemia upon L-leucine treatment (Boultwood et al., 2013, 
Jaako et al., 2012, Payne et al., 2012). In patient trials within 6 months the patients 
became transfusion independent and showed increased erythroid differentiation 
(Pospisilova et al., 2007). L-leucine is able to trigger the mTOR pathway (Lynch, 2001, 
Gran and Cameron-Smith, 2011) which has recently been closely linked to the 5S RNP 
via the proline-rich AKT Substrate of 40kDa (PRAS40) (Havel et al., 2014). Investigation 
of this link may further the understanding of the regulation of the 5S RNP and make 
treatment of DBA more effective.  
PRAS40, also known as AKT1S1, is a protein that was first identified as AKT substrate 
that, when phosphorylated by AKT, is able bind to the scaffold protein, 14-3-3 
(Kovacina et al., 2003). One of the major pathways that PRAS40 is important for is the 
regulation of mTORC1. mTORC1 is a complex of the mammalian Target of Rapamycin 
(mTOR), Raptor and mammalian lethal with SEC13 protein 8 (mLST8) that promotes 
cell growth in response to growth signals (Kim et al., 2003, Kim et al., 2002, Fonseca et 
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al., 2007). One way that mTORC1 is regulated via AKT is through PRAS40. When 
PRAS40 is non-phosphorylated, it binds to Raptor and inhibits mTORC1s kinase activity. 
In the presence of growth factors, PRAS40 is phosphorylated by mTORC1 and AKT, 
dissociates from Raptor and results in the activation of mTORC1 (Thedieck et al., 2007, 
Fonseca et al., 2007). 
 
Havel et al. (2014) demonstrated, by immunoprecipitation, that nuclear PRAS40 was 
able to bind RPL11 and that this binding was dependent upon the phosphorylation of 
PRAS40 via mTORC1 and AKT at residues S221 and T246. Due to the nuclear nature of 
this binding, it was suggested that PRAS40-RPL11 complex does not occur within 
ribosomes. Further to this, it was shown that PRAS40 depletion in U2OS cells lead to an 
increase in p53 protein levels in an RPL11 dependent manner. When ActD was used at 
levels that increase p53 via the 5S-RNP pathway in conjunction with PRAS40 depletion, 
PRAS40 knockdown was found to have an additive effect suggesting that the two 
pathways were linked. It was hypothesised that PRAS40 may block RPL11 translocation 
from the nucleoli to the nucleoplasm and thus prevents its interaction with MDM2 as 
summarised in Figure 4.2. Interestingly, the complex containing RPL11 and PRAS40 was 
found to have a high molecular weight of between 300-700kDa and thus it was 
 
Figure 4.2 Summary of the current knowledge of the involvement of PRAS40 and SRSF1 in p53 signalling. 
PRAS40 is known to interact with RPL11, preventing its interaction with MDM2. MDM2 polyubiquitinates 
p53 and targets it for proteasomal degradation, thus inactivating p53. SRSF1 interacts with RPL5 and MDM2 
to block the ubiquitin ligase activity of MDM2, thus activating p53 and triggering senescence.  
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hypothesised that this could contain other unidentified proteins. Questions, therefore, 
arise as to whether these proteins could be the other 5S RNP components.  
Whilst PRAS40 may be suppressing the 5S RNP pathway, a potential activator of the 
pathway has also been identified. Serine/Arginine rich Splicing Factor 1 (SRSF1, also 
known as Alternative Splicing Factor- ASF) was shown to interact with RPL5 and induce 
p53. SRSF1 is an alternative splicing factor involved in a variety of different cellular 
processes such as chromatin remodelling (Loomis et al., 2009), translation (Michlewski 
et al., 2008), and mRNA surveillance (Zhang and Krainer, 2004). SRSF1 is upregulated in 
cancers such as breast cancer and over-expression of SRSF1 is able to trigger oncogenic 
transformation in mouse and human cells (Anczukow et al., 2012). Furthermore, SRSF1 
interacts with translating ribosomes (Sanford et al., 2005, Sanford et al., 2004). SRSF1 
regulates alternative splicing of the ribosomal protein S6 kinase (S6K), producing S6K 
short isoforms which bind to mTORC1 and enhance 4E-BP phosphorylation, increasing 
translation initiation (Karni et al., 2007, Ben-Hur et al., 2013). Like PRAS40, SRSF1 is 
also able to interact with mTORC1 and increases the phosphorylation of S6K and 4E-
BP, enhancing translation efficiency (Michlewski et al., 2008) as summarised in Figure 
4.3.   
 
Figure 4.3 The role of PRAS40 and SRSF1 in the regulation of translation via mTORC1. Schematic 
representation of the two pathways SRSF1 regulates translation. The first pathway is indicated by 
black arrows. SRSF1 interacts with mTORC1 and results in phosphorylation of S6K and 4E-BP. 
Phosphorylation of S6K promotes ribosome biogenesis whilst phosphorylation of 4E-BP results in 
enhanced translation. The second pathway is indicated by green arrows. SRSF1 results in the 
generation of an alternatively spliced S6K variant that is able to upregulate mTOR and increase 
translation through the inhibition of 4E-BP. PRAS40 binds to and inhibits mTORC1, resulting in 
decreased ribosome biogenesis and translation.  
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Fregoso et al. (2013) demonstrated a role for SRSF1 in p53 signalling via RPL5. 
Interactions were identified between RPL5 and SRSF1, whereas there was no evidence 
of the involvement of RPL11 or the 5S rRNA. SRSF1 depletion was able to counteract 
the p53 induction from ActD treatment. As Act D, at concentrations below 10ng/ml, is 
able to stimulate p53 in a specifically 5S-RNP dependent manner, this suggested that 
SRSF1 was important for p53 induction via Actinomycin D. In addition, it was shown 
that when SRSF1 was over-expressed in BJ-TT cells, p53 was induced in an RPL5 
dependent manner. This p53 response resulted in senescence. SRSF1 was also found to 
bind to MDM2 and thus it was suggested that RPL5, MDM2 and SRSF1 form a distinct 
complex as summarised in Figure 4.2. This contradicts the findings that all 3 
components of the 5S RNP are required to activate p53 (Sloan et al., 2013a, Donati et 
al., 2013) and so it is currently unclear as to whether the 5S RNP is involved or whether 
RPL5 is acting independently.  
SRSF1 was shown to assist in RPL5-dependent p53 activation, whilst PRAS40 was 
demonstrated as an inhibitor of RPL11-dependent p53 activation. Furthermore, as 
SRSF1 enhances mTOR activity whilst PRAS40 negatively regulates the pathway (Figure 
4.3), these data together suggest that the SRSF1 and PRAS40 may antagonise one 
another. As mTOR is activated by L-leucine, this could be an important step to 
understanding the role of L-leucine treatment in patients with DBA.  
The aims of this chapter were to establish whether SRSF1 and PRAS40 interact with the 
5S RNP as a whole and investigate how this affects ribosome biogenesis and 5S RNP-
p53 signalling in U2OS cells. During this chapter I investigated the effect of both over-
expression and depletion of SRSF1 and PRAS40 on the 5S RNP signalling pathway 
through investigating the 5S RNP integration into the ribosome, p53 signalling, 
localisation of RPL5 and RPL11, and cell cycle progression.  
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4.2 Results 
4.2.1 Creation of inducible cell lines expressing FLAG-SRSF1 and 
FLAG-PRAS40 
In order to study over-expression of SRSF1 and PRAS40 in cells, cell lines were created 
expressing FLAG-tagged SRSF1 and PRAS40. Furthermore, the effect of depletion of 
SRSF1 and PRAS40 was investigated. As previous experiments into SRSF1 and PRAS40 
interacting with the 5S RNP had been carried out in different cell lines (Fregoso et al., 
2013, Havel et al., 2014), it was necessary to establish that endogenous PRAS40 and 
SRSF1 could be detected in U2OS cells. Therefore, SRSF1 and PRAS40 protein levels 
were investigated in a panel of human cell lines; HEK293, HeLa, MCF-7 and U2OS.  
The cells were grown at 37oC in growth medium until 80% confluent before harvesting, 
separating whole cell extracts via SDS-PAGE and western blotting. Anti-PRAS40 and 
anti-SRSF1 antibodies were used with an α-Tubulin antibody as a loading control 
(Figure 4.4A-B).  In Figure 4.3A, it was noted that the PRAS40 antibody gave an 
additional signal of a higher molecular weight which was presumably cross reactivity or 
an isoform of PRAS40 with a higher molecular weight. Depletion of PRAS40 (shown 
later in Section 4.2.6) resulted in a decrease in the lower molecular weight signal, 
identifying this as PRAS40. SRSF1 and PRAS40 could be detected in all 4 cell lines 
(Figure 4.4A-B). As the cell lines expressed endogenous PRAS40 and SRSF1, it was 
therefore possible to study the effect of depletion of the proteins in these cell lines.  
In order to create cells expressing FLAG-tagged SRSF1 and PRAS40, U2OS Flp-In cells 
were co-transfected with pcDNA5 plasmids containing either the PRAS40 or SRSF1 
coding sequences. The pcDNA5 plasmid contains a tetracycline inducible promoter and 
thus the expression of the protein can be controlled. The cells containing the insert 
were selected using hygromycin B and selection was maintained throughout culture.  
The selected cells were incubated at 37oC with media supplemented with 0-1 µg/ml 
tetracycline for 48 hours before harvesting and separating whole cell lysates via SDS-
PAGE. Western blot analysis (Figure 4.4C-D) showed that both proteins were induced, 
as indicated by an additional signal from the anti-SRSF1 and anti-PRAS40 antibodies 
and a signal from the anti-FLAG which is not present in the un-induced cells. A higher 
molecular weight signal was seen using the PRAS40 antibody without the addition of 
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tetracycline. As this was not detected with the anti-FLAG antibody, it is possible that 
this a cross-reactive band as seen in Figure 4.4A. 
 
This data as a whole suggested that the proteins were being expressed in U2OS cells 
and that 1 µg/ml was an appropriate concentration of tetracycline to use for future 
experiments using the FLAG-SRSF1 and FLAG-PRAS40 stable cell lines as this showed a 
high level of expression.  
4.2.2 Localisation of FLAG-SRSF1 and PRAS40 
In order to ensure that FLAG-tagged SRSF1 and PRAS40 were being localised as 
expected, immunofluorescence was utilised. SRSF1 is normally localised in the nucleus 
in nuclear speckles (Koizumi et al., 1999, Caceres et al., 1997) whilst PRAS40 shuttles 
between the nucleus and the cytoplasm and has been shown to co-localise with RPL11 
in the nucleoli in U2OS cells (Havel et al., 2014).  
 
 
Figure 4.4. SRSF1 and PRAS40 expression in cell lines. (A) and (B) Endogenous PRAS40 and SRSF1 
expression across different cell lines. Cells harvested from HeLa, HEK 293, MCF-7 and U2OS cells 
were grown until 80% confluent before whole cell extracts were separated by SDS-PAGE. Western 
blot analysis was performed using anti-PRAS40 and anti-SRSF1 antibodies to show endogenous 
expression. * indicates cross reactivity. (C) and (D) Western blots to show expression of the FLAG-
tagged proteins. U2OS cells containing FLAG-tagged PRAS40 or SRSF1 were induced with 0-1 µg/ml 
tetracycline, to induce expression, for 48 hours before harvesting. Whole cell extracts were 
separated by SDS-PAGE before western blotting using antibodies raised against FLAG, PRAS40, 
SRSF1, or Karyopherin.  
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U2OS SRSF1 or PRAS40 expressing cells were grown on cover slips and incubated for 
48 hours at 37oC in media supplemented with 1 µg/ml tetracycline. The cells were then 
used in immunofluorescence with anti-FLAG (to target the FLAG-tagged SRSF1 or 
PRAS40), anti-fibrillarin (to show nucleolar localisation) and DAPI (to stain the nucleus) 
(figure 4.5). The anti-FLAG antibody gave signal mostly in the nucleus with the 
expression of FLAG-SRSF1, as shown by co-localisation with DAPI. There was no 
evidence of any enrichment in the nucleoli as the signal was evenly distributed 
throughout the nuclei and did not have any stronger signal coinciding with the 
fibrillarin signal. There was very little SRSF1 detected in the cytoplasm. 
 
In the cells expressing FLAG-PRAS40, the anti-FLAG antibody was detected most 
strongly in the cytoplasm.  There was little co-localisation of the FLAG antibody with 
the DAPI staining, suggesting that FLAG-PRAS40 is not found in the nucleus. Similarly to 
the FLAG-SRSF1 cells, there was no enrichment of FLAG-PRAS40 in the nucleoli as 
demonstrated by no co-localisation of the FLAG antibody signal with that of the 
fibrillarin antibody. This suggests the possbility that the FLAG-PRAS40 used in this 
project is not normally localised in the nucleoli of U2OS cells, in contrast to what was 
previously found using a different FLAG-PRAS40 expression system (Havel et al., 2014).  
 
Figure 4.5. Localisation of FLAG-tagged SRSF1 and PRAS40. U2OS cells stably expressing tetracycline-
inducible FLAG-SRSF1 or FLAG-PRAS40 were grown at 37oC on cover slips for 48 hours in medium 
containing 1 µg/ml tetracycline to induce protein expression. Cells were fixed in 4% paraformaldehyde 
and incubated with anti-FLAG (red) anti-fibrilliarin to indicate the nucleoli (green) and DAPI to stain the 
nuclei (blue). Examples of nucleoli are shown with white arrows. Scale bar represents 1 µm. 
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4.2.3 Expression of FLAG-tagged SRSF1 and PRAS40 increase p53 
levels in U2OS cells 
SRSF1 over-expression was shown to induce p53 in BJ-TT cells, however, the effect of 
PRAS40 over-expression on p53 had not been reported, therefore SRSF1 and PRAS40 
over-expression studies were carried out to see whether this could be replicated in 
U2OS cells. U2OS Flp-In cells expressing either PRAS40 or SRSF1 were incubated in 
growth medium supplemented with 0-1µg/ml tetracycline for 48 hours. Whole cell 
lysates were separated by SDS-PAGE before western blotting (Figure 4.6). Karyopherin 
was used as a loading control. 
 
In agreement with previous findings (Fregoso et al., 2013), expression of FLAG-tagged 
SRSF1 (Figure 4.6A) resulted in an increase in p53 protein levels, suggesting that 
expression of SRSF1 induces p53. When analysed by densitometry analysis (Figure 
4.6C), this expression gave, on average, a 5.5 fold increase in the levels of p53. 
Interestingly, expression of the FLAG-tagged PRAS40 (Figure 4.6B) also resulted in an 
increase in p53 protein levels. When analysed by densitometry analysis (Figure 5.6C), 
the expression of PRAS40 resulted in, on average, a 3 fold increase in the levels of p53. 
This suggests that, in U2OS cells, expression of FLAG-tagged PRAS40 or SRSF1 results in 
an increase in p53 levels.  
Previously it was shown that over-expression of PRAS40 combined with over-
expression of RPL11 resulted in reduced p53 protein levels compared to expression of 
Figure 4.6. The effect of SRSF1 and PRAS40 over-expression on p53. (A+B) Representative western blots to 
show the effect of over-expression of SRSF1 and PRAS40 on p53 levels. U2OS cells expressing FLAG-SRSF1 or 
FLAG-PRAS40 were induced with 1-1000 ng/ml tetracycline as indicated for 48 hours prior to harvesting. 
Whole cell extracts were separated by SDS-PAGE and immunoblotted using antibodies against the 
endogenous proteins, p53, and karyopherin as indicated on the right. Karyopherin was used as a loading 
control. (C) Densitometry analysis of A+B. Each bar in C represent the mean ± the standard deviations of the 
means, n=3. Statistical analysis was determined by paired t test. NS= non-significant, *= P ≤ 0.05, **= p≤ 0.01, 
***= p≤ 0.001. 
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RPL11 alone (Havel et al., 2014). However, the effect of PRAS40 over-expression alone 
on p53 levels was not reported and thus cannot be compared to the results shown 
here.  
4.2.4 SRSF1 and PRAS40 over-expression does not affect cell cycle 
progression 
As the data suggested that FLAG-PRAS40 and FLAG-SRSF1 expression in U2OS cells 
appeared to result in increases in p53 protein levels, it was important to investigate 
the effects on cell cycle progression as p53 is a regulator of the cell cycle through its 
downstream effectors such as p21, GADD45 and 14-3-3 (Waldman et al., 1995, Carrier 
et al., 1994, Hermeking et al., 1997).  
U2OS cells were induced for 48 hours with 1 µg/ml tetracycline and fixed in ice cold 
ethanol before propidium iodide staining and flow cytometry analysis. Figure 4.7A 
depicts the representative dot plots and histograms produced whilst Figure 4.7B is a 
graphical representation of the percentage of cells at each stage in the cell cycle.  
The control cells, on average, had 54% of cells in G1/G0, 25% of cells in S phase and 
21% of cells in G2/M phase. There was no significant change in the cells expressing 
FLAG-tagged SRSF1 or PRAS40. When analysed using a paired t-test, the p value for the 
percentage of cells in G2/M for SRSF1 compared to the control was 0.89 and thus not 
significant. The p value for the G2/M for PRAS40 compared to the control was 0.2031, 
also considered to be not significant. This suggests that PRAS40 and SRSF1 over-
expression had no effect on cell cycle progression in U2OS cells, despite increases in 
p53 protein levels, possibly suggesting that they do not increase p53 activity.  
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4.2.5 SRSF1, but not PRAS40, co-purifies with the 5S rRNA. 
In order to investigate how SRSF1 and PRAS40 are involved in the 5S RNP pathway, 
immunoprecipitations were utilised to study the association of SRSF1 and PRAS40 with 
the 5S rRNA. The experiment was carried out in the presence or absence of ActD as the 
ability of these proteins to bind the 5S RNP could be dependent upon ribosomal stress. 
Cells expressing either control, SRSF1 or PRAS40 flag-tagged proteins were induced for 
48 hours with 1 µg/ml tetracycline followed by 5 ng/ml ActD treatment for 16 hours. 
The cells were incubated with anti-FLAG agarose for 2 hours before RNA extraction 
and northern blotting using 32P labelled probes that anneal to the 5S and 5.8S rRNAs 
 
Figure 4.7. Cell cycle analysis of SRSF1 and PRAS40 over-expression. (A) Control, SRSF1 or PRAS40 
expressing U2OS cells were induced with 1 µg/ml tetracycline for 48 hours before harvesting, fixing 
in ethanol and propidium iodide staining before flow cytometric analysis. The forward scatter (FSC) 
was plotted against the side scatter (SSC) and the live population of cells was gated on as shown in 
blue. The different stages of the cell cycle were then selected from the histograms. (B) Graphical 
representation of the percentage of cells at each stage in the cell cycle. Each bar in B represents the 
means ± the standard deviations of the means, n=3.  
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(Figure 4.8A). The northern blot was exposed to a phosphorimager screen and scanned 
to visualise the rRNAs. The FLAG-tag alone from the control cells expressing an empty 
pcDNA5 vector, did not show any interaction with the 5S or 5.8S rRNAs, suggesting 
that any binding seen was specific.  
The 5S rRNA or the 5.8S rRNA did not co-purify with FLAG-PRAS40 in control or ActD 
treated cells, suggesting that it PRAS40 not found in a complex with the 5S RNP in 
normal cells or those experiencing ribosomal stress. FLAG-SRSF1 co-purified with both 
the 5.8S and the 5S rRNA. SRSF1 interacts with translating ribosomes (Sanford et al., 
2005, Sanford et al., 2004) and thus interaction with the ribosomal proteins would be 
expected. However, when densitometry analysis was utilised (Figure 4.8B), it revealed 
that SRSF1 interacted with a higher percentage of the 5S rRNA than the 5.8S rRNA. As 
there 5.8S rRNA is mostly found in ribosomes whilst a high proportion of the 5S rRNA is 
non-ribosomal (Sloan et al., 2013a), this implies that SRSF1 may be interacting with 
free 5S rRNA as well as ribosome bound. Upon ActD treatment, the percentage of the 
total 5S rRNA and 5.8S rRNA bound by SRSF1 decreased suggesting that when the cells 
are undergoing ribosomal stress, SRSF1 interaction with ribosomes and/or the 5S RNP 
is decreased.  
As PRAS40 did not co-immunoprecipitate with the 5S rRNA, it was decided to look for 
interactions between PRAS40 and RPL5 and RPL11 as it had been previously reported 
that  RPL11 and PRAS40 interacted (Havel et al., 2014). Control, RPL5 and RPL11 Flp-In 
cells were induced for 48 hours with media containing 1 µg/ml tetracycline. The cells 
were lysed and incubated with anti-FLAG agarose for 2 hours prior to washing, elution, 
separation of the proteins by SDS-PAGE and western blotting (Figure 4.8C). MDM2 and 
PRAS40 antibodies were utilised as MDM2 is known to interact with RPL5 and RPL11 
(Marechal et al., 1994, Lohrum et al., 2003) and thus acts as a control. The FLAG-only 
control did not show any interaction with MDM2 whilst RPL5 and RPL11 showed 
interactions with MDM2.  
As with MDM2, PRAS40 did not co-purify with the FLAG-only control (Figure 4.8C). 
PRAS40 also did not co-purify with RPL5, suggesting that PRAS40 does not interact with 
RPL5. However, PRAS40 co-purified with the FLAG-RPL11, suggesting that PRAS40 is 
found in complexes with RPL11 exclusively and not RPL5 or the 5S rRNA. This further 
supports the evidence that PRAS40 may not interact with the 5S RNP.    
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4.2.6 Depletion of PRAS40 increases p53 activity whilst depletion of 
SRSF1 reduces p53 activity.  
In order to investigate the role of SRSF1 and PRAS40 in p53 signalling, PRAS40 or SRSF1 
were depleted in U2OS and MCF-7 cells. Both U2OS cells and MCF-7 cells have wild 
type p53 and so act as a good comparison. U2OS or MCF-7 cells were incubated in 
growth medium post-transfection with 20 µM siRNA duplexes targeting control, SRSF1 
or PRAS40 for 48 hours prior to harvesting. Whole cell lysates were separated by SDS 
PAGE and analysed by western blot using antibodies raised against SRSF1 and PRAS40 
(Figure 4.9A-B) and p53 and p21 (Figure 4.9C). Karyopherin was used as a loading 
control. Treatment of U2OS or MCF-7 cells with siRNAs targeting PRAS40 and SRSF1 
achieved a good level of knockdown of PRAS40 (Figure 4.9A) and SRSF1 (Figure 4.9B).  
 
Figure 4.8. SRSF1 interacts with the 5S RNP whilst PRAS40 only interacts with RPL11. (A) 
Representative northern blot of three repeats to show co-purification of PRAS40 and SRSF1 with the 
5S and 5.8S rRNAs. U2OS cells expressing empty vector, FLAG-SRSF1 or FLAG-PRAS40 were induced 
for 48 hours with 1 µg/ml tetracycline before treatment with 5ng/ml ActD in half of the samples for 
the final 16 hours. Cells were harvested and lysed before being incubated with anti-FLAG agarose for 
2 hours before washing. The bound complexes were eluted and RNA extracted before separating 
with acrylamide gel electrophoresis and northern blotting using 32P ATP labelled probes that 
hybridise to the 5S and 5.8S rRNAs. T denotes the 5% total loaded. (B) Densitometry analysis of A. 
The percentage of 5S and 5.8S bound from the total is shown. (C) Western blot to show 
immunoprecipitation using control, FLAG-RPL5 or FLAG-RPL11 U2OS cells. The cells were grown for 
48 hours in media supplemented with 1 µg/ml tetracycline to induce the expression of the FLAG-
tagged proteins. Cells were harvested and the lysates incubated with anti-FLAG agarose for 2 hours. 
The bound complexes were eluted and separated by SDS-PAGE before western blotting using 
antibodies raised against MDM2 and PRAS40. Each bar in B represents the means ± the standard 
deviations of the means, n=2. 
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In U2OS cells SRSF1 depletion did not affect p53 levels or p21 levels (Figure 4.9C). This 
suggested that SRSF1 depletion in U2OS cells does not induce p53. PRAS40 depletion 
caused, on average, a 2.5 fold increase in p53 levels (Figure 4.9D). There was also an 
increase in the p53 downstream effector, p21, suggesting that p53 levels and the 
activity of p53 were both increased.  
In MCF-7 cells, SRSF1 depletion resulted in the p53 protein levels reducing by half 
(Figure 4.9D). There was also a decrease in p21 levels. In contrast to the situation in 
U2OS cells, depletion of PRAS40 in MCF-7 cells had no noticeable impact on p53 or p21 
protein levels. This data shows that SRSF1 depletion results in a decrease in p53 
activity in MCF-7 cells and whereas PRAS40 depletion results in an increase in p53 
levels and activity in U2OS cells. This could be due to differences between the cell lines 
as later discussed.  
 
Figure 4.9. PRAS40 and SRSF1 depletion affects p53 and p21 levels. (A+B) Representative western 
blots to show the depletion of PRAS40 and SRSF1 in U2OS and MCF-7 cells. U2OS cells or MCF-7 cells 
were incubated with control, PRAS40 or SRSF1 siRNAs for 48 hours. Whole cell lysates were separated 
by SDS PAGE and western blotted for SRSF1 or PRAS40. (C) Representative western blot to show the 
effect of PRAS40 and SRSF1 depletion on p53 and p21 protein levels. U2OS or MCF-7 cells were treated 
with control, SRSF1 or PRAS40 siRNAs for 48 hours prior to harvesting. Whole cell extracts were 
separated by SDS-PAGE and western blotted using antibodies against p53 and p21. Karyopherin was 
used as a loading control. (D) Densitometry analysis of C. Each bar in D represents the means ± the 
standard deviation of the means, n=3. Statistical analysis was determined by paired t test. NS= non-
significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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4.2.7 SRSF1 and PRAS40 have opposing effects on ActD treatment 
It was previously demonstrated that SRSF1 depletion could counteract the p53 
response following ActD treatment whilst PRAS40 depletion had the opposite effect, 
resulting in increased p53 levels (Fregoso et al., 2013, Havel et al., 2015) however this 
had not been shown in the same cell lines and so it was decided to repeat these 
experiments in U2OS cells. U2OS cells were incubated in growth medium for 48 hours 
post-transfection with 20 µM SRSF1 or PRAS40 siRNA duplexes, followed by 5 ng/ml 
ActD treatment for the final 18 hours. Western blot analysis was carried out using 
antibodies raised against p53 along with a karyopherin antibody for a loading control 
(Figure 4.10A).   
In cells treated with the control siRNA, ActD treatment resulted in increased p53 levels 
compared to the untreated. However, in the SRSF1 depleted cells, the drug had a 
much milder effect with p53 protein levels reduced by half (Figure 4.10A+B). 
Interestingly, PRAS40 depletion had the opposite effect and resulted in a 2 fold 
increase in p53 in ActD treated cells (Figure 4.10A+B). In both cases, these results were 
found to be not quite significant by statistical analysis, although a general trend can be 
seen to support the previously published data and suggests that SRSF1 and PRAS40 
may be acting antagonistically in the 5S-RNP pathway.  
In order to determine whether the activity of p53 was affected, U2OS cells stably 
expressing a p53-regulated luciferase reporter under the control of p53 were 
incubated post-transfection with 20 µM siRNA duplexes targeting SRSF1 or PRAS40 for 
48 hours. In the final 18 hours, 5 ng/ml ActD was added to simulate ribosomal stress. 
As seen in Figure 4.10C, ActD treatment resulted in, on average, a 7 fold increase in 
luciferase levels above the control, suggesting p53 activation. 
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Depletion of PRAS40, however, showed a slight, but non-significant, reduction in this 
level whilst SRSF1 depletion shows a significant reduction in luciferase levels. This 
suggests that SRSF1 is required for both the increase in p53 levels and activity whilst 
PRAS40 depletion increases p53 levels, although not significantly, but does not 
significantly impact upon p53 activity. Interestingly, in the untreated cells, depletion of 
PRAS40 did not illicit increased p53 activity. As it has been previously seen that PRAS40 
depletion results in an increase in p53 protein levels, this suggests that PRAS40 
depletion is able to increase p53 protein levels but does not affect p53 activity above 
 
Figure 4.10. SRSF1 and PRAS40 have opposite effects upon ActD treatment. (A) Western blot to 
show p53 signalling after ActD treatment. U2OS cells were incubated at 37oC post-transfection with 
20 µM control, SRSF1 or PRAS40 siRNA duplexes for 48 hours. In the final 18 hours, 5 ng/ml ActD or 
an ethanol control was added. Cells were harvested and whole cell extracts separated by SDS-PAGE. 
Levels of p53 were analysed by western blot with karyopherin as a loading control. (B) Densitometry 
analysis was carried out on A using Image J software and the levels of induction normalised to the 
loading control. (C) U2OS cells stably expressing a p53-regulated luciferase reporter were depleted 
of SRSF1 or PRAS40 for 48 hours, followed by 5 ng/ml ActD treatment for the final 18 hours, as in A. 
Luciferase assays were used to determine firefly luciferase levels. A Bradford assay was used to 
normalise Luciferase levels to protein levels. Each bar in B+C represents the mean ± the standard 
deviation of the mean, n=3. Statistical analysis was determined by paired t test. NS= non-significant, 
*= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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that of ActD treatment alone. This could be the result of saturation whereby an 
increase in p53 levels can no longer result in an increase in p53 activity.  
4.2.8 Depletion of SRSF1 and PRAS40 counteract the p53 response 
from RPL5 and RPL11 over-expression. 
It was shown previously that RPL5 knockdown was able to counteract the p53 
response from SRSF1 over-expression (Fregoso et al., 2013). In order to determine 
whether SRSF1 had an effect on RPL11-mediated p53 signalling as well as RPL5-
mediated p53 signalling, the effect of depletion of SRSF1 on the p53 response from 
RPL5 or RPL11 expression was investigated.  
U2OS cells expressing FLAG-tagged RPL11 and RPL5 U2OS cells (Figure 4.11A) were 
incubated in growth medium for 48 hours post-transfection with 20 µM SRSF1 siRNA 
duplexes at 37oC. For the final 36 hours, 1 µg/ml tetracycline was added to the 
medium to induce the expression of the FLAG-tagged proteins. It was important to 
ensure that the knockdown had occurred before the expression of the FLAG-tagged 
proteins. After harvesting the cells and separating whole cell lysates by SDS-PAGE, a 
western blot was carried out with anti-p53, using anti-karyopherin as a loading control 
(Figure 4.11B).  
When densitometry analysis was applied to the blots (Figure 4.11C), it was observed 
that when SRSF1 was depleted, the p53 response was decreased in the RPL5 cells. A 
greater reduction in p53 protein levels was seen in the RPL11 cells, which is interesting 
because RPL11 was suggested to not be involved in the SRSF1-RPL5 mediated p53 
response.  
Furthermore, to investigate the role of PRAS40 on p53 signalling via the 5S RNP the 
effect of PRAS40 depletion on p53 protein levels as a result of SRSF1, RPL5, or RPL11 
expression was studied. U2OS cells over-expressing RPL5, RPL11, or SRSF1 were 
transfected with 20 µM SRSF1 (RPL5 and RPL11 only) or PRAS40 siRNA duplexes. In the 
final 36 hours, 1 µg/ml tetracycline was added to the medium to induce the expression 
of RPL5, RPL11, (Figure 4.11D) or SRSF1 (Figure 4.11E). Western blots (Figure 4.11F) 
were carried out as previously described.   
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Figure 4.11 Depletion of SRSF1 or PRAS40 counteracts the p53 response from RPL5 and RPL11 
over-expression. (A) Western blot analysis of RPL5 and RPL11 expression in U2OS cells. Cells 
expressing FLAG-tagged RPL5 or RPL11 were incubated in growth medium supplemented with 1 
µg/ml tetracycline for 48 hours to induce the expression of the proteins. Whole cell extracts were 
separated by SDS-PAGE and western blotted using an anti-FLAG antibody. Karyopherin was used as a 
loading control. (B) Western blot analysis of the effect of SRSF1 depletion in U2OS cells expressing 
RPL5 and RPL11. U2OS cells expressing FLAG-tagged RPL5 or RPL11 were incubated with growth 
medium post-transfection with 20 µM SRSF1 siRNA for 48 hours. In the final 36 hours, 1 µg/ml 
tetracycline was added to the medium to induce expression of the FLAG-tagged proteins. Whole cell 
extracts were separated by SDS-PAGE and western blotted using an anti-p53 antibody with anti-
karyopherin as a loading control. (C) Densitometry analysis of B. Bars represent the mean ± the 
standard deviation of the mean, n=3. NS= non-significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
(D) Western blot to show the effect of SRSF1 and PRAS40 depletion on the p53 induction after RPL5 
and RPL11 expression. Inducible U2OS cells expressing empty vector, FLAG-RPL11 or FLAG-RPL5 
were treated with siRNA against SRSF1 for 48 hours followed by induction of RPL5 or RPL11 with 
1µg/ml tetracycline for the final 36 hours. Cells were harvested and whole cell extracts separated by 
SDS-PAGE before western blotting for p53. Karyopherin was used as a loading control. (E) As in A, 
using FLAG-SRSF1 cells with a depletion of PRAS40. (F) Densitometry analysis of A+B showing the 
effect of PRAS40 depletion on p53 levels after expression of RPL11, RPL5, or RPL11, n=1.  
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As previously demonstrated in Figure 4.11B, RPL5 and RPL11 expression resulted in 
increased p53 in an SRSF1-dependent manner. In Figure 4.11D and 4.11F, PRAS40 
depletion resulted in a similar decrease in p53. This suggests that PRAS40 and SRSF1 
may both required for p53 induction upon the expression of RPL5 and RPL11. 
Furthermore, the effect of SRSF1 over-expression combined with depletion of PRAS40 
was studied. If SRSF1 and PRAS40 were acting antagonistically, an additive effect 
would be expected. However, these results show that SRSF1 over-expression induces 
p53 in a PRAS40-dependent manner (Figure 4.11E-F). All of this data taken together 
suggest that SRSF1 and PRAS40 are required for p53 activation via the 5S RNP. This is 
in contrast to the previous findings that depletion of SRSF1, RPL5 or RPL11 counteracts 
the p53 response after ActD treatment but PRAS40 depletion does not.  
4.2.9 Knockdown of SRSF1 and PRAS40 have effects the localisation 
of 5S RNP components. 
Havel et al. (2014) hypothesised that PRAS40 sequesters RPL11 to the nucleolus to 
prevent interactions between RPL11 and MDM2, however the effect of SRSF1 on RPL5 
or RPL11 localisation had not been studied. In order to investigate this, PRAS40 or 
SRSF1 were depleted in cells expressing FLAG-tagged RPL5 and RPL11 and, using 
immunofluorescence, localisation of the FLAG-tagged proteins was studied. U2OS 
expressing FLAG-RPL5 or FLAG-RPL11 were transfected with siRNAs targeting SRSF1 or 
PRAS40 and grown on coverslips in growth medium 48 hours with the addition of 1 
µg/ml tetracycline, to induce the RPL5 or RPL11 expression, for the final 24 hours. Cells 
were then fixed in 4% paraformaldehyde and used in immunofluorescence with anti-
FLAG antibody and DAPI staining to show the location of the nucleus (figure 4.12).  
In control cells, RPL11 was strongly localised in the nucleoli with the FLAG-antibody 
showing even distribution of RPL11 throughout the nucleus and cytoplasm. However, 
SRSF1 depletion resulted in a reduction of cytoplasmic staining in the cells. PRAS40 
depletion resulted in an enrichment of cytoplasmic RPL11 and some loss of nucleolar 
staining suggesting that PRAS40 may play a role in the cytoplasmic and nucleolar 
localisation of RPL11.  
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The control RPL5 cells showed the strongest anti-FLAG signals in the nucleoli and the 
nucleus and with almost no cytoplasmic signals. In the SRSF1 depleted cells, the 
enrichment of nucleolar FLAG signal was reduced, suggesting that SRSF1 may be 
required for nucleolar localisation of RPL5.  In the PRAS40 depleted cells, RPL5 showed 
a very similar localisation to the control cells, with strong nucleolar and nuclear signals. 
This suggests that whilst PRAS40 had an effect on RPL11 localisation, it is not involved 
in RPL5 localisation. SRSF1 depletion affected the localisation of both RPL5 and RPL11 
thus supporting the hypothesis that SRSF1 interacts with the 5S RNP but, as PRAS40 
only affected RPL11 localisation, this may support previous findings that PRAS40 only 
interacts with RPL11.  
4.2.10 Depletion of SRSF1 affects integration of the 5S RNP into the 
ribosome 
As SRSF1 depletion had an impact on the localisation of both RPL5 and RPL11 it was 
possible that this may impact upon the ability of RPL5 and RPL11 to be incorporated 
into ribosomes. Therefore, cell lysates from cells expressing FLAG-tagged RPL5 and 
RPL11 with control or SRSF1 siRNA treatment were applied to a glycerol gradient to 
 
Figure 4.12. SRSF1 and PRAS40 depletion affects localisation of RPL5 and RPL11. U2OS cells 
containing a tetracycline-inducible FLAG-tagged RPL5 or RPL11 were grown for 48 hours in the 
presence of SRSF1, PRAS40 or control siRNAs. In the final 24 hours, 1µg/ml tetracycline was added 
to induce the expression of RPL5 or RPL11. The cells were fixed in paraformaldehyde and used in 
immunofluorescence with anti-FLAG antibody (red). DAPI (blue) was used to stain the nucleus. Scale 
bar represents 1 μm.  
1 μm
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identify the proportion of the protein in small, free complexes as opposed to large, 
ribosome complexes. 
 
To do this, U2OS cells expressing FLAG-tagged RPL5 or RPL11 were depleted of SRSF1 
and induced by incubating in medium containing 1 µg/ml tetracycline for 48 hours at 
37oC. The cells were harvested and lysates applied to a 10-40% glycerol gradient and 
subjected to ultra-centrifugation. The gradient was fractionated and used separated by 
SDS-PAGE before western blotting with an anti-FLAG antibody to detect the FLAG-
tagged proteins in different gradient fractions (Figure 4.13A). Densitometry analysis 
 
Figure 4.13. Depletion of SRSF1 affects integration of RPL5 and RPL11 into the ribosome. (A) 
Western blot to show the presence of RPL11 and RPL5 in large and small complexes. Cells expressing 
FLAG-tagged RPL11 or RPL5 were induced for 48 hours with 1µg/ml tetracycline before harvesting. 
Lysates were applied to a glycerol gradient to separate the larger and smaller complexes. Fractions 
through the gradient were collected and separated by SDS-PAGE before western blotting with anti-
FLAG antibody. (B) Densitometry analysis of A using Image J software. Fractions 1-8 were denoted as 
‘free’ whilst fractions 9-17 were denoted as ‘ribosomal’. Bars in B represent the mean ± the standard 
deviations of the means, n=3. Statistical analysis determined by paired t test. NS= non-significant, *= 
P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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was utilised to quantify the percentage of the protein (Figure 4.13B) in either the ‘free’ 
(Figure 4.13A fractions 1-8) or ‘ribosomal’ fractions (Figure 4.13A fractions 9-17).  
In the control cells, 90% of the FLAG-tagged RPL11 protein was detected in the 
ribosome fractions, however only 60% of the FLAG-tagged RPL5 was detected in the 
ribosome fractions. This is in agreement with previous findings that there is more non-
ribosomal RPL5 in the cells than RPL11 (Sloan et al., 2013a). When SRSF1 was depleted, 
the percentage of FLAG-RPL11 and FLAG-RPL5 incorporated into ribosomes 
significantly reduced to 48% and 45% respectively. This indicated that SRSF1 may be 
required for efficient integration of the 5S RNP into the ribosome or that SRSF1 is 
required for ribosome production.  
4.2.11 Knockdowns of SRSF1 and PRAS40 have no significant effect 
on rRNA processing in pulse-labelling experiments 
As SRSF1 had an impact on both localisation of RPL5 and RPL11 and their integration 
into the ribosome and PRAS40 depletion affected RPL11 localisation, it was  important 
to study the impact of SRSF1 depletion on ribosome biogenesis as many ribosome 
biogenesis factors affect localisation and ribosomal integration of the 5S RNP (Sloan et 
al., 2013a). In order to do this, cells were phosphate starved with phosphate free 
medium before the addition of 32P orthophosphate medium and a chase period with 
standard medium. This method allows for the specific evaluation of newly synthesised 
rRNAs that have incorporated labelled phosphate.  
U2OS cells were depleted of SRSF1 or PRAS40 along with RPL5, as a control for the 
disruption of ribosome production, for 48 hours prior to the pulse-labelling 
experiment. After the three hour chase with normal medium, RNA was extracted from 
the cells and separated using a glyoxal-agarose gel (Figure 4.14A- top panel) to 
separate the rRNA species. The U.V scanned 18S rRNA was used as a loading control.  
RPL5 depletion resulted in an almost complete loss of the labelled 28S rRNA with an 
accumulation of the 47/45S and 32S rRNA precursors, in agreement with previously 
published data (Sloan et al., 2013a). In the cells depleted of SRSF1, there was a slight 
32S pre-rRNA increase. In the cells depleted of PRAS40 there was a slight increase in 
the 47/45S pre-rRNAs and a slight decrease in 32S pre-rRNA.  However, when analysed 
with a paired t-test all p-values were greater than 0.5, thus suggesting that depletion 
of SRSF1 or PRAS40 has no significant effect on ribosome biogenesis. This suggests that 
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the effects seen on localisation and integration are more likely to be direct rather than 
due to defects in ribosome biogenesis. 
 
4.2.12 p53 induction from Deguelin treatment is RPL5-dependent. 
Finally, the effect of drug treatments on p53 that were linked to SRSF1 and PRAS40 
were investigated. Deguelin is an AKT inhibitor (Chun et al., 2003, Baba et al., 2015) 
which results in mTORC1 inhibition (Jin et al., 2007) and thus would be expected to 
trigger 5S RNP mediated p53 signalling via PRAS40. AKT is an activator of mTORC1 
(Sengupta et al., 2010, Rosen and She, 2006, Manning and Cantley, 2007)  which, in 
turn, activates PRAS40 and results in p53 inhibition via RPL11 (Havel et al., 2014). 
However, previous reports have shown that deguelin treatment was able to counteract 
 
Figure 4.14. Analysis of the effect of depletion of SRSF1 or PRAS40 on rRNA processing. (A) Pulse-
labelling experiment with 32P orthophosphate to show the newly synthesised rRNA precursors. U2OS 
cells were transfected with siRNAs targeting control, RPL5, SRSF1 or PRAS40 siRNAs for 48 hours prior to 
1 hour labelling with a 3 hour chase period with standard media. RNA was extracted and separated by 
acrylamide gel electrophoresis, transferred to a nylon membrane and exposed to a phosphorimager 
screen. (B) Schematic representation of the rRNA processing events in humans. The precursors visible in 
A are shown in black. (C) Densitometry analysis of A analysed using ImageQuant™. Each bar represents 
the means ± the standard deviation of the means, n=3. Statistical analysis determined by paired t test. 
NS= non-significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
NS
NS
NS
NS
NS
NS
**
***
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the p53 response after ActD treatment (Chen et al., 2014) and, therefore, the role of 
the 5S RNP-signalling after deguelin treatment was investigated.  
 
U2OS cells stably expressing a p53 luciferase reporter were incubated with 20µM 
control or RPL5 siRNA in growth medium for 48 hours at 37oC. For the final 24 hours, 
100 nM deguelin was added. As a control, cells were treated with 5 nM ActD or 5 µM 
Nutlin 3A for 16 hours. ActD and Nutlin 3A were chosen as controls as ActD activates 
p53 through the 5S RNP whilst Nutlin 3A activates p53 independent of the 5S RNP 
 
Figure 4.15 The effect of deguelin, L-leucine and arginine treatment in U2OS cells. (A) U2OS cells 
containing a p53 regulated luciferase reporter were incubated at 37oC post-transfection with 20 µM 
control or RPL5 siRNA duplexes in growth medium for 48 hours. For the final 24 hours, 100nM 
deguelin was added, or for the final 16 hours 5 nM ActD, or 5 µM Nutlin 3A. Cells were harvested 
and assayed for luciferase compared to untreated cells (Untr.). (B) U2OS cells containing a p53 
regulated luciferase reporter were incubated in growth medium at 37oC for 48 hours. After 24 hours, 
100 nM deguelin was added to the medium followed by 5 nM ActD for the final 16 hours. Cells were 
harvested and assayed for luciferase compared to untreated cells (Untr.). (C) U2OS cells were 
incubated at 37oC in growth medium with the addition of 10 mM L-leucine (L), arginine (A) or both 
(B) for 12, 24 or 48 hours as indicated.  C denotes the control. For the final 18 hours, 5 nM ActD was 
added. Whole cell extracts were separated by SDS-PAGE and western blotted using antibodies raised 
against karyopherin, p53 or p21. Each bar in A and B represents the means ± the standard deviation 
of the means, n=3. Statistical analysis was carried out using a paired t-test. NS= non-significant, *= P 
≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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(Lindstrom and Nister, 2010, Bursac et al., 2012).  After harvesting, the cells were lysed 
and assayed for luciferase activity (Figure 4.15A).  
All three drugs resulted in an increase in luciferase levels, suggesting an increase in p53 
activity. In agreement with previous findings, RPL5 depletion resulted in a significant 
decrease in luciferase levels after ActD treatment, but not after Nutlin 3A treatment 
(Lindstrom and Nister, 2010, Sloan et al., 2013a, Bursac et al., 2012). RPL5 depletion 
also resulted in a significant decrease in luciferase levels after deguelin treatment. This 
suggests that the p53 response from deguelin treatment is dependent upon RPL5.  
Deguelin treatment was previously shown to counteract the p53 response after ActD 
treatment (Chen et al., 2014). However, if deguelin activates p53 via the 5S RNP as 
shown in Figure 4.14A, then this would not be expected.  
Therefore, U2OS cells stably expressing a p53 reporter were incubated in growth 
medium at 37oC for 48 hours to achieve the desired cell density. After 24 hours, 100 
nM deguelin was added to the medium followed by 5 nM ActD for the final 16 hours.  
After harvesting, the cells were lysed and assayed for luciferase activity (Figure 4.15B). 
The data shows that ActD treatment increased luciferase levels above the untreated 
cells. Furthermore, deguelin and ActD treatment have a significant additive effect over 
treatment with ActD alone. This supports the previous finding (Figure 4.15A) that 
deguelin activates p53 via the 5S RNP.  
Furthermore, the ability of L-leucine or arginine treatment to counteract the p53 
response after treatment of cells with ActD was investigated. Both arginine and L-
leucine trigger the mTOR signalling pathway (Kong et al., 2012, Lynch, 2001) and L-
leucine treatment has been shown to be a successful treatment in DBA patients  
(Pospisilova et al., 2007). Therefore, U2OS cells were grown in medium at 37oC with 
the addition of 10 mM L-leucine, arginine or both. For the final 18 hours, 5 nM ActD 
was added. Treatment of ActD resulted in an increase in p53 and p21 levels, as 
expected (Figure 4.15C). However, treatment with leucine, arginine, or a combination 
of both, did not decrease the p53 levels as expected suggesting that, under the 
conditions used, treatment of cells with leucine or arginine was not sufficient to 
reduce p53 levels after treatment with ActD.  
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4.3 Discussion 
This chapter aimed to gain a greater understanding of the role of SRSF1 and PRAS40 as 
regulators of the 5S RNP-p53 pathway through studying the effect over-expression and 
depletion of the two proteins.  
The first factor studied was SRSF1, an alternative splicing factor, commonly 
upregulated in cancers (Anczukow et al., 2012), that has many roles within the cell 
such as mRNA nuclear export, mRNA translation and nonsense mediated decay (Long 
and Caceres, 2009). SRSF1 regulates translation through its ability to positively 
regulate mTOR signalling pathways (Michlewski et al., 2008).  However, SRSF1 had also 
been linked to RPL5-mediated p53 signalling to induce senescence (Fregoso et al., 
2013).  
The presented in this thesis showed that FLAG-SRSF1 was localised in the nucleus 
similar to what had been seen by previous groups (Koizumi et al., 1999, Caceres et al., 
1997). However, it also suggested that SRSF1 may affect localisation of RPL5 and 
RPL11. Depletion of SRSF1 resulted in a loss of cytoplasmic signal from FLAG-RPL11 and 
nucleolar localisation of RPL5. Therefore, it is possible that SRSF1 is required for the 
localisation of RPL11 in the cytoplasm and RPL5 into the nucleolus. However, it is not 
clear whether this is direct or indirect as SRSF1 has many roles in the cell such as 
splicing and translation and thus could be affecting a number of other factors with 
these effects. However, as SRSF1, whether directly or indirectly, affected localisation of 
the 5S RNP components, this led to the question as to whether SRSF1 played a role in 
5S RNP recruitment into the ribosome.  
In yeast, Rrs1 and Rpf2 form a complex with the 5S RNP and are responsible for the 
integration of the 5S RNP into 90S pre-ribosomes containing the 35S pre-rRNA (Zhang 
et al., 2007, Morita et al., 2002, Kharde et al., 2015, Madru et al., 2015). However, in 
human ribosome biogenesis, the 5S RNP recruitment relies more upon the nucleolar 
protein, PICT-1 than the Rpf2/Rrs1 homologues (Sloan et al., 2013a). This suggesting 
that human 5S RNP incorporation may vary to yeast. Indeed, depletion of SRSF1 
resulted in an accumulation of free, non-ribosome bound, FLAG-RPL5 and FLAG-RPL11 
in U2OS cells compared to the control (Figure 4.13). This suggested that SRSF1 was 
required for the integration of RPL5 and RPL11 into ribosomes. One caveat with this 
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experiment is that the RPL5 and RPL11 proteins investigated are not the endogenous 
proteins. However, studying the endogenous proteins would be more problematic as 
the majority of the protein would already be incorporated into ribosomes and thus the 
ability to see changes in integration would be determined by ribosome turnover rates. 
A way to counteract this would be to investigate the integration of the 5S rRNA using 
pulse-labelled cells. This would allow for visualisation of the newly-synthesised 5S 
rRNA and would help to determine the integration of the endogenous 5S RNP.  
As the data presented in this chapter implies that SRSF1 depletion results in the 5S 
RNP not being incorporated into ribosomes, this would imply that SRSF1 depletion 
should activate p53 by an accumulation of non-ribosomal 5S RNP, unless it was part of 
the complex involved in activating p53. It was demonstrated that depletion of SRSF1 in 
MCF-7 cells resulted in a decrease in p53 and p21 protein levels (Figure 4.9). This 
suggested that SRSF1 may form part of the 5S RNP complex that activates p53 and, 
along with the 5S RNP (Sloan et al., 2013a), is involved in maintaining p53 homeostasis. 
Interestingly, Fregoso et al. (2013) demonstrated that SRSF1 inductions in BJ-TT cells 
caused an increase in p53 levels. In this study, expression of FLAG-SRSF1 for 48 hours 
in U2OS cells showed a slight increase in p53 and p21 protein levels when analysed by 
western blot (Figure 4.6) however the previous observations in BJ-TT cells showed a 
much greater induction of p53. Whilst Fregoso et al. (2013) showed that SRSF1 
expression led to senescence, they did not study the cell cycle progression. p53 
induction can result in an accumulation of cells in G1 or G2 (Agarwal et al., 1995, 
Waldman et al., 1995), however the cells expressing SRSF1 showed no cell cycle 
defects (Figure 4.7), further supporting the fact that SRSF1 expression has only a small 
effect on p53 in U2OS cells. BJ-TT cells are primary cells and so the signalling pathways 
will be more akin to normal cell signalling. Therefore, in the future, it would be 
beneficial to attempt to express SRSF1 in more clinically relevant cells in order to see 
how these cells are affected. As ribosome biogenesis defects often lead to anaemia 
and blood related disorders, cells from a red-blood cell lineage may be the most 
appropriate choice to carry the study forward.  
Furthermore, the data presented in this chapter demonstrates that, in agreement with 
Fregoso et al. (2013), SRSF1 interacts with RPL5, but it was also determined that SRSF1 
associates with the 5S rRNA, possibly outside of ribosomes (Figure 4.8). As SRSF1 
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associates with translating ribosomes (Sanford et al., 2005, Sanford et al., 2004), 
interaction with ribosome components would be expected. However the proportion of 
5S rRNA bound was greater than 5.8S, suggesting that whilst SRSF1 is interacting with 
ribosomes, it is also interacting with free 5S rRNA, and thus, possibly, the 5S RNP. It 
was not possible to detect RPL11 interaction with SRSF1 due to poor quality 
antibodies. However, RPL11 requires binding of RPL5 to the 5S rRNA before it is 
recruited (Scripture and Huber, 2011) and thus it is possible that SRSF1 interacts with 
the complex before RPL11 binding. Further investigations of the interaction with SRSF1 
and RPL11 are, therefore, required. 
Previous studies concluded that depletion of PICT-1, a factor shown to affect 5S RNP 
incorporation into the ribosome, resulted in a severe reduction in the 28S and the 5.8S 
rRNAs (Sloan et al., 2013a) and thus it is possible that SRSF1 depletion would have a 
similar effect. However, no significant difference in the ratios of the mature rRNAs or 
the rRNA precursors was seen in the control cells compared to those depleted of 
SRSF1, suggesting that SRSF1 is not required for rRNA processing. This was surprising 
as depletion of SRSF1 had such an impact on 5S RNP recruitment into the ribosome 
and suggests that SRSF1 may be directly involved in 5S RNP recruitment instead of 
simply affecting ribosome biogenesis as a whole. However, it is possible that SRSF1 
depletion causes subtle defects that were not detectable by pulse-labelling and thus 
more detailed analysis of the pre-rRNA precursors is required. Unfortunately it was not 
possible, due to time constraints, to investigate this any further. In order to further this 
investigation, the pulse-labelling could be attempted with different time points as 
there may be very subtle defects. It could also be possible to utilise northern blots 
using probes specific to different pre-rRNA precursors to look at the rRNA processing 
in more detail.  
One important tool for studying 5S RNP-mediated p53 signalling is through the use of 
ActD. ActD is a drug that selectively inhibits RNA polymerase I (Sobell, 1985) and 
activates p53 through the 5S RNP pathway exclusively (Bursac et al., 2012, Donati et 
al., 2013, Sloan et al., 2013a). SRSF1 depletion had been shown to counteract the 
effect of p53 induction in BJ-TT cells (Fregoso et al., 2013), and this was able to be 
repeated in U2OS cells (Figure 4.10). Furthermore, Fregoso et al. (2013) had 
demonstrated that RPL5 depletion could counteract the p53 response from SRSF1 
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over-expression in BJ-TT cells and, therefore, it was important to determine whether 
this could be repeated in U2OS cells to further address the role of SRSF1 in 5S RNP-
mediated p53 signalling. As the p53 inductions were not very strong with SRSF1 
expression, RPL5 and RPL11 cells were utilised instead and it was found that SRSF1 
could counteract the p53 induction from both RPL5 and RPL11 expression (Figure 
4.11). These data further supported the evidence that there is a possibility that SRSF1 
forms a complex with the 5S RNP to activate p53.   
The 5S RNP-p53 signalling pathway appears extremely complicated but the regulation 
of the pathway may be a step closer to being understood. This chapter has shown that 
SRSF1 interacts with the 5S rRNA, possibly outside of the ribosome, and is involved in 
integration of the 5S RNP into the ribosome and thus may be an important assembly 
factor. It has given evidence towards a model whereby SRSF1 is involved in integration 
of the 5S RNP into the ribosome and aids in the activation of p53 as summarised in 
Figure 4.16. Whilst interaction with RPL11 has not yet been confirmed, it is probable 
that SRSF1 is able to interact with the entire 5S RNP in order to activate p53 as all 
three components of the RNP are required for p53 activation. 
 
The second factor investigated in this chapter was PRAS40. PRAS40 is a substrate of 
AKT (Kovacina et al., 2003) that is involved in negatively regulating mTOR signalling in 
cells (Thedieck et al., 2007, Fonseca et al., 2007). PRAS40 was shown to sequester 
 
Figure 4.16 A proposed model for SRSF1 in the 5S-RNP mediated activation of p53. RPL5 and the 5S rRNA 
recruit RPL11 and SRSF1. In normal cells, SRSF1 is lost and the 5S RNP is incorporated into the ribosome. 
However, in ribosomal stress, the 5S RNP with SRSF1 binds to MDM2 and blocks its ubiquitin ligase activity, 
leading to p53 activation. p53 affects DNA repair, senescence and apoptosis through its role as a 
transcription factor.  
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RPL11 to the nucleolus and act as a negative regulator of RPL11-mediated p53 
signalling (Havel et al., 2014).  
This study has shown FLAG-PRAS40 was localised in the cytoplasm and did not co-
localise with the nucleolar marker, fibrillarin (Figure 4.5). This is contradictory to the 
findings by Havel et al. (2014) who demonstrated, in U2OS cells, that FLAG-PRAS40 co-
localised with RPL11 in the nucleoli. Furthermore, investigations revealed that PRAS40 
depletion reduced the nucleolar localisation of FLAG-RPL11 but not RPL5 (Figure 4.12). 
Havel et al. (2015) suggested that PRAS40 blocked translocation of RPL11 from the 
nucleoli to the nucleoplasm and so this data may support that theory, despite the fact 
that FLAG-PRAS40 could not be detected in the nucleoli. Therefore, it would be 
beneficial to investigate the localisation of the endogenous PRAS40, especially with 
leptomycin B treatment to affect nuclear shuttling. Further investigations could also be 
carried out into the effect of over-expression of PRAS40 on the localisation of RPL11 to 
see whether this results in an increase in nucleolar RPL11. Furthermore, the PRAS40-
RPL11 complex was suggested to contain other components (Havel et al., 2014). This 
raised the question about the identity of the other components- the obvious 
candidates being RPL5 and the 5S rRNA. However, PRAS40 did not associate with the 
5S rRNA, in the presence or absence of ribosomal stress (Figure 4.8). Using FLAG-RPL5 
or FLAG-RPL11 expressing cells, there was also no co-purification of PRAS40 and RPL5. 
In agreement with Havel et al. (2014), however, PRAS40 did co-purify with RPL11 
(Figure 4.8). As the data presented in this chapter in conjunction with previous findings 
suggests that PRAS40 is involved in nucleolar localisation of RPL11 and that PRAS40 
only interacts with RPL11, this implies that the role of PRAS40 is specific to RPL11 and 
may sequester RPL11 away from the other components of the 5S RNP, preventing 5S 
RNP formation and p53 activation. 
PRAS40 was shown to increase p53 protein levels further than ActD treatment alone in 
U2OS cells (Havel et al., 2014) and the data in this chapter was in agreement with this. 
However, when the activity of p53 was studied using a p53-regulated Luciferase 
reporter, it was found that PRAS40 had little impact on luciferase levels after ActD 
treatment. This suggests that PRAS40 increased p53 levels but not activity after ActD 
treatment. It is possible that this was the result of a plateau of p53 activity that cannot 
be increased any further, regardless of p53 levels in the cell. However, further 
124 
 
investigations into the role of PRAS40 on p53 activity would be beneficial to further 
elucidate the role of PRAS40 in p53 signalling. Expression of FLAG-PRAS40 in U2OS cells 
resulted in elevated p53 and p21 protein levels, although to a lesser extent than the 
expression of SRSF1 (Figure 4.6). It was previously demonstrated that over-expression 
of PRAS40 resulted in inhibition of mTORC1 (Sancak et al., 2007) and thus it is possible 
to hypothesise, based on the observation that over-expression of PRAS40 activates 
p53, that this feedback mechanism would result in decreased phosphorylation of 
PRAS40, release of RPL11 from PRAS40 and activation of p53. Despite increases in p53 
and p21 (Figure 4.6), over-expression of PRAS40 did not result in p53-mediated cell 
cycle arrest (Figure 4.7). It would, therefore, be beneficial to investigate apoptosis with 
Annexin V and 7-AAD or β-galactosidase with flow cytometry as these would give an 
indication as to whether apoptosis or senescence was occurring.  
Furthermore, PRAS40 depletion in U2OS cells resulted in increased p53 and p21 levels 
(Figure 4.9) which supports evidence from the previous study (Havel et al., 2014). As 
SRSF1 was shown to decrease p53 levels, these opposing effects may suggest that they 
may have antagonising roles in p53 signalling. However, the effect of SRSF1 depletion 
was more pronounced in the MCF-7 cells than in the U2OS where SRSF1 depletion had 
very little impact on p53 levels. Similarly, the depletion of PRAS40 had very little effect 
on p53 expression in MCF-7 cells but had a greater impact in U2OS cells. Both MCF-7 
and U2OS cells have wild type p53 but are lacking ARF. U2OS cells have MDM2 over-
expression (Florenes et al., 1994) and thus the p53 response may be greater in the 
MCF-7 cells due to less inhibition. Furthermore, MCF-7 cells express constitutively 
active PRAS40, phosphorylated at T246 (Huang and Porter, 2005). T246 
phosphorylation was shown to be crucial for interactions between RPL11 and PRAS40 
(Havel et al., 2014) and thus these cells would have a higher level of suppression of 
p53. It is possible that depletion of PRAS40 in these cells is not sufficient to induce p53. 
It would be important in the future to perform the same experiment in more clinically 
relevant cell lines as these would give a clearer indication of how this is affecting 
diseases such as a Diamond Blackfan Anaemia. Interestingly, the data indicated that 
PRAS40 may also be required for p53 activation via RPL5, RPL11 and SRSF1. This 
suggests that whilst phosphorylated PRAS40 inhibits interactions between RPL11 and 
MDM2, PRAS40 may also be required for activation of p53 via the 5S RNP and p53. This 
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leads to contradictory roles for PRAS40 in 5S RNP-mediated p53 signalling. However, it 
is possible that phosphorylated PRAS40 may retain RPL11 in the nucleolus whilst 
PRAS40 is also required in a different capacity to activate p53 signalling via the 5S RNP 
complex, without direct interaction with the complex. Therefore, it is currently unclear 
as to the role in PRAS40 in 5S RNP-mediated p53 signalling and further investigation is 
required to elucidate the role of PRAS40. For example, PICT-1 was initially also 
believed to sequester RPL11 to the nucleolus (Sasaki et al., 2011), however it has since 
been demonstrated to be crucial for 5S RNP recruitment into the ribosome. Due to 
time constraints, experiments investigating the role of PRAS40 in the recruitment of 
the 5S RNP could not be optimised. However, this could still be studied in the future 
using gradients to investigate the incorporation of the 5S rRNA, RPL5, or RPL11 into the 
ribosome. 
 
Finally, inhibitors of AKT were shown to activate p53 via the 5S RNP. AKT is an activator 
of mTORC1 which, in turn, activates PRAS40 by phosphorylation and results in p53 
inhibition. It was, therefore, possible that AKT inhibition would induce p53. Inhibition 
of AKT with deguelin resulted in an RPL5 dependent p53 activation (Figure 4.15). 
 
Figure 4. 17. The mechanism of Deguelin activating p53 via the 5S RNP. A Schematic representation 
of how AKT inhibitors such as deguelin activate p53. Deguelin inhibits AKT, preventing 
phosphorylation of PRAS40 via mTORC1 and AKT. Non-phosphorylated PRAS40 does not bind to 
RPL11 and thus RPL11 can bind to the 5S RNP to inactivate MDM2 and stabilise p53.  
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Furthermore, deguelin treatment in combination with ActD treatment resulted in an 
increase in p53 levels compared to ActD treatment alone, similar to what was seen 
with a depletion of PRAS40. This suggests that inhibition of AKT results in a 5S RNP-
dependent activation of p53 as summarised in Figure 4.17 and, therefore, conversely 
that activation of AKT may counteract 5S RNP-dependent p53 activation and thus 
could be a potential therapeutic for the treatment of ribosomopathies.   
In this chapter, L-leucine or arginine treatment was not able to reduce the p53 
response after treatment of cells with ActD. Many similar experiments have been 
carried out with serum starvation first (Ou et al., 2014, Singh et al., 2011) however, 
serum starvation abrogates ribosome biogenesis and activates p53 via RPL11 
(Strezoska et al., 2000, Ahamad et al., 2015, Bhat et al., 2004). As only one 
concentration of leucine or arginine was tested, it would be beneficial to attempt to 
treat cells with different concentrations in the future without having to serum starve 
cells first as greater concentrations have been suggested to have an effect without 
prior starvation (Kitsy et al., 2014). Furthermore, addition of L-glutamine to the 
medium may improve the uptake of leucine (Xu et al., 2013, Nyman et al., 1983).  
The role of PRAS40 is not yet clear, but the data from this study suggests that the role 
of PRAS40 in regulation of RPL11 is more complex than originally demonstrated (Havel 
et al., 2014). The data is in agreement with previously published data and showed that 
PRAS40 is exclusively associated with RPL11 and may prevent RPL11 from interacting 
with MDM2 and, presumably, the other 5S RNP components (Havel et al., 2014). This 
would propose a mechanism for negatively regulating the 5S RNP and, as treatments 
for Diamond Blackfan Anaemia appear to target this pathway, could be further 
assessed. This chapter identified that PRAS40 over-expression as well as depletion of 
PRAS40 induces p53, possibly as a result of a feedback loop with mTORC1, suggesting 
there may be multiple mechanisms of regulating p53 via PRAS40. Furthermore, 
inhibition of AKT resulted in p53 activation, presumably through abrogating the RPL11-
PRAS40 interactions. However, most surprisingly, the data indicated the possibility that 
PRAS40 may be required for p53 activation upon RPL5, RPL11, or SRSF1 expression.  
These findings have led to an increased knowledge about the role of PRAS40 in 
suppressing 5S RNP-regulated p53 signalling but also raised new questions about why 
PRAS40 may be required for p53 activation via the 5S RNP.   
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CHAPTER FIVE: THE ROLE OF PHOSPHORYLATION OF 
RPL5 IN CELL SIGNALLING VIA P53 
5.1 Introduction 
Ribosomes are important molecular machines required for the translation of mRNA 
into proteins. Production of ribosomes requires large quantities of cellular energy and, 
as a result, impacts upon the proliferation rate of cells (Warner, 1999a). Furthermore, 
ribosome biogenesis defects result in the activation of p53 (Holzel et al., 2010, Donati 
et al., 2012). Recently, a link between recurrent mutations in ribosomal proteins and 
ribosome biogenesis factors and diseases has been reported, and many of these 
diseases have been linked to the dysregulation of p53 (Fumagalli and Thomas, 2011).   
TP53 is a tumour suppressor gene that is frequently deleted or inactivated in cancers. 
The TP53 gene encodes the p53 protein which, when activated, coordinates with a 
variety of signalling pathways that result in DNA repair, apoptosis, senescence or G1 
cell cycle arrest (Ko and Prives, 1996, Timofeev et al., 2013, Sperka et al., 2012, 
Sugikawa et al., 1999). The major repressor of p53 is Mouse Double Minute 2 (MDM2- 
HDM2 in humans), an ubiquitin ligase which promotes the ubiquitination and 
degradation of p53 by targeting it to the 26S proteasome (Honda and Yasuda, 1999). In 
stressed conditions, MDM2 activity is suppressed and this leads to the stabilisation and 
activation of p53 (Michael and Oren, 2003). One other suppressor of p53 is MDMX, an 
MDM2 homolog that can bind to p53 to inhibit p53 activity (Danovi et al., 2004) but 
lacks E3 ubiquitin ligase activity and thus cannot target p53 for degradation (Jackson 
and Berberich, 2000). MDMX is involved in stabilising MDM2 (Gu et al., 2002) and the 
interaction between MDM2 and MDMX is required for the E3 ubiquitin ligase activity 
of MDM2 (Kawai et al., 2007). Furthermore, MDM2 is able to polyubiquitinate MDMX 
and target it for degradation (Pan and Chen, 2003), resulting in a feedback loop 
between these two proteins.  
One prominent factor contributing to diseases as a result of ribosome biogenesis 
defects is the 5S RNP. The 5S RNP is a processing intermediate of the ribosomal large 
subunit, consisting of RPL5, RPL11, and the 5S rRNA. There are multiple ways that the 
5S RNP is able to activate p53- through interactions with ARF and MDM2. Interestingly, 
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the 5S RNP is not only responsible for the regulation of p53 under ribosomal stress 
situations, it is also important for normal p53 homeostasis (Sloan et al., 2013a). All 
three components of the 5S RNP are involved with mutually dependent interactions 
with MDM2, thus stabilising p53 (Sloan et al., 2013a, Donati et al., 2013), as shown in 
Figure 5.1. Furthermore, the 5S RNP was shown to be essential for the cellular p53 
response to ARF (Sloan et al., 2013a). ARF binds to and inhibits MDM2, promoting p53 
stabilisation (Honda and Yasuda, 1999).  
 
Furthermore, it has also been demonstrated that the 5S rRNA, RPL5 and RPL11 play a 
vital role in regulation of MDMX. The interaction between RPL11 and MDM2 was 
shown to be induced upon nucleolar stress, resulting in MDMX degradation and p53 
activation (Gilkes et al., 2006). In contrast, the 5S rRNA was shown to associate with 
MDMX and protect it from degradation by MDM2 (Li and Gu, 2011). These data 
suggest that the 5S RNP may have different roles in the regulation of MDMX under 
different cellular conditions.  
 
Figure 5.1 The 5S RNP activates p53 via interactions with MDM2. A schematic representation of the 5S 
RNP-p53 signalling pathway in response to ribosome biogenesis defects or over-expression of the oncogene, 
ARF. In unstressed cells, MDM2 polyubiquitinates p53 and targets it for proteasomal degradation via the 
26S proteasome and the 5S RNP binds to MDM2 and maintains normal p53 homeostasis. When ribosome 
biogenesis defects occur, the integration of the 5S RNP into the ribosome is blocked and more of the free 5S 
RNP interacts with MDM2, blocking its ubiquitin ligase activity. When ARF is over-expressed, ribosome 
biogenesis is disrupted and ARF interacts with the free 5S RNP to promote p53 stabilisation.   
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In addition to their interactions with p53, RPL5 and RPL11 have also been implicated in 
the activation of p73 (Zhou et al., 2015), a p53 homolog (Jost et al., 1997, Kaghad et al., 
1997) which can transactivate many of the same gene targets as p53 (Zhu et al., 1998). 
These data taken together suggest a diverse role for the 5S RNP in the regulation of 
p53. 
The mechanisms of regulating the 5S RNP-p53 pathway are not yet fully understood. 
Sloan et al. (2013a) proposed that any proteins involved in ribosomal integration, 
localisation or formation of the 5S RNP were crucial in regulating p53. One way that 
the 5S RNP-p53 pathway could be regulated is through post-translational modifications 
such as phosphorylation and NEDDylation.  
MDM2 promotes NEDDylation of RPL11 and protects RPL11 from destabilisation 
(Xirodimas et al., 2008, Sundqvist et al., 2009). ActD treatment was found to decrease 
NEDDylation of RPL11 and cause re-localisation of RPL11 to the nucleoplasm, where it 
can activate p53 (Sundqvist et al., 2009). This suggests that NEDDylation of RPL11 is a 
mechanism by which to prevent activation of p53 via RPL11. However, Mahata et al. 
(2012) found that, in cells undergoing ribosomal stress, RPL11 and NEDD8 were both 
crucial for the acetylation, and thus activation, of p53. The authors demonstrated that 
NEDDylation of RPL11 was required for the recruitment of RPL5 and RPL11 to 
promoter sites of p53 regulated genes in an MDM2-dependent manner. These data, 
when assessed in combination with the later findings that the 5S RNP is crucial for p53 
activation (Donati et al., 2013, Sloan et al., 2013a), indicate that NEDDylation is an 
important regulator of 5S RNP-mediated p53 activation.  
Whilst only NEDDylation has been shown to regulate the 5S RNP signalling to date, 
phosphorylation may also be important for protein regulation. Phosphorylation is a key 
regulator in p53 signalling. p53 is phosphorylated at a number of different sites to 
regulate function, for example, p53 can be activated by phosphorylation of serine 37 
by ATR and CK2 in response to chemotherapeutic drugs or U.V light (Meek, 1999). In 
addition, phosphorylation of p53 serine 15 has been demonstrated to be critical for 
stimulating transactivation at p53-responsive promoters (Loughery et al., 2014). 
Phosphorylation of MDM2 by the kinases ATM and C-Abl inhibits p53 degradation 
upon DNA damage (Goldberg et al., 2002, Maya et al., 2001). Furthermore, DNA 
damage results in phosphorylation of MDMX via Chk1, Chk2 and ATM, activating p53 
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(Jin et al., 2006, Chen et al., 2005). These data taken together show an important role 
for phosphorylation in the regulation of p53.  
 
Many ribosomal proteins such as RPS3 (Kim et al., 2009, Lee et al., 2010), RPS6 
(Ruvinsky and Meyuhas, 2006, Khalaileh et al., 2013), and RPS14 (Ventimiglia and 
Wool, 1974) have been shown to be phosphorylated. Furthermore, it has been shown 
in vitro that RPL5 has the potential to be phosphorylated (Park and Bae, 1999). As RPL5 
and RPL11 are crucial to 5S RNP-mediated p53 signalling, phosphorylation of these 
proteins may play a role in the regulation of this pathway. According to Phosphosite 
(http://www.phosphosite.org), RPL5 has 17 reported phosphorylation sites (Figure 
5.2). Out of the 17 phosphorylations, 9 of these are tyrosine. Tyrosine 
phosphorylations are uncommon in cells (Cooper, 1989) and, therefore it is possible 
that these may play an important role in the regulation of RPL5. It is important to note 
that these are reported phosphorylation sites and thus may not necessarily be 
representative of the actual phosphorylation sites in RPL5. Interestingly, some of the 
mutations have been reported in multiple data sets, for example phosphorylation of 
Y30 was demonstrated in 14 different data sets, whilst Y31 has been reported in 3.  
Currently, very little is known about RPL5 phosphorylation or the kinases and 
phosphatases that may be involved. RPL5 phosphorylation by CK2 at serine residues 
was shown to prevent binding of RPL5 to the 5S rRNA in vitro (Park and Bae, 1999). 
Thus, phosphorylation of RPL5 by CK2 could affect 5S RNP formation and, 
subsequently, ribosome biogenesis. RPL5 has also been shown to interact with, and 
potentially be phosphorylated by, one other kinase, the Death-associated protein 
kinase (DAPk) (Bialik et al., 2008).  
 
Figure 5.2 Reported phosphorylation sites on RPL5. Schematic representation of the RPL5 protein with the 
phosphorylation sites as reported on Phosphosite (http://www.phosphosite.org). RPL5 contains 17 reported 
phosphorylation sites, 9 tyrosine phosphorylation sites (blue), 7 serine phosphorylation sites (red) and 1 threonine 
phosphorylation site (black).  
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As 5S RNP-p53 signalling has been implicated in diseases, it is crucial that the 
regulation of this pathway is fully elucidated. Ribosomopathies are diseases of 
ribosome dysfunction and many have reported changes in p53. One such 
ribosomopathy is Diamond Blackfan Anaemia (DBA), which is a rare autosomal 
recessive condition characterised by a reduction in erythroid production and thus 
anaemia. 50-70% of all DBA patients present with a mutation in ribosomal proteins, 
including RPS7, RPS19, RPS27, RPS26, RPL27, RPL5, RPL11 (Smetanina et al., 2015, 
Wang et al., 2015, Mirabello et al., 2014, Konno et al., 2010). These mutations are 
mostly deleterious resulting in haploinsufficiency. The pathogenesis of DBA is thought 
to be attributed to defects in ribosome biogenesis resulting in p53 activation and 
apoptosis of the red blood cell precursors, which rely upon a high rate of ribosome 
biogenesis (Dai and Lu, 2004, Zhang et al., 2011).  
Little is currently known about how phosphorylation regulates the 5S RNP. Therefore, 
the aim of this chapter was to characterise the role of RPL5 phosphorylation in 
regulating the 5S RNP-p53 pathway and ribosome biogenesis. To do this, several 
mutants of RPL5 were expressed in human U2OS cells and studied for their ability to 
activate p53, their effect on cell cycle, and their ability to integrate into the ribosome.  
5.2 Results 
5.2.1 Tyrosines 30, 31 and 44 of RPL5 are located on the interaction 
surface with the ribosome and, thus, if phosphorylated, may block 
ribosomal integration.  
Several tyrosine residues in RPL5 have been reported to be phosphorylated. The 
phosphorylation sites were mapped onto the structure (Figure 5.3A) of the human 
ribosome (Khatter et al., 2015) and assessed for their proximity to the 5S rRNA or the 
large subunit of the ribosome.  
The three most interesting phosphorylation sites seen in this study were tyrosines 30, 
31 and 44 (Y30, Y31 and Y44) as shown in yellow, green and orange respectively in 
Figure 5.3A-B. Y30, Y31 and Y44 were shown to be located on the interaction surface 
between the 28S rRNA and RPL5 (Figure 3.5B). This was interesting as phosphorylation 
at these sites could affect RPL5 being integrated into the ribosome. None of the three 
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phosphorylation sites appeared to be in a position to disrupt the RPL5 and 5S rRNA 
interaction.   
Furthermore, when aligning RPL5 protein sequences across a spectrum of eukaryotic 
organisms, it was clear that the Y30, Y31 and Y44 sites were generally highly conserved 
(Figure 5.3C). However, Y31 was not conserved in two lower eukaryotes (D. discoidium 
and T. gondii). Furthermore, in zebrafish (D. rerio), Y31 is mutated to phenylalanine (F); 
this is interesting as phenylalanine cannot be phosphorylated and thus suggests 
phosphorylation of this site is species specific. These data taken together imply that it 
is possible that phosphorylation of Y30, Y31 and Y44 may disrupt integration of the 5S 
RNP into the ribosome.  
 
Therefore, it was important to validate these predicted phosphorylation sites and test 
whether phosphorylation of RPL5 in U2OS cells could be detected. In order to do this, 
Phos-Tag acrylamide gels were utilised. In Phos-Tag acrylamide gels, the 
 
Figure 5.3. RPL5 Y30, Y31 and Y44 are located within the interaction surface with the ribosome and 
Y30 and Y44 are highly conserved in eukaryotes. (A) The cryo-EM structure of the 5S RNP showing 
the position of Y30, Y31 and Y44 of RPL5. The first image depicts the human ribosome structure 
(Khatter et al., 2015) of RPL5 (red), RPL11 (purple) and the 5S rRNA (white).  The three potentially 
phosphorylated tyrosines are shown: Y30 in yellow, Y31 in green and Y44 in orange. The second and 
third images depicts Y30 and Y31 (yellow and green), showing their close interaction the 28S rRNA in 
grey (C) Sequence alignment showing the sequence similarity between the RPL5 in various 
eukaryotic organisms. Y30 and 31 are indicated with a red border and Y44 with yellow.  
A
B 30 31 44
R. norvegicus
C. elegans
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D. discoideum
D. rerio
G. galus
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D. melanogaster
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phosphorylated proteins are retarded in their migration through the gel and thus 
phosphorylated proteins become separated from non-phosphorylated.  
U2OS cells expressing either an empty pcDNA5 vector or the RPL5-FLAG pcDNA5 
vector were incubated in growth medium with the addition of 1 µg/ml tetracycline for 
48 hours. Whole cell lysates were then separated by SDS-PAGE using 13% acrylamide 
gels with or without the addition of the Phos-Tag. Anti-FLAG antibody was utilised and 
showed FLAG-RPL5 expression in the induced cells.  
 
The PhosTag gel showed an additional signal that was not present on the control gel, 
suggesting the presence of phosphorylated RPL5 in U2OS cells (Figure 5.4). 
5.2.2 Creation of inducible cell lines expressing FLAG-tagged RPL5 
phosphorylation mutants 
In order to study the effect of phosphorylation of RPL5, RPL5 mutants were generated 
that attempted to mimic phosphorylation (Y to E) or prevented phosphorylation (Y to 
F) of sites Y30, Y31 and Y44. U2OS cell lines were generated that would express FLAG-
tagged wild type or mutant RPL5 upon induction with tetracycline. To do this, pcDNA5-
FRT plasmids containing wild type RPL5 were subjected to site-directed mutagenesis 
using primers specific to each mutation. The resultant plasmids were then co-
transfected into Flp-In U2OS cells with a vector expressing Flp recombinase (pOG44). 
Six of the intended cell lines were successfully created- Y30E, Y30F, Y44F, Y44E, and a 
double mutant of Y30F Y31F.  
 
 
Figure 5.4. Phosphorylation of RPL5 in cells. U2OS Flp-In cells stably transfected with an RPL5-FLAG 
pcDNA5 construct were incubated at 37oC in growth medium containing 1 µg/ml tetracycline for 48 
hours to induce the FLAG tagged protein. Whole cell lysates were separated via SDS-PAGE using 
either 13% acrylamide or 13% acylamide with PhosTag acrylamide prior to transferring to a 
nitrocellulose membrane via western blotting. Anti-FLAG antibody was used to probe the 
membranes.   
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In order to establish their ability to express the proteins, the cells expressing the wild 
type or mutant RPL5 were incubated at 37oC with medium containing 1 µg/ml 
tetracycline for 48 hours before harvesting, separating whole cell extracts by SDS-PAGE 
and western blotting for RPL5 (Figure 5.5A). Upon expression of the wild type or RPL5 
mutants, a larger molecular weight protein of RPL5 origin was detected using an anti-
RPL5 antibody, indicating that the FLAG-RPL5 mutants were expressed as the FLAG-tag 
increases the size of the protein, thus affecting the migration through the gel. 
However, there were clear differences between the levels of induction of the proteins 
with the Y30F mutant exhibiting the highest induction of RPL5. 
 
As the level of protein expression for some mutants did not reach levels of wild type 
protein, comparable conclusions from these mutants would be inaccurate. Therefore, 
in order to rectify this issue, the Y30F Y31F, Y31F and Y30F mutants were incubated, as 
before, in normal medium containing 1000ng/ml tetracycline for 48 hours and 
compared to a 48 hour induction of the Wild type at varying tetracycline 
concentrations (Figure 5.5B). By analysing at the signal from the anti-FLAG antibody, it 
 
Figure 5.5. Inductions of RPL5 and the mutants in U2OS cell lines. (A) U2OS cell stably expressing 
RPL5 wild type and mutant proteins, as shown, were grown for 48 hours in the presence of 1µg/ml 
tetracycline before harvesting the cells. Whole cell lysates were separated by SDS-PAGE and western 
blotted for RPL5 using Karyopherin as a loading control. The endogenous (End) and FLAG-tagged 
(FLAG) RPL5 are denoted on the left. (B) U2OS cells expressing RPL5 Y30F Y31F, Y31F or Y30F were 
induced for 48 hours with 1000 ng/ml tetracycline as indicated. The wild type RPL5 U2OS cells were 
similarly induced for 48 hours with a range of tetracycline concentrations from 1ng/ml-1000ng/ml 
tetracycline. Whole cell extracts were separated by SDS-PAGE and analysed by western blotting.   
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was clear that the wild type protein expression did not increase proportionally with 
increased tetracycline levels and that it was not possible to reduce the expression of 
the wild type protein to the levels seen for the Y31F and Y30F/Y31F mutants. As the 
expression of some of the mutants was poor this meant that downstream experiments 
were often difficult as there was not enough expression to detect signals via western 
blot. Therefore, only the two highest expressing mutants, Y30E and Y30F, were carried 
forward for further studies.  
5.2.3 Mutation of RPL5 tyrosine 30 does not affect the localisation 
of RPL5.  
In addition to affecting protein-protein interactions, phosphorylation can also affect 
localisation of proteins (Stulke, 2010). In order to ascertain whether the mutations in 
RPL5 affected localisation of the protein, U2OS cells expressing either the mutant or 
wild type FLAG-tagged RPL5 were cultured with 1 µg/ml tetracycline-containing 
medium, at 37oC, for 48 hours before fixing in 4% paraformaldehyde and analysing by 
immunofluorescence using antibodies raised against the FLAG tag and fibrillarin (to 
highlight the nucleoli). DAPI staining was used to indicate the nucleus (Figure 5.6).  
 
 
Figure 5.6. Mutation of Y30 does not affect localisation of RPL5. U2OS cells expressing wild type, 
Y30E or Y30F FLAG-tagged RPL5 were grown on coverslips and induced with 1 µg/ml tetracycline for 
48 hours. The cells were fixed in 4% paraformaldehyde and prepared for immunofluorescence using 
anti-Fibrillarin (green), anti-FLAG (red) and DAPI (blue). Scale bar represents 1 µm. 
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In agreement with previous studies, FLAG-RPL5 signal was enriched in the nucleolus 
and nucleoplasm (Sloan et al., 2013a). Very little cytoplasmic FLAG-signal was 
detected, due to the short induction times as 5S RNP incorporation into the ribosome 
is slow (Sloan et al., 2013a). As both the wild type and mutant RPL5 showed the same 
localisation pattern, this suggests that mimicking phosphorylation, or lack thereof, 
tyrosine 30 does not affect the regions in which RPL5 is localised.  
5.2.4 Mutating Y30 to phenylalanine or glutamic acid does not 
affect RPL5-5S rRNA interactions. 
RPL5 has been previously demonstrated to be required for the maturation of the 5S 
rRNA and formation of the 5S RNP is essential for ribosome production and, as all 
three factors of the 5S RNP are required to bind MDM2, p53 activation (Donati et al., 
2013, Sloan et al., 2013a). RPL5 association with the 5S RNA is crucial for the 
production of the 5S RNP, therefore it was important to establish whether RPL5 
mutants could associate with the 5S rRNA. 
 
U2OS cells expressing either an empty pcDNA5 vector (control), wild type, Y30E RPL5, 
or Y30F RPL5 were grown in medium containing 1 µg/ml tetracycline at 37oC for 48 
hours before harvesting and lysing the cells. For the RNA immunoprecipitations, IgG 
sepharose alone (control) or in conjunction with anti-FLAG antibody (IP) were 
incubated with the lysates followed by RNA extractions, acrylamide gel 
electrophoresis, and northern blotting. The blots were incubated with 32P-labelled 
probes specific for the 5S and 5.8S rRNAs (Figure 5.7).  
 
Figure 5.7. Interactions between RPL5 wild type and mutants with the 5S rRNA.  Representative 
northern blot from three independent experiments to show association of wild type or mutant RPL5 
with the 5S rRNA. U2OS cells expressing the wild type or mutant RPL5 were induced as in A for 48 
hours before harvesting. Cell lysates were incubated with IgG sepharose with anti-FLAG antibody for 
2 hours prior to washing, elution and RNA extraction. RNAs were separated by acrylamide gel 
electrophoresis and northern blotted and probed using 32P labelled probes against 5S rRNA. T 
denotes 10% RNA totals.  
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The empty pcDNA5 vector control and no antibody control (denoted c) showed little–
to-no signal in the IP lane, showing that the FLAG-tag or IgG sepharose alone do not 
associate with the 5S rRNA. Wild type RPL5 and the mutants all co-purified with 5S 
(Figure 5.7). This suggests that mutations of Y30 to phenylalanine or glutamic acid does 
not affect RPL5-5S RNA interactions and means that these mutants still have the 
potential to form the 5S RNP.  
5.2.5 Expression of RPL5 Y30E results in increased levels of non-
ribosomal RPL5 compared the RPL5 Y30F mutant and wild type 
RPL5. 
As the mutants interacted with the 5S rRNA, the next step was to investigate whether 
they were still incorporated into ribosomes. To do this, a 10-40% glycerol gradient was 
utilised to separate the free and ribosomal bound RPL5.   
U2OS cells expressing either the wild type or Y30 mutant FLAG-tagged RPL5 were 
incubated for 48 hours with 1 µg/ml tetracycline-containing media before harvesting. 
The cells were lysed and applied to a 10-40% glycerol gradient and separated by 
ultracentrifugation, before collecting 200 µl fractions from the gradient. The fractions 
were separated by SDS-PAGE and used in western blot analysis using an anti-RPL5 
antibody (figure 5.8A) in order to see the endogenous RPL5. The ‘free’ and ‘ribosomal’ 
fractions were defined as fractions 1-7 and 9-20 respectively based on previous 
experiments (Sloan et al., 2013a). Magnesium was omitted from the lysate during 
sonication in order to prevent the nucleoli staying intact as this is where most of the 
RPL5 is present (Figure 5.6).  
The endogenous RPL5 showed the same distribution through the fractions (Figure 5.6A 
labelled end) upon expression of the wild type or mutant FLAG-RPL5. The wild type 
RPL5 gave a strong RPL5-FLAG signal in the ribosomal fractions (Figure 5.8A fractions 9-
20). When densitometry analysis (Figure 5.8B) was carried out, it revealed that the wild 
type had, on average, 20% of the protein in the ‘free’ fractions (Figure 5.8A fractions 1-
7). Similar results were seen with the Y30F mutant, with no significant difference 
between the percentages of free RPL5 present when using a paired t-test.  
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The Y30E mutant, however, showed a very different profile from the wild type and 
Y30F mutant. Most of the FLAG-RPL5 Y30E was in the ‘free’ fractions (Figure 5.8A 
fractions 1-7). The Y30E mutant had around 85% of protein in the ‘free’ fractions 
(Figure 5.8B) which was highly significantly different from the wild type when analysed 
using a paired t-test. This suggested that mimicking phosphorylation of Y30 may 
prevent integration of RPL5 into the ribosome, whilst preventing phosphorylation has 
no effect.  
5.2.6 RPL5 shows evidence of differential phosphorylation between 
non-ribosomal and ribosomal RPL5 
As the data suggested that phosphorylation of tyrosine 30 prevents ribosomal 
integration of RPL5, it was important to establish whether there was preferential 
 
Figure 5.8. Mimicking phosphorylation of RPL5 Y30 leads to decreased ribosomal integration of RPL5. (A) 
Representative western blots from three independent experiments to show incorporation of wild type or 
mutant RPL5 into the ribosome. U2OS cell lines expressing FLAG-tagged wild type, Y30F, or Y30E RPL5 were 
grown in the presence of 1 µg/ml tetracycline for 48 hours to induce protein expression. The cells were 
harvested and lysates prepared and applied to a 10-40% glycerol gradient to separate the large and small 
complexes. The resultant gradient was fractionated, separated by SDS-PAGE and analysed by western blot 
using an anti-RPL5 antibody. (B) The western blot in A was subjected to densitometry analysis and the density 
of the FLAG-tagged RPL5 signal was quantified using ImageJ. Each bar in B represents the means ± the 
standard deviation of the means, n=3. Statistical significance was determined using a paired t-test. NS= non-
significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
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phosphorylation of free RPL5 over ribosomal RPL5. In order to investigate this, Phos-
Tag acrylamide was utilised as it enables separation of phosphorylated and non-
phosphorylated proteins as described in section 5.2.1. As the previous experiment 
(Figure 5.4) had shown a ‘smear’ of RPL5 phosphorylation, the gels were separated for 
longer using a lower percentage of acrylamide to allow for better resolution. 
 
U2OS cells expressing wild type FLAG-RPL5 were incubated with 1 µg/ml tetracycline-
containing medium, at 37oC, for 48 hours prior to harvesting. The cells were lysed and 
applied to a 10-40% glycerol gradient before ultracentrifugation to separate the large 
and small complexes. The resultant gradient was sequentially aliquoted into 200µl 
fractions. Based on previous gradient experiments (Figure 5.8), fractions 1-7 and 
fractions 9-20 were pooled as the ‘free’ and ‘ribosomal’ pools of RPL5 respectively. The 
pooled protein fractions were separated using a 7% acrylamide gel or a 7% acrylamide 
gel containing 50µmol/L Phos-tag and 100µmol/L MnCl2 (Figure 5.9). The proteins 
were transferred via western blotting to a nitrocellulose membrane and probed using 
an anti-FLAG antibody.  
With the standard 7% acrylamide SDS-PAGE gel, there was a single signal from the 
anti-FLAG antibody that denoted the FLAG-RPL5 protein. However, the Phos-tag gel 
had multiple signals of a higher molecular weight than the FLAG-RPL5 signal (denoted 
P-FLAG-RPL5), suggesting the presence of phosphorylated proteins. A higher molecular 
 
Figure 5.9. RPL5 is differentially phosphorylated when incorporated into ribosomes. U2OS Flp-In 
cells stably transfected with an RPL5-FLAG pcDNA5 construct were incubated with 1 µg/ml 
tetracycline for 48 hours to induce the FLAG tagged protein. The cells were harvested, lysed and 
separated by 10-40% glycerol gradient centrifugation. Fractions were taken from the resultant 
gradient and fractions 1-8 were combined and denoted ‘free’ 5S RNP whilst fractions 9-16 were 
combined and denoted ‘ribosomal’ 5S RNP. The pooled fractions were separated via SDS-PAGE using 
either 7% acrylamide or 7% acylamide with PhosTag acrylamide prior to transferring to a 
nitrocellulose membrane via western blotting. Anti-FLAG antibody was used to probe the 
membranes. The signals indicating FLAG-RPL5 and the two phosphorylated RPL5 signals are 
indicated on the right.  
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weight signal was detected specifically in the total protein and the ‘free’ fraction that 
did not appear to be detected in the ‘ribosomal’ fraction. Furthermore, an additional 
higher molecular weight signal was detected in the ‘ribosomal’ pool but appeared not 
to be in the ‘free’ pool. This suggests that different phosphorylations may be present in 
the ‘free’ and ‘ribosomal’ pools of RPL5 and may support the theory that 
phosphorylation may regulate 5S RNP integration into the ribosome.  
5.2.7 FLAG-RPL5 Y30 mutants associate with MDM2 and p53 
Looking at the cryo-EM structure of the human ribosome, the RPL5 Y30 residue 
appeared to be in close proximity to helices 83-85 of the 28S rRNA. This region has 
been shown to bind to RPL11 in the same region that MDM2 binds (Zheng et al., 2015), 
thus suggesting that phosphorylation of this site may disrupt 5S-RNP MDM2 
interactions. Therefore, immunoprecipitations were utilised to look for interactions 
between wild type or mutant RPL5 and MDM2.  
U2OS cells expressing either an empty pcDNA5 vector (control), wild type, Y30E RPL5, 
or Y30F RPL5 were grown in medium containing 1 µg/ml tetracycline at 37oC for 48 
hours before harvesting and collection of lysates. The lysates were incubated with anti-
FLAG conjugated agarose beads for 2 hours before elution of the protein, separation 
by SDS-PAGE and western blot analysis (Figure 5.10). The control FLAG-tag did not co-
purify MDM2 or p53, suggesting any interactions were specific to RPL5.  
 
 
Figure 5.10. The RPL5 mutants interact MDM2 and p53. Representative western blot from two 
independent experiments to show RPL5 association with MDM2 and p53. U2OS cells expressing the 
wild type or mutant RPL5 were incubated in growth medium containing 1 µg/ml tetracycline for 48 
hours before harvesting. Cell lysates were collected and incubated with FLAG-conjugated agarose for 
2 hours followed by elution, separation by SDS-PAGE and western blotting. T denotes 5% total 
protein. HC indicates cross-reactivity with the IgG heavy chain. 
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MDM2 co-purified with RPL5 and both of the mutants strongly, suggesting that 
phosphorylation of Y30, or lack thereof, has no effect on RPL5 association with MDM2. 
Furthermore, the 5% total protein (denoted T) for both the MDM2 and p53 was 
extremely weak, suggesting that the percentage being bound by RPL5 was much 
higher than the 5% total loaded. This suggests that RPL5 associates with a large 
percentage of the MDM2 in the cell.  
The p53 binding site (Chi et al., 2005) and binding sites for the 5S RNP (Zhang et al., 
2011, Zheng et al., 2015) do not overlap on MDM2, suggesting that the 5S RNP and 
p53 may simultaneously interact with MDM2. Marechal et al. (1994) detected the 
presence of an RPL5-MDM2-p53 complex in cells. Therefore, it was possible that the 
MDM2-5S RNP complex also contained p53. Furthermore, (Bursac et al., 2012) showed 
that p53 co-purified with MDM2, RPL5 and RPL11 and it has also been shown that 
RPL11 is recruited to promoter sites of p53 regulated genes (Sundqvist et al., 2009). 
However, it was recently shown that p53 does not associate with RPL5 or RPL11 (Zhou 
et al., 2015) and thus the presence of p53 in the RP-MDM2 complex remained 
uncertain. Therefore, a p53 antibody was utilised in the western blots to investigate 
p53 association with RPL5. Interestingly, the data shows that p53 co-purified with both 
the wild type RPL5 and mutants (Figure 5.10).  This suggests that it is possible that p53 
interacts with the 5S RNP/MDM2 complex.  
5.2.8 The wild type and mutant RPL5 all increase p53 levels but the 
Y30F mutation does not increase p53 activity 
It has been shown that expression of RPL5 in U2OS cells causes an increase in p53 
(Horn and Vousden, 2008). It has also been hypothesised that anything regulating 5S 
RNP integration into the ribosome would be central in regulating p53 stabilisation via 
MDM2 (Sloan et al., 2013a). As mimicking phosphorylation of Y30 appeared to block 
integration of RPL5 into the ribosome, expression of the RPL5 Y30E or the Y30F mutant 
was investigated to see whether it would result in a changes in p53 activation 
compared to wild type RPL5.  
U2OS cells expressing FLAG-tagged wild type, Y30E or Y30F RPL5 were grown at 37oC in 
media containing 1 µg/ml tetracycline for 48 hours to induce the expression of the 
proteins. The cells were harvested and whole cell extracts separated by SDS-PAGE and 
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analysed by western blot for p53 and its downstream effector, p21 (Figure 5.8A). 
Karyopherin was used as a loading control.  
 
Figure 5.11. Expression of the RPL5 mutants affects p53 protein levels and activity. (A) Representative 
western blot from three independent experiments to show how expression of the proteins affects p53 
and p21 levels. U2OS cells expressing either wild type or mutant FLAG-tagged RPL5 were induced with 1 
µg/ml tetracycline for 48 hours prior to harvesting and separating the whole cell lysates by SDS-PAGE 
before western blotting. Karyopherin was used as a loading control. (B) Densitometry analysis of p53 and 
p21 levels in A relative to the control. Each bar in B represents the means ± the standard error of the 
means from three experiments. (C) Representative western blot from two independent experiments to 
show the effect of RPL5 wild type or Y30 mutant expression on MDM2 protein levels. U2OS cells 
expressing wild type or mutant FLAG-tagged RPL5 were expressed as in A, separated by SDS-PAGE and 
analysed by western blotting using anti-MDM2 and p53 antibodies with an anti-α-tubulin loading control. 
Bars represent Densitometry analysis of C. (D) Luciferase assay to determine p53 activity upon expression 
of the wild type or mutant FLAG-RPL5. U2OS cells expressing the proteins as in A+B were transfected with 
a plasmid containing Renilla luciferase under a constitutive promoter and a plasmid containing firefly 
luciferase under the control of p53 regulated promoters. Luciferase was measured after 48 hours and 
normalised against relative protein concentrations. Each bar in B, C and D represents the means ± the 
standard deviation of the means, n=3. Statistical analysis determined by a paired t test. NS= non-
significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
 
***
**
****
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Both the mutants and the wild type cell lines expressed significantly more p53 protein 
than the control, with the Y30E mutant showing the greatest increase in p53 (Figure 
5.11 A-B). Whilst the difference between the p53 levels upon expression of the Y30E 
mutant were significant when compared to wild type (P=0.007), the difference 
between p53 levels upon expression of Y30F mutant compared to wild type were not. 
This suggests that RPL5 Y30F expression results in a similar p53 induction to wild type 
but expression of RPL5 Y30E results in a greater p53 induction. Interestingly, when 
studying the effect of the p53 downstream effector, p21, it was noted that expression 
of the mutant or wild type RPL5 resulted in increased p21 levels compared to control. 
However, when analysed by densitometry (Figure 5.11B), it revealed that expression of 
the Y30F mutant resulted in a lesser p21 response compared to the wild type or Y30F 
mutant RPL5. This suggested that whilst p53 protein levels had increased with RPL5 
Y30F expression compared to the control cells, the amount of p53 activity had not 
increased proportionally.  
Increased p53 expression results in increased MDM2 levels due a feedback loop 
between p53 and MDM2 (Barak et al., 1993). However, as the main regulator of p53 
activity, increased levels of MDM2 can result in suppression of p53 (Bond et al., 2004, 
Jones et al., 1998). Therefore, the effect of wild type or mutant RPL5 expression on 
MDM2 protein levels were also studied.  U2OS cells expressing wild type or mutant 
RPL5 were expressed as previously described and whole cell lysates separated by SDS-
PAGE before western blotting. The resultant western blot revealed that expression of 
wild type RPL5 resulted in an increase in MDM2 protein levels (Figure 5.11C). 
Expression of the Y30E mutant resulted in a similar increase in MDM2 levels to the wild 
type. However, when analysed by densitometry analysis (bars- Figure 5.11C), it 
appeared that the MDM2 increase upon induction of the Y30F mutant was much 
greater than that upon induction of the wild type or Y30E mutant.  
To further explore the effect of the RPL5 mutants on p53 activity rather than protein 
levels, plasmids containing p53-regulated Luciferase were utilised (Figure 5.11D). Cells 
containing wild type or mutant RPL5-FLAG were co-transfected with the pG13-LUC 
plasmid, which contains 13 copies of the p53 binding consensus linked to a luciferase 
reporter gene (el-Deiry et al., 1993), and the control pRL-TK renilla luciferase plasmid 
(Promega). Twelve hours after transfection, the cells were incubated in medium 
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supplemented with 1 µg/ml tetracycline for 48 hours to induce the FLAG-tagged 
proteins. The cells were then lysed and assayed for luciferase activity using the 
Promega Dual Luciferase kit. The results were normalised against Renilla luciferase 
activity to account for any differences in transfection efficiency.  
The results (Figure 5.11D) show that expression of wild type RPL5 results in just under 
a 3-fold increase in p53 transcriptional activity whereas expression of the RPL5 Y30E 
mutant brings about a 6-fold increase in p53 activity. Interestingly, induction of the 
Y30F mutant showed only a 50% increase in p53-regulated luciferase, supporting the 
hypothesis that the Y30F mutant increases p53 protein levels but does not lead to as 
successful of an activation of p53.  
These data suggest that expression of RPL5 harbouring a mutation of Y30 to glutamic 
acid results in increased p53 protein levels and increased activation of p53. However, 
expression of RPL5 harbouring a mutation of Y30 to phenylalanine results in an 
increase in p53 protein levels but the p53 is less active.   
5.2.9 Expression of the wild type RPL5 and the mutants all lead to 
decreased cellular growth rate. 
As the induction of RPL5 and the mutants increased p53 levels, it was possible that this 
would impact upon growth of the cells. It had been noted during the previous 
experiments that the mutants tended to grow much slower than the wild type, which 
in turn, was slower than the control cells. Therefore, it was important to study this 
further with growth assays. 
 
 
Figure 5.12. RPL5 expression slows the growth of U2OS cells. Cell counting experiment to show the 
effect of RPL5 expression on the cell growth over a 72 hour period. U2OS cells expressing FLAG-
tagged wild type, Y30E, or Y30F mutant RPL5 cells were grown in the presence of 1 µg/ml 
tetracycline. Live cell numbers were counted at the time intervals as indicated. Each point on the 
graph represents the mean ± the standard deviations of the means, n=3. 
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U2OS cells expressing the FLAG-tagged wild type or mutant RPL5 constructs were 
incubated with 1 µg/ml tetracycline-containing medium, at 37oC, to induce the 
expression of the proteins. Cells were counted at 24, 48 and 72 hours and total cell 
number was plotted (Figure 5.12). Expression of the wild type RPL5 reduced cell 
number; however the reduction in cell number of the two mutants was more marked.  
As p53 is involved in cell cycle regulation through p21, and apoptosis, this suggests 
that expression of the two mutant RPL5 proteins may be impeding cell cycle 
progression, despite the evidence for differences in their ability to activate p53.  
5.2.10 Expression of the wild type, Y30E or Y30F mutants leads to 
an accumulation of cells in G1/G0 in a p53-dependent manner 
Whilst the effect of altered RPL5 protein levels on p53 expression has been extensively 
studied, few experiments have studied the effect of altered RPL5 protein levels on cell 
cycle progression. Teng et al. (2013) reported that depletion of RPL5 had no effect on 
cell cycle progression, whilst Singh et al. (2014) demonstrated in mice that RPL5 
haploinsufficiency resulted in delayed G2 progression. One study involving U2OS cells 
showed that RPL5 expression promoted p53-dependent cell cycle arrest (Dai and Lu, 
2004).  Furthermore, it has also recently been determined that RPL5 over-expression, 
in p53 null SAOS-2 cells, induces apoptosis (Zhou et al., 2015). Therefore, to further 
elucidate the role of RPL5 over-expression on cell cycle progression, flow cytometry 
using Propidium Iodide (PI) was utilised (Figure 5.13). U2OS cells expressing control or 
FLAG-tagged RPL5 wild type or the Y30 mutants were induced with 1 µg/ml 
tetracycline for 48 hours, harvested and fixed in cold 70% ethanol before staining with 
propidium iodide and analysing by flow cytometry (Figure 5.13A-B). The cell cycle 
analysis was gated as shown in blue (Figure 5.13A) and only includes cells with a 
uniform size and shape.  
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Figure 5.13. Expression of RPL5 induces an accumulation of cells in G1. (A) Representative 
distribution of cells from cell cycle analysis. U2OS cells expressing empty vector, wild type RPL5 or 
the Y30 mutants were induced with 1 µg/ml tetracycline for 48 hours prior to ethanol fixation and 
cell cycle analysis using propidium iodide. The forward scatter (FSC) was plotted against the side 
scatter (SSC) and the live population of cells was gated on as shown in blue.  (B) Quantitation of the 
cell cycle distribution in A. (C) Quantification of the cell cycle distribution as in A+B, including a 
depletion of p53 for 48 hours using 20 µM p53 siRNA.  Bars in B and C represent the means ± the 
standard deviation of the means, n=3. Statistical analysis determined by a paired t test. NS= non-
significant, *= P ≤ 0.05, **= p≤ 0.01, ***= p≤ 0.001. 
147 
 
Expression of FLAG-RPL5, FLAG-RPL5 Y30E, or FLAG-RPL5 Y30F resulted in an 
accumulation of cells in G1/G0, which is consistent with p53 activation. Statistical 
analysis using a paired t-test showed a small, but significant, difference between the 
percentage of cells in G1 between the wild type and the Y30E mutant with a p-value of 
0.0032. The difference between the control and the wild type RPL5 had a very 
significant p-value of <0.0001 whilst the wild type compared to the Y30F mutant had a 
non-significant p-value of 0.5155. As the Y30E mutant shows the greatest level of p53 
induction, it suggests that this increased p53 induction leads to increased cell cycle 
arrest.  In order to determine whether the G1/G0 accumulation was caused by an 
increase in p53 activity, the inductions were carried out 12 hours post-transfection 
with 20 µM p53 siRNA duplex (Figure 5.13C). In all cases, the depletion of p53 resulted 
in a reduction in the number of cells in G1/G0. Statistical analysis was carried out 
between the single and double knockdowns and, with p-values between 0.016 and 
0.045, there was a significant decrease upon p53 knockdown in all cases, suggesting 
that the accumulation of cells in G1/G0 was p53 dependent.  
This is surprising as the Y30F mutant showed similar cell cycle defects to the wild type, 
despite having less of an effect on p21 levels although this could be due to other 
factors as discussed later.  
5.3 Discussion 
Post-translational modifications such as ubiquitination, NEDDylation, phosphorylation 
and acetylation are key in the regulation of p53 signalling (Meek, 1999, Xirodimas et 
al., 2004, Brooks and Gu, 2006, Vogelstein et al., 2000, Kumazawa et al., 2015). As 
NEDDylation has been demonstrated to regulate p53 signalling via RPL11 (Mahata et 
al., 2012, Sundqvist et al., 2009, Xirodimas et al., 2008), in this study it was proposed 
that other types of post-translational modifications, such as phosphorylation, could be 
important in regulating p53 signalling via 5S RNP. p53 signalling is regulated by 
multiple phosphorylation events in p53, MDM2, and MDMX (Chen et al., 2005, 
Goldberg et al., 2002, Jin et al., 2006, Loughery et al., 2014, Maya et al., 2001, Meek, 
1999) and thus it was possible that, as regulators of p53, RPL5 and RPL11 may also be 
phosphorylated to modulate p53 signalling. Previous in vitro studies identified two 
different kinases that interact with RPL5 (Bialik et al., 2008, Park and Bae, 1999). 
Furthermore, phosphorylation of RPL5 at serine residues has been shown to prevent 
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interaction with the 5S rRNA in vitro (Park and Bae, 1999), however there have been 
no in vivo experiments and no phosphorylation sites have yet been characterised that 
affect 5S RNP integration into the ribosome and result in the activation of p53. This 
chapter focused on the characterisation of reported phosphorylation sites that, based 
on the cryo-EM structure of the human ribosome, may affect integration of the 5S RNP 
into the ribosome.  
Analysis of the cryo-EM structure indicated that Y30, Y31 and Y44 of RPL5 were in close 
proximity to the 28S rRNA in the human ribosome (Figure 5.3) and thus mutations 
were introduced that mimicked phosphorylation (Y to E) or could not be 
phosphorylated (Y to F). Upon expression of the mutant RPL5 proteins, it was decided 
that only the Y30 mutations could be reliably used for experimentation due to poor 
expression and survival of the cells expressing the other RPL5 mutants. The toxicity of 
these mutations suggested a vital role in cell survival and thus they could prove to be 
extremely interesting to study. It would be of interest in the future to try to improve 
their expression. It is possible that only a small proportion of the cells were expressing 
the proteins and therefore clonally selecting the cell colonies could help to rectify this 
problem.  
Whilst mutations that attempted to mimic phosphorylation of, or lack thereof, Y30 did 
not appear to affect the areas in which RPL5 was localised (Figure 5.6), mimicking 
phosphorylation of Y30 did appear to abrogate RPL5 incorporation into the ribosome 
(Figure 5.8). As the Y30E mutant was expressed more strongly than the other two 
proteins, an excess of ‘free’ protein may be expected. If the rate of incorporation of 
the 5S RNP into ribosomes was steady between the wild type and mutants, there 
should have been equal amounts of each mutant incorporated into the ribosome 
regardless of how much additional ‘free’ RPL5 was present. These data taken together 
indicate that mimicking phosphorylation of RPL5 at Y30 by mutating it to glutamic acid 
may prevent integration of RPL5 into the ribosome. As discussed in previous chapters, 
this could be due to the mutations having a direct effect on ribosomal incorporation of 
RPL5 or it may abrogate interactions with proteins responsible for RPL5 recruitment. 
This could be further investigated by looking for interactions between these mutants 
and proteins known to be involved in 5S RNP recruitment- such as PICT-1.  
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Furthermore, glycerol gradients were utilised to determine whether it was possible 
detect phosphorylated RPL5 in ribosomes. The small ‘free’ 5S RNP fractions were 
directly compared to the large ‘ribosomal’ bound 5S RNP fractions. A higher molecular 
weight signal was present on a phos-tag western blot in the free pool that was not 
present in the ‘ribosome’ pool. Furthermore, there was a higher molecular weight 
signal present in the ‘ribosome’ pool that was not present in the ‘free’ pool, suggesting 
the evidence of differential phosphorylation (Figure 5.9). However, this experiment 
only demonstrates that phosphorylation is present in ‘free’ and ‘ribosomal’ pools, but 
does not reveal which residues are phosphorylated. The experiment was carried out 
with the expression of RPL5-FLAG cells using an anti-FLAG antibody and not the 
endogenous protein and, therefore, is not necessarily representative of the 
endogenous protein. However, the RPL5 antibodies were not specific enough to use; 
resulting in too many off-target signals. Another limitation of this study is that this is an 
artificial situation and has already induced ribosomal stress due to over-expression of 
ribosomal proteins resulting in p53 activation. Therefore, this is not a true 
representation of what would happen in a normal, unstressed cell. If a more specific 
RPL5 antibody were used, this may give a better result with the endogenous protein. It 
would also be possible to utilise an anti-phosphotyrosine antibody in an 
immunoprecipitation experiment followed by gradient centrifugation and western 
blotting for RPL5 as this would only show phosphorylated tyrosine.  
As RPL5 over-expression has been shown to stabilise p53  (Horn and Vousden, 2008), it 
was unsurprising that expression of the wild type, Y30E, or Y30F RPL5 resulted in 
increased p53 levels (Figure 5.11A-B). In addition, RPL5 Y30E expression resulted in a 
greater increase in p53 levels compared to the wild type. This is presumably as a result 
of RPL5 Y30E not being incorporated into ribosomes or due to the higher levels of 
expression of the RPL5 Y30E mutant, although it is not yet clear which.  
It has been demonstrated that MDM2 binds to the RPL11 in the same region that 
RPL11 binds helices 83-85 of the 28S rRNA (Zheng et al., 2015). As the Y30 residue was 
in very close proximity to the 28S rRNA binding site (Figure 5.3A), it was possible that 
mutating this site would affect RPL5-MDM2 interactions. However, the wild type, 
Y30E, and Y30F RPL5 mutations associated with MDM2 (Figure 5.10) thus suggesting 
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that mimicking phosphorylation of RPL5 Y30 does not abrogate MDM2-RPL5 
association.  
Furthermore, the levels of MDM2 protein were analysed upon induction of the wild 
type or mutant FLAG-RPL5 proteins (Figure 5.11C) and it was found that expression of 
the wild type or mutant RPL5 increased MDM2 expression, possibly as a result of the 
MDM2-p53 feedback loop whereby p53 increases can drive MDM2 expression (Barak 
et al., 1993). Furthermore, whilst the interaction between the 5S RNP and p53 had 
previously been debated (Zhou et al., 2015, Bursac et al., 2012, Marechal et al., 1994), 
in this study, association between RPL5 and p53 was detected (Figure 5.10). This 
suggested that RPL5 associates with p53 and MDM2 and that mimicking 
phosphorylation of Y30 does not affect these associations. As RPL11 had been 
previously shown to be recruited to promoter sites of p53 regulated genes (Sundqvist 
et al., 2009), the data in this study may support the theory that the 5S RNP complex 
with p53 may be recruited to p53 promoters.  
When the downstream effector of p53, p21, was analysed, expression of the Y30F 
mutation appeared to have a lesser impact on p21 levels compared to the wild type or 
Y30E expression. This was supported by the fact that expression of the RPL5 wild type 
or Y30E mutant in cells transfected with a p53-driven luciferase reporter resulted in an 
increase in luciferase levels, but expression of the Y30F mutant had no significant 
effect (Figure 5.11D). This may suggest that expression of RPL5 Y30F is not sufficient to 
increase activity of p53. This could potentially mean that the Y30 site of RPL5 is 
required for adequate activation of p53 as summarised in figure 5.14.   
One explanation for the reduced p53 activity could be due to interactions with p73 as 
RPL5 and RPL11 can activate the p53 homolog, p73. RPL5 and RPL11 bind to the N-
terminal transactivation domain of p73, blocking MDM2 binding to this domain and 
increasing p73 activity (Zhou et al., 2015). As p73 has the ability to transactivate many 
of the same genes involved in cell cycle arrest and apoptosis as p53 (Jost et al., 1997, 
Zhu et al., 1998), this may provide insight into why the RPL5 Y30F mutant does not 
increase p53 activity but can still affect cell cycle progression.  
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It was previously demonstrated, using the pG13 luciferase reporter, that p73 induction 
results in a small increase in luciferase levels compared to p53. However, when p53 
and p71 were both expressed, the luciferase levels remained similar to that of p73 
induction alone (Vikhanskaya et al., 2000). Therefore, one possible explanation for the 
reduced luciferase levels upon induction of RPL5 Y30F compared to the control is that 
expression of RPL5 Y30F may lead to an increase in p73 levels and thus cause only a 
small luciferase increase, despite p53 increases.  
Another explanation for the lack of p53 activity in the Y30F mutation could be 
explained by interactions with MDMX. Unlike MDM2, MDMX does not have E3 ligase 
activity and instead inhibits p53 by binding to its transactivation domain (Danovi et al., 
2004, Jackson and Berberich, 2000). This means that MDMX inhibits p53 without 
affecting p53 levels. Recently, the 5S rRNA was shown to be involved in the stability of 
MDMX (Li and Gu, 2011) whilst RPL11-MDM2 interactions were shown to be involved 
in the degradation of MDMX under ribosomal stress conditions (Gilkes et al., 2006). 
Although, currently it is believed that RPL5 and RPL11 do not interact with MDMX 
(Gilkes et al., 2006), given that the 5S rRNA is often found in a complex with RPL5 
and/or RPL11, it is possible that RPL5 Y30F, in conjunction with the 5S rRNA and/or 
RPL11 results in increased stability of MDMX and thus p53 activity but not levels are 
 
Figure 5.14 Schematic representation of the proposed role of phosphorylation in 5S RNP signalling. 
Non-phosphorylated RPL5 is incorporated as part of the 5S RNP complex into the ribosome. If RPL5 is 
phosphorylated, the 5S RNP is not incorporated into ribosomes and can interact with MDM2 and p53 
to promote p53 stabilisation and activation. 
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affected as shown in Figure 5.15. Furthermore, as MDMX regulates the stability of 
MDM2 (Gu et al., 2002), this may explain the higher MDM2 protein levels seen upon 
expression of the RPL5 Y30F mutant. In order to further test these theories, it would 
be beneficial in the future to assess the mutants for their ability to increase p73 
activity or their interactions with MDMX in order to understand the mechanisms 
behind the differences in p53 activity between the mutants.  
 
In this chapter, it was shown that expression of RPL5, whether wild type or mutant, in 
U2OS cells resulted in a decreased total cell number compared to the control (Figure 
5.12) and caused cells to accumulate in G1/G0 in a p53-dependent manner (Figure 
5.13). This is in agreement with results from several groups (Hiebert et al., 1995, 
Agarwal et al., 1995, Kastan et al., 1991) who have shown that p53 activation causes 
G1 cell cycle arrest in a range of cell types. The Y30E mutant showed a small but 
significantly higher proportion of cells in G1/G0 than the wild type expression. This 
correlates with the higher p53 levels seen in these cells, whereas the Y30F mutation 
had a similar profile to the wild type. The gating used for the cell cycle analysis is only 
focused upon regularly shaped cells and specifically excludes dead cells and debris. To 
further explore the effect of these mutations on cell death, Annexin V and 7-AAD 
staining could be used to look for signs of apoptosis (Zembruski et al., 2012).  
 
Figure 5.15. Proposed model for phosphorylation in the regulation of p53 via MDMX. In normal cells, RPL5 
(unphosphorylated at Y30) with RPL11 and the 5S rRNA bind to MDMX and inactivate p53. Upon nucleolar 
stress, RPL5 (phosphorylated at Y30) with RPL11 and the 5S rRNA bind to MDM2 to promote ubiquitination of 
MDMX and activate p53.  
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One limitation of this chapter as a whole is that phosphorylation mimics are not always 
an accurate representation of phosphorylation in the cell. Phosphorylated tyrosine is a 
difficult amino acid to mimic; glutamic acid makes a good mimic for phosphoserine 
(Maciejewski et al., 1995) as they have similar structures. However, there is no natural 
amino acid that is similar to phosphotyrosine. However, if the kinase or phosphatase 
could be identified, this would allow the phosphorylation to be up-regulated or down-
regulated by manipulating the kinase or phosphatase levels in cells. Whilst no kinases 
have yet been identified, investigation into the possible kinases involved through the 
use of the Group based predicition system, GPS (Xue et al., 2008), identified several 
kinases with the potential to phosphorylate tyrosine 30 of RPL5- Anaplastic lymphoma 
kinase (Alk), the Proto-oncogene tyrosine-protein kinase MER, Fibroblast growth factor 
receptor 3 kinase, Janus kinase 3 (JAK3), the insulin receptor tyrosine kinase and the 
tyrosine-protein kinase HCK. Further investigation into these tyrosine kinases may 
reveal an insight into whether this phosphorylation of RPL5 does, indeed, exist in cells. 
In this chapter, the possibility that phosphorylation may be an important regulator 
involved in 5S RNP-mediated p53 signalling was highlighted. Mimicking 
phosphorylation of tyrosine 30 of RPL5 by mutating it to glutamic acid appears to 
prevent the integration of RPL5 into the ribosome and enhances p53 signalling. 
Interestingly, mimicking phosphorylation of tyrosine 30 also appears to be important 
for activation of p53, suggesting that it is an important regulation step in the pathway.  
As the 5S RNP has been implicated in diseases such as Diamond Blackfan Anaemia, a 
greater understanding of the regulation of the pathway could be crucial to the 
discovery of novel treatments for DBA. This chapter has highlighted the possibility that 
phosphorylation of RPL5 may be important for the activation of p53 and thus the 
kinases involved, if specific to RPL5, could be manipulated to affect 5S RNP-mediated 
p53 activation. However, at present, the specific Y30 phosphorylation has not been 
confirmed in cells and no tyrosine kinases have been identified that interact with RPL5 
and therefore it remains unclear which kinases could be responsible for the 
phosphorylation of tyrosine residues in RPL5.  
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CHAPTER SIX: CONCLUSIONS AND DISCUSSION 
6.1 Introduction 
The aim of this project was to investigate the factors contributing to the regulation of 
the 5S RNP-mediated p53 signalling pathway. Ribosomes are crucial cellular machines 
that catalyse the translation of mRNA into proteins. Ribosome biogenesis is an 
extremely complex process and thus has to be tightly regulated. When ribosome 
biogenesis is disrupted, the 5S RNP, a component of the large ribosomal subunit, is 
free to bind to MDM2, the major suppressor of p53, and activate p53 (Sloan et al., 
2013a, Donati et al., 2013). However, the regulation of this pathway is not yet fully 
understood.  
In this thesis, I investigated factors involved in 5S RNP integration into the ribosome 
and post-translational modifications of RPL5. One primary mechanism of 5S RNP-
mediated regulation of p53 is through control of the integration of 5S RNP into the 
ribosome. This project has shown that the large subunit ribosomal proteins, RPL7, 
RPL18, and RPL21, are ribosome biogenesis factors that appear to be required for the 
5S RNP integration into the ribosome. Furthermore, this project has demonstrated in 
vitro that RPL11 can bind to a small fragment of the 28S rRNA that could possibly be 
used prevent interactions between the 5S RNP and MDM2.  
Phosphorylation of p53 and its regulators plays a vital role in the regulation of p53 
signalling pathways (Goldberg et al., 2002, Maya et al., 2001, Jin et al., 2006, Chen et 
al., 2005, Meek, 1999). I wanted to investigate the role of phosphorylation in 
regulating the 5S RNP to elucidate if phosphorylation of RPL5 could activate p53 
signalling. I found that expression of a mutated RPL5 mimicking RPL5 phosphorylation 
(RPL5 Y30E) resulted RPL5 ribosomal integration defects coupled with p53 activation.  
In this project I have also expanded on previous data showing that SRSF1 and PRAS40 
interact with components of the 5S RNP to regulate p53 signalling (Fregoso et al., 
2013, Havel et al., 2014). SRSF1 was demonstrated to associate with RPL5 and MDM2 
to activate p53 (Fregoso et al., 2013), whilst PRAS40 was shown to associate with 
RPL11 and sequester it to the nucleoli, preventing it from binding to MDM2. However, 
studies have since shown that 5S RNA, RPL5 and RPL11 are all required for p53 
activation (Donati et al., 2013, Sloan et al., 2013a) and thus I questioned whether these 
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proteins interacted with the 5S RNP. I have shown that SRSF1 interacts with the 5S 
rRNA and is required for the integration of RPL5 and RPL11 into the ribosome. 
Furthermore, I have demonstrated that both SRSF1 and PRAS40 are required for 
activation of p53 via the 5S RNP.  
6.2 rRNA processing in humans 
In eukaryotic organisms, three of the four rRNAs are transcribed by RNA polymerase I 
as a single 47S (35S in yeast) polycistronic precursor in the nucleolus (Nazar, 2004). 
This precursor then undergoes a series of processing steps in order to produce the 
mature 28S (25S in yeast), 18S and 5.8S rRNAs. It is known that ribosomal proteins are 
required throughout the ribosome biogenesis pathway (O'Donohue et al., 2010) 
however, most of the current understanding of rRNA processing has been from studies 
in yeast, and human rRNA processing is less understood.  
In both yeast and humans, processing of the internal spacer region, ITS1, is an 
important step as it separates the large and small subunit rRNAs. In humans, there are 
two pathways involved in ITS1 processing. The major pathway involves cleavage at site 
2 followed by processing by exonucleases, whereas the minor pathway involves 
cleavage at site 2a and acts to compensate for a block in site 2 cleavage (Sloan et al., 
2013b). I demonstrated that depletion of RPL7 or RPL18 resulted in accumulation of 
the 36SC processing intermediate, suggesting a defect in site 2 cleavage. Site 2 is 
located within the internal transcribed space region 1 (ITS1), and is thought to be 
equivalent to A3 cleavage in yeast (Sloan et al., 2013a) and thus responsible for the 
separation of the small and large subunit precursor rRNAs.  It was previously 
demonstrated that the 36SC precursor accumulated upon depletion of RBM28 or BOP1 
and could be rescued by depletion of the exonuclease responsible for processing the 
36S precursor to the 32S precursor, XRN2 (Sloan et al., 2013a). Therefore, this suggests 
that, like RBM28 and BOP1, RPL7, RPL18, and RPL21 are also required for site 2 
cleavage, furthering the current understanding of site 2 cleavage in humans. 
Interestingly, it was recently demonstrated that RPL7, along with RPL8, might be 
necessary for the association and function of the A3 assembly factors in yeast 
(Jakovljevic et al., 2012), suggesting that RPL7 is involved in A3/site 2 cleavage in both 
humans and yeast.  
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Further processing of the pre-rRNAs occurs within a second internal transcribed spacer 
region, ITS2. ITS2 contains two cleavage sites known as 3’ and 4a and separates the 
5.8S rRNA from the 28S rRNA. Cleavage at the 3’-region of ITS2 results in the 
generation of the 12S pre-rRNA (Hadjiolova et al., 1993) and further cleavage at site 4a 
results in a 7S pre-rRNA (Farrar et al., 2008). In eukaryotes, ITS2 excision is required for 
the formation of an evolutionarily conserved helix joining of the 3’ end of the 5’8S 
rRNA and the 5’ end of the 28S rRNA in mature ribosomes (Peculis and Greer, 1998) 
and thus is a crucial step in ribosome biogenesis. My data suggested that RPL21 
depletion resulted in inefficient cleavage of the 32S rRNA, therefore presenting a role 
for RPL21 in ITS2 processing in humans.  
Furthermore, I investigated the role of SRSF1 and PRAS40 in rRNA processing with 
pulse-labelling experiments. I found that neither depletion of SRSF1 nor PRAS40 
showed any significant differences in the production of the 28S or 18S rRNAs over 3 
experiments. However, SRSF1 depletion resulted in a slight increase in 32S with a slight 
decrease in 28S, suggesting that there could be very subtle large subunit processing 
defects, possibly in ITS2. Furthermore, PRAS40 depletion resulted in a slight increase in 
47S with a slight decrease in 32S suggesting that PRAS40 may have subtle effects on 
ITS1 processing. However, as there was no significant differences, it would be of 
interest to investigate the effect of SRSF1 or PRAS40 using specific probes to ITS1 and 
ITS2 to reveal more subtle defects.  
Therefore, these data taken together suggest a role for the ribosomal proteins, RPL7, 
RPL18, and RPL21, and possibly SRSF1 and PRAS40 in large subunit biogenesis, helping 
to unravel the complexity of human ITS1 and ITS2 processing. 
6.3 The recruitment of the 5S RNP into the ribosome 
There are several factors involved in regulating p53 via the 5S RNP. It has been 
suggested that any factors that affect the formation, localisation or ribosomal 
integration of the 5S RNP will have an impact on p53 signalling (Sloan et al., 2013a). 
Therefore, understanding factors involved in the recruitment of the 5S RNP into the 
ribosome is crucial to understanding p53 activation via the 5S RNP. However, this 
process is not yet fully elucidated in humans. In yeast, the recruitment of the 5S RNP 
into the ribosome is known to require Rrs1 and Rpf2. Rrs1 and Rpf2 form a complex 
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with the 5S RNP and are responsible for the integration of the 5S RNP into 90S pre-
ribosomes containing the 35S pre-rRNA (Zhang et al., 2007, Morita et al., 2002). 
Recently, the crystal structure of Rrs1 and Rpf2 complex has been solved in Aspergillus 
nidulans (Asano et al., 2014, Kharde et al., 2015) and yeast (Madru et al., 2015) leading 
to a greater understanding of the role of the Rpf2/Rrs1 complex in 5S RNP recruitment 
in these organisms. RPL5 and RPL11 are delivered to the nucleus and probably 
assembled onto the 5S rRNA by the symportin, Syo1 (Calvino et al., 2015) to form the 
5S RNP. When the 5S RNP is recruited into the ribosome, it is locked into conformation 
by the C-terminal tail of Rpf2, Rsa4 and Nsa2 to prevent any rotation (Kharde et al., 
2015, Bassler et al., 2015) and docks onto helix 84 of the 25S rRNA (Rhodin et al., 
2011). Rea1, a dynein-related nuclear AAA-ATPase, releases Rsa4 from the 5S RNP and 
rotates the structure by 180o to form the correct conformation for the formation of 
the central protuberance (Bassler et al., 2015, Leidig et al., 2014).  
Based on the T. thermophila crystal structure, I originally hypothesised that four 
ribosomal proteins, RPL7, RPL10, RPL18, and RPL21, formed a binding pocket for the 5S 
RNP in the ribosome. In light of the recent findings about the rotation of the 5S RNP, 
this may suggest that these proteins may not directly contact the 5S RNP in pre-
ribosomes. However, I demonstrated that depletion of the ribosomal proteins RPL7, 
RPL18, and RPL21 affected ribosomal integration of the 5S RNP. However, it still 
remains unclear as to whether the defects in 5S RNP ribosomal integration are caused 
purely by ribosome biogenesis defects or whether these proteins play a direct role in 
5S RNP recruitment, although the latter seems more likely as it was previously 
demonstrated that depletion of ribosome biogenesis factors reduced 5S rRNA 
recruitment into the ribosome, but that depletion of the factors involved in direct 
recruitment of the 5S RNP (RPL11, PICT-1, BOP1, and NOP2) had a stronger effect 
(Sloan et al., 2013a). At present, it appears that the RPL7, RPL18 and RPL21 depletions 
had a similar effect on 5S rRNA recruitment to RPL11, suggesting that they have a role 
in 5S RNP recruitment and are not just ribosome biogenesis factors. This suggests that 
the 5S RNP may not only contact the 28S rRNA upon binding, but may also require 
interaction with the surrounding ribosomal proteins.  Interestingly, RPL10 depletion 
had no effect on the ribosomal integration of the 5S RNP. However, in yeast, RPL10 
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integration is affected by Rrs1 and Rpf2 depletion (Zhang et al., 2007), thus suggesting 
that, like in yeast, RPL10 is recruited after 5S RNP integration.  
In human ribosomes, 5S RNP integration appears to be somewhat different to yeast. 
The human homologues of Rrs1 and Rpf2, RRS1 and BXDC1 have been shown to be 
involved in localisation of the 5S RNP but do not play a crucial role in ribosomal 
recruitment (Sloan et al., 2013a). Furthermore the nucleolar protein, PICT-1 (also 
known as Glioma tumour suppressor candidate region gene- GLTSRC2), directly 
contacts the 5S rRNA and has a more profound effect on 5S RNP recruitment into the 
ribosome than BXDC1 or RRS1. The data presented within this project may suggest 
that SRSF1 is also required for ribosomal recruitment of the 5S RNP. However, it is not 
clear whether SRSF1 is directly involved in the integration of the 5S RNP or whether it 
is involved in earlier steps such as formation of the 5S RNP particle. Previous reports 
demonstrated that depletion of the 5S RNP components, or PICT-1, resulted in rRNA 
processing defects (Sloan et al., 2013a), however the data in this study suggested that 
SRSF1 depletion did not. This may suggest that whilst SRSF1 and PICT-1 are both 
required for the ribosomal recruitment of the 5S RNP, they differ in the fact that PICT-1 
is required for rRNA processing, but SRSF1 is not. This may show that SRSF1 has a more 
direct role in 5S RNP recruitment rather than affecting ribosome biogenesis as a whole, 
however, to fully explore this possibility, northern blot analysis of the pre-rRNA 
precursors upon depletion of SRSF1 is required.  
Furthermore, I investigated the possibility that phosphorylation of RPL5 may affect 
integration of the 5S RNP into the ribosome. My data suggests that mimicking 
phosphorylation of RPL5 at Y30 prevents integration of RPL5 into the ribosome. The 
phosphorylation of serine residues on RPL5 was previously demonstrated to prevent 
interaction between RPL5 and the 5S rRNA in vitro (Park and Bae, 1999). This, together 
with the data presented in this thesis, would suggest that phosphorylation of RPL5 may 
play roles in both 5S RNP formation and 5S RNP integration into the ribosome.  
Interestingly, my data also showed evidence of phosphorylation present in ribosomal 
RPL5 that was not present in ‘free’ RPL5, suggesting that some phosphorylation sites 
may in fact be required for 5S RNP recruitment. In addition to Y30 there are many 
other phosphorylation sites in RPL5 and therefore investigating these other sites may 
provide greater insight into the role of phosphorylation in RPL5 regulation. 
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Furthermore, Phosphosite (http://www.phosphosite.org) also lists multiple 
phosphorylation sites for RPL11. Initial work in the Watkins lab by Zhao Zhao has 
revealed that mimicking phosphorylation of RPL11 may also have similar effects to that 
seen in this project (Wakins lab- unpublished data) and thus may be a mechanism for 
regulation of 5S RNP integration. 
 
As I have also shown that SRSF1 is important for integration of the 5S RNP into the 
ribosome, it would be interesting to evaluate whether phosphorylation of RPL5 affects 
interactions between SRSF1 and RPL5. Similarly, SRSF1 phosphorylation is important 
for regulation of the localisation and function of SRSF1 (Hagopian et al., 2008, Lai et al., 
2001, Ngo et al., 2005) and thus it is possible that phosphorylation of SRSF1 may affect 
its ability to interact with the 5S RNP. Therefore, studies into the effect of 
phosphorylation on SRSF1 and RPL5 interactions could further elucidate the role of 
SRSF1 in 5S RNP-mediated p53 signalling.  
The data presented in this project has helped to further understand the factors 
involved in recruitment of the 5S RNP into the ribosome as summarised in Figure 6.1.  
6.4 Regulation of the 5S RNP pathway 
In this project, we also wanted to investigate factors that directly regulate p53 
signalling via the 5S RNP. SRSF1 and PRAS40 had been previously demonstrated to be 
involved in p53 signalling via the 5S RNP and, therefore, we wanted to further 
elucidate these roles. Furthermore, as phosphorylation is a key regulator in p53 
 
Figure 6.1 Proposed  5S RNP ribosomal  integration pathway. Schematic representation of our proposed 
model of 5S RNP recruitment into the ribosome. Free pools of the 5S RNP contain phosphorylated RPL5. We 
propose that this phosphate group is removed by an unknown phosphatase before the 5S RNP is 
incorporated into the ribosome, although different sites may be phosphorylated at this stage. Incorporation 
of the 5S RNP into the ribosome requires PICT-1 and SRSF1 and also requires interactions with the 28S rRNA, 
RPL7, RPL18 and RPL21 in the pre-ribosome.  
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signalling pathways, we wanted to investigate whether phosphorylation of RPL5 
affected the 5S RNPs ability to bind to MDM2 and activate p53.  
6.4.1 PRAS40 and SRSF1 
As previously described, one of the potential candidates for regulating the p53 
response to ribosomal stress is PICT-1. PICT-1 interacts with RPL5 and RPL11 and it was 
suggested that PICT-1 sequesters RPL11 to the nucleolus (Sasaki et al., 2011) to 
prevent interactions between the 5S RNP and MDM2. The proline-rich Akt Substrate of 
40kDa (PRAS40, also known as AKT1S1), was suggested to have a similar role to PICT-1 
in sequestering RPL11 to the nucleolus to suppress p53 activation (Havel et al., 2014). 
Havel et al. (2014) demonstrated that nuclear PRAS40 was able to bind RPL11 and 
prevent activation of p53 via ActD treatment. Furthermore, this binding was 
dependent upon the phosphorylation of PRAS40 via mTORC1 and AKT at residues S221 
and T246. Interestingly, the complex containing RPL11 and PRAS40 was found to have 
a high molecular weight  and it was hypothesised that this could contain other 
unidentified proteins (Havel et al., 2014). However, my data suggests that these 
proteins are not the other 5S RNP components as PRAS40 did not co-
immunoprecipitate with the 5S rRNA or RPL5. Therefore, we hypothesised that PRAS40 
was involved in negative regulation of the 5S RNP pathway by sequestering RPL11 to 
the nucleolus. However, my data also presented some new observations regarding 
PRAS40 activity. PRAS40 appeared to be required for activation of p53 via SRSF1, RPL5, 
and RPL11, contradicting the previous findings that PRAS40 prevents p53 activation via 
RPL11 (Havel et al., 2014). However, unlike RPL5, RPL11 or SRSF1 depletion, PRAS40 
depletion did not abrogate the p53 response after ActD treatment, suggesting that it is 
not essential for p53 activation upon ribosomal stress. This may present differing roles 
for PRAS40 in the regulation of the 5S RNP whereby it is both able to negatively and 
positively regulate p53 signalling. Phosphorylation of PRAS40 is essential for its 
interaction with RPL11, resulting in MDM2-mediated degradation of p53 (Havel et al., 
2014).  Therefore, it may be possible that altering the phosphorylation state of PRAS40 
affects its role in 5S RNP signalling. Therefore, further investigation into PRAS40 
signalling could focus on using PRAS40 phosphorylation mutants to evaluate the 
impact on p53 signalling.   
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One other factor shown to regulate p53 signalling upon ribosomal stress was Serine-
Arginine Rich Splicing Factor 1 (SRSF1- also Alternative Splicing Factor- ASF). SRSF1 is a 
28kDa member of the SR protein family of splicing factors which are involved in 
constitutive and alternative splicing as well as being involved in mRNA nuclear export, 
mRNA translation and nonsense mediated decay (Long and Caceres, 2009). Fregoso et 
al. (2013) demonstrated a role for SRSF1 in p53 signalling via RPL5. It was suggested 
that RPL5, MDM2 and SRSF1 form a complex to stabilise p53 and induce senescence. 
However, as Donati et al. (2013) and Sloan et al. (2013a) both demonstrated that RPL5, 
RPL11 and the 5S RNP were all required for p53 activation in response to ribosomal 
stress I questioned whether SRSF1 interacted with the 5S RNP as a complex. Indeed, 
my data also shows that SRSF1 interacts with the 5S rRNA, although it was not possible 
to show interactions with RPL11 due to problems with antibodies. Recent studies in 
the Watkins lab have, however, demonstrated that SRSF1 is able to interact with RPL11 
in vitro and thus may strengthen the hypothesis that SRSF1 interacts with the entire 5S 
RNP (Watkins lab-unpublished data). Furthermore, my data suggests that SRSF1 may 
form part of the 5S RNP complex involved in activating p53 upon ribosomal stress and 
maintaining normal p53 homeostasis.  
I have also shown that SRSF1 depletion resulted in a reduction in nucleolar RPL5 as 
well as a reduction in cytoplasmic RPL11. Indeed, it was previously demonstrated that 
depletion of any factors crucial for large subunit ribosome production resulted in an 
increased re-localisation of cytoplasmic RPL11 to the nucleoplasm (Sloan et al., 2013a). 
As RPL5, RPL11 and the 5S rRNA are integrated into the ribosome as a complex 
(Calvino et al., 2015, Kharde et al., 2015, Leidig et al., 2014, Madru et al., 2015), it 
follows that depletion SRSF1 will also affect 5S rRNA integration, however this should 
be followed up in future experiments by investigating 5S rRNA integration into the 
ribosome. 
The data presented in this thesis provides a foundation for future studies into the 
potential therapeutic targets for ribosomopathies such as DBA and 5q-syndrome. As 
localisation and ribosomal integration of the 5S RNP are crucial factors in the 
regulation of the 5S RNPs ability to activate p53, it follows that targeting factors that 
affect localisation or integration of the 5S RNP may be a viable treatment option for 
patients with ribosomopathies. Furthermore, the data presented in this project reveals 
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that the 5S RNP complex may be more complex than previously suggested, as my data 
suggests that the 5S RNP complex also contains SRSF1.  
6.4.2 Phosphorylation of RPL5 
One further way that proteins are regulated is via post-translational modifications. 
Indeed, RPL11 has been demonstrated to be NEDDylated to regulate its stability and 
ability to activate p53 (Bursac et al., 2012, Mahata et al., 2012, Sundqvist et al., 2009, 
Xirodimas et al., 2008). However, the role of phosphorylation in 5S RNP regulation has 
yet to be reported in the literature. Phosphorylation of p53 is a key post-translational 
modification that regulates p53 signalling. p53 is phosphorylated at many different 
sites to regulate its function (Meek, 1999). In addition, phosphorylation of the p53 
regulators, MDM2 and MDMX also regulates their ability to suppress p53 (Goldberg et 
al., 2002, Maya et al., 2001, Jin et al., 2006, Chen et al., 2005).  
Therefore, I hypothesised that, as regulators of p53, the 5S RNP components may also 
be differentially phosphorylated to regulate p53 signalling. As a previous study 
demonstrated that RPL5 can undergo phosphorylation in vitro (Park and Bae, 1999), I 
focused my studies on RPL5.  
At present, very little is known about phosphorylation of RPL5. Several 
phosphorylation sites have been reported on Phosphosite 
(http://www.phosphosite.org), but the relevance of these has not been investigated.  
I have shown that the RPL5 Y30F mutation, to prevent Y30 phosphorylation, reduces 
the p53 response from RPL5 expression and that mutation to glutamic acid in an 
attempt to mimick phosphorylation affects RPL5 recruitment into the ribosome. This 
suggests that phosphorylation could be a key mechanism for controlling whether the 
5S RNP is incorporated into the ribosome, and if it is not, how it affects p53 signalling. 
Unfortunately, there was not time within this project to identify the kinase responsible 
for the phosphorylation of RPL5 and to further investigate its existence in cells. RPL5 
has been shown to interact with two different kinases (Park and Bae, 1999, Bialik et al., 
2008), but neither are able to phosphorylate tyrosine residues. This should be 
investigated further, using a kinome screening technique, to reveal kinases and 
phosphatases involved in regulating the 5S RNP pathway.  
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Interestingly, according to Phosphosite, T73 and Y119 are potential phosphorylation 
sites of RPL11 and these residues fall within the binding site of MDM2 (Zhang et al., 
2011, Zheng et al., 2015). This could be a further mechanism for blocking RPL11-
MDM2 interactions. Therefore, it would be beneficial to further investigate how these 
phosphorylations are regulated. 
6.4.3 Summary 
In summary (Figure 6.2), my data in combination with previous observations in the lab 
suggests that SRSF1 interacts with the 5S RNP to facilitate in the activation of p53. 
Furthermore, PRAS40 associates with RPL11 and possibly sequesters it to the nucleolus 
but, in direct contrast to the literature, also may be involved in the activation of p53.  
Furthermore, my data suggests that phosphorylation of RPL5 at Y30 may be a 
requirement for p53 activation and thus it is possible that the phosphorylation of RPL5 
may also regulate interactions between SRSF1 and the 5S RNP. Therefore, it would be 
beneficial to test association between SRSF1 and the RPL5 phosphorylation mutants to 
further understand this regulation pathway.  
6.5 Future treatments for disease 
This project has revealed many avenues that could be explored to aid in finding new 
therapeutics for ribosomopathies, such as DBA and 5q-syndrome. I have mainly 
focused my investigation on DBA as the role of the 5S RNP signalling in this disease has 
been well studied.  
The interaction with SRSF1 and PRAS40 with the 5S RNP is extremely interesting as one 
of the most promising treatments for DBA currently available is leucine treatment 
(Jaako et al., 2012, Payne et al., 2012, Pospisilova et al., 2007). However, despite its 
efficiency at treating DBA, it has little effect in 5q-syndrome patients (Yip et al., 2012, 
Steensma and Ebert, 2013). Leucine is an activator of the mTOR pathway (Lynch, 
2001). Interestingly, mTORC1 is able to phosphorylate PRAS40 at S221 and this 
phosphorylation was thought to be essential for RPL11-PRAS40 interactions (Havel et 
al., 2014). Therefore, it follows that leucine treatment is an effective therapy as it 
activates mTORC1 leading to phosphorylation of PRAS40 and thus RPL11 is 
sequestered to the nucleolus and can no longer interact with MDM2 to activate p53. 
Furthermore, SRSF1 is able to activate mTORC1 (Michlewski et al., 2008, Ben-Hur et al., 
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2013, Karni et al., 2007), suggesting that SRSF1 and PRAS40 may work in a conjunction 
to maintain p53 levels within the cell via the 5S RNP. In this project, I was not able to 
demonstrate leucine treatment reducing p53 levels upon ribosomal stress. However, 
future experiments altering the dosage of leucine or the effectiveness of leucine 
uptake would be required to fully understand this pathway. Furthermore, leucine 
treatment in conjunction with PRAS40 activation could be a more effective treatment 
than either treatment alone and thus future experiments could be carried out to this 
effect.  
In addition to leucine treatment, drugs that activate mTORC1 may be useful in treating 
ribosomopathy patients of whom have increased 5S RNP-mediated p53 levels. One of 
the main activators of mTORC1 in the cell is AKT (Huang and Manning, 2009) and my 
data shows that inhibition of AKT activates p53 via RPL5. Therefore, I hypothesise that 
activation of AKT could potentially block p53 accumulation through the 5S RNP.  One 
activator that would be worth testing as a potential therapeutic for DBA and 5q-
syndrome would therefore be SC-79 which activates AKT (Jo et al., 2012).   
During the course of this project it was demonstrated that mimicking phosphorylation 
of RPL5 at Y30 prevented integration of the 5S RNP into the ribosome. Based on the 
data in Chapter 5 that mimicking phosphorylation of Y30 results in inefficient RPL5 
incorporation into the ribosome, it is possible that blocking the kinase would 
potentially prevent accumulation of ‘free’ 5S RNP and prevent activation of p53. 
Therefore, if the kinase involved in this phosphorylation could be identified, this would 
present a potential therapeutic target for ribosomopathy patients. 
This project also demonstrated that a small fragment of the 28S rRNA (helix 83-85) can 
bind to RPL11 in vitro. This fragment of the 28S rRNA has been shown to bind to RPL11 
in the same region as MDM2 (Zheng et al., 2015). Therefore, it would be beneficial in 
the future to attempt to introduce the rRNA fragment into human cell lines to see 
whether it has the ability to block RPL11-MDM2 interactions. This could be an 
interesting therapeutic as, if it could be targeted specifically to the nucleoplasm, it 
would promote MDM2-mediated p53 degradation in patients with ribosomopathies 
without affecting ribosome production.  
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Furthermore, despite the fact that RPL5 and RPL11 depletion does not activate p53 
(Sloan et al., 2013a), severe truncations of RPL5 and RPL11 (resulting in 
haploinsufficiency) have been reported in patients with DBA (Singh et al., 2014, Cmejla 
et al., 2009, Delaporta et al., 2014). In this project, RPL5 depletion was shown to 
induce cell cycle defects, with cells accumulating in G2/M. This was in agreement with 
previous studies that haploinsufficiency of RPL5 results in a G2/M arrest (Singh et al., 
2014). This suggests that the mechanism of DBA pathogenesis in patients with RPL5, 
and presumably RPL11, mutations differ from that of the other ribosomal proteins. 
Therefore, patients harbouring these mutations would not benefit from targeting of 
p53. This is similar to what is seen in cancer as p53 is lost or mutated in a large 
proportion of cancers (Muller and Vousden, 2013), upregulation of p53 signalling in 
cancer patients may not be an effective treatment. Several of the ribosomopathies 
have a predisposition to cancer and RPL10 and RPL5 mutations have been described in 
patients with AML. Therefore, a greater understanding of the pathogenesis of these 
diseases and 5S RNP signalling could help to provide novel treatments for cancer. 
Further investigation into the mechanism behind the G2/M arrest upon RPL5 depletion 
would help to discover novel therapeutic targets. This could be performed using a gene 
expression array in conjunction with depletion of RPL5 or RPL11 to identify changes in 
the expression of cell cycle regulators. 
6.6 Conclusions 
This work has shown the complex nature of regulation of the 5S RNP in p53 signalling. 
It was shown that helices 83-85 of the 28S rRNA could bind in vitro to RPL11 and could 
be potentially used to prevent RPL11-MDM2 interactions. Three ribosomal proteins 
were identified: RPL7, RPL18, and RPL21, which appear to be required for the 
integration of the 5S RNP into the ribosome and, if depleted, cause 5S RNP-dependent 
p53 induction and cell cycle arrest. These findings also demonstrate a role for SRSF1 as 
a potential regulator of the 5S RNP-p53 pathway and show that, whilst PRAS40 is 
potentially required for the p53 response from RPL5 and RPL11 expression, it does not 
interact with the intact 5S RNP. Furthermore, phosphorylation of the RPL5 has been 
identified as a potential key regulator of the complex. Mimicking phosphorylation of 
Y30 on RPL5 prevents integration of the 5S RNP into the ribosome but it was also 
shown that phosphorylation of RPL5 may be required for p53 activation. Further 
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analysis will be required to fully understand the regulation of the 5S RNP via SRSF1, 
PRAS40 and post-translational modifications.  
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